Hyperinsulinaemia, insulin resistance and endogenous fibrinolysis in ischaemic heart disease by Wright, Robert Anthony
HYPERINSULINAEMIA, INSULIN RESISTANCE AND




The University of Edinburgh
1996
ABSTRACT
The work presented in this thesis has explored the hypotheses that
disturbances of insulin and of endogenous fibrinolysis are a feature of patients with
established ischaemic heart disease and investigated the potential manipulation of
these by an inhibitor of the angiotensin converting enzyme.
Hyperinsulinaemia implies either abnormally elevated fasting concentrations
of insulin, or an increased insulin response to a stimulus - usually an orally or
intravenously administered glucose load. Insulin resistance describes a state in which
the biological effect of insulin on glucose metabolism is less than it should be, and
this usually leads to a chronic compensatory hyperinsulinaemia.
The possibility that the presence of either a previous myocardial infarction or
of heart failure might influence the development of hyperinsulinaemia was studied.
Only patients with heart failure showed fasting hyperinsulinaemia, whereas the
increased insulin response to an oral glucose load in those with heart failure or
previous myocardial infarction was similar, and greater than the response in patients
with stable angina. Hyperinsulinaemia has been previously associated with impaired
peripheral muscle glucose uptake and metabolism and might contribute to the
development of muscular fatigue on exertion in patients with previous myocardial
infarction or with heart failure.
Amongst patients with ischaemic heart disease who had a normal fasting
plasma glucose, one fifth had impaired glucose tolerance on formal testing and this
group exhibited significantly greater fasting and stimulated hyperinsulinaemia.
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Including all patients, there was an inverse relationship between left ventricular
ejection fraction and fasting plasma insulin concentration.
The angiotensin converting enzyme inhibitor captopril has been shown to
improve prognosis after acute myocardial infarction. The possibility that captopril
might favourably influence alterations of insulin secretion or insulin resistance in
patients with recent uncomplicated myocardial infarction was investigated but no
significant effect could be demonstrated.
Impaired endogenous fibrinolysis has been associated with an adverse
prognosis in patients with ischaemic heart disease. The effect of captopril upon
tissue-type plasminogen activator and on plasminogen activator inhibitor type 1 was
investigated in patients with recent uncomplicated myocardial infarction. Captopril
caused a significant reduction in antigen levels of both tissue-type plasminogen
activator and of plasminogen activator inhibitor type 1. This may help to explain the
reduction in acute coronary syndromes that has been associated with the use of
captopril following acute myocardial infarction.
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The truth is rarelypure, and never simple
Oscar Wilde
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CHAPTER 1
A REVIEW OF INSULIN, ENDOGENOUS FIBRINOLYSIS AND
THEIR POSSIBLE IMPLICATIONS FOR PATIENTS WITH
ISCHAEMIC HEART DISEASE
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1.1 THE BIOLOGY OF INSULIN
1.1.1 INSULIN AND ITS SECRETION
The human insulin gene is 1500 base pairs long and is located on the short
arm of chromosome 11. Insulin is a polypeptide hormone secreted by the p cells
within the islets of Langerhans in the endocrine pancreas. It is synthesised as
preproinsulin and the pre-sequence is removed within the endoplasmic reticulum to
form proinsulin (Espinal 1989).
The proinsulin molecule is transported to the Golgi apparatus, where
proteolysis and packaging into secretory granules begins. Proinsulin consists of
3 units - the A (acidic) chain, the B (basic) chain, and the C (connecting) peptide.
The proinsulin molecule undergoes a series of site-specific peptide cleavages that
lead, via the intermediate species of 32,33 split proinsulin and 65,66 split proinsulin,
to the formation ofmature insulin and C peptide in equimolar concentrations.
The insulin molecule consists of the A chain, which has 21 amino acids, and
the B chain, which has 30 amino acids. The molecule contains 3 disulphide bridges:
2 linking the A and B chains and an internal one in the A chain. The evolutionary
conservation of this structure is remarkable and hints at the biological importance of
the molecule.
The conversion of proinsulin to insulin takes place as the secretory granules
mature, and usually this processing is about 95% complete prior to secretion. At the
time of secretion, mature granules fuse with the plasma membrane and discharge
their contents into the extracellular fluid. Insulin and C peptide are released into the
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pancreatic vein, which empties into the portal vein. This is an important arrangement,
since the liver is a primary site of action for insulin. Insulin has no plasma carrier
protein and its plasma half-life is less than 5 minutes under normal conditions. The
major organs involved in insulin metabolism are the liver and kidneys (and the
placenta during pregnancy) and at least 2 enzyme systems are responsible for its
metabolism. The first involves an insulin-specific protease, which is present in many
tissues, and the second involves hepatic glutathione insulin transhydrogenase. Thus,
the highest concentrations of insulin occur in the hepatic portal vein prior to first-
pass metabolism.
Under normal conditions, a small amount of proinsulin and its split products
are released with the insulin and C peptide from the secretory granules. These have a
significantly longer half-life than insulin, although they have less than 5% of the
bioactivity of insulin because the active site of insulin is occluded in the precursor
molecule. Proinsulin and its split products may cross-react with insulin antisera, and
if present in increased concentrations they may cause a radioimmunoassay for
"insulin" to overestimate the bioactivity of "insulin" in plasma. The C peptide has no
known biological activity and is a distinct molecule from an antigenic standpoint.
The normal human pancreas secretes 40-50 units of insulin daily, which
represents about 15-20% of its stores. The most physiologically important stimulus
to the release of insulin is an increase in plasma glucose. Insulin secretion is also
increased by P adrenergic agonists and by chronic exposure to Cortisol, growth
hormone, oestrogen, progesterone and human placental lactogen. Alpha adrenergic
agonists inhibit release of insulin.
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There are two hypotheses that explain the mechanism by which the (3 cell
recognises glucose, and both are referred to as the "glucoreceptor model." The first
model describes a classical membrane receptor for glucose that transmits the signal
to intracellular pathways leading to insulin secretion. Unfortunately, no such receptor
has been identified. Most evidence supports the alternative hypothesis, that the
"glucoreceptor" is the metabolism of glucose itself. Randle recently reviewed the
hypothesis and suggested that the "glucoreceptor" is the phosphorylation of glucose,
which in the [3 cells is catalysed by glucokinase (Randle 1993). The transport of
glucose into p cells and hepatocytes is by GLUT-2, an insulin independent glucose
transporter protein with a high capacity, facilitating a rapid equilibration between
intracellular and extracellular glucose. The first step in the metabolism of glucose in
animal tissues is phosphorylation to glucose 6-phosphate, which in p cells and
hepatocytes is catalysed by glucokinase, and in all other tissues by hexokinase. This
is significant because the concentration of glucose at which the rate of
phosphorylation catalysed by glucokinase is half the maximal rate (Km, or the
Michaelis constant) is high (6.1 - 8.9 mmol/L), which means that the rate of glucose
phosphorylation varies with changes in the glucose concentration throughout the
physiological range. Thus it acts as an accurate sensor by which to regulate the
secretion of insulin, developing a greater stimulus with increasing levels of plasma
glucose, and providing very little stimulus at basal glucose concentrations (3.8 - 5.2
mmol/L).
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1.1.2 THE INSULIN RECEPTOR
The actions of insulin are mediated by an integral plasma membrane protein,
the insulin receptor. The insulin receptor gene is located on the short arm of
chromosome 19 and is even more highly conserved in evolution than the gene for
insulin itself. The processed receptor consists of 2 a subunits, which are located on
the outer surface of the membrane and contain the insulin binding site, and 2 (3
subunits, which traverse the membrane and are protein tyrosine kinases in their
cytosolic domain. Tyrosine phosphorylation is unusual in mammalian cells
(phosphotyrosine accounts for < 0.1% of the phosphoaminoacid content of normal
cells), and yet it is interesting to note that, amongst others, platelet derived growth
factor, angiotensin II, insulin-like growth factor I and many viral oncogene products
also act on receptors which have tyrosine kinase activity. The low intracellular
concentration of proteins containing phosphotyrosine suggests that they may well
have a regulatory function.
Insulin receptors are found on most mammalian cells, in concentrations of up
to 20,000 per cell, and often on cells not typically thought of as being insulin targets.
For example, most of the insulin binding capacity of mixed leukocyte preparations
resides with monocytes. The receptor is constantly being synthesised and degraded,
and its half-life is 7-12 hours. The receptor is translated as a single chain peptide in
the rough endoplasmic reticulum and is processed within the Golgi apparatus to form
the mature a and |3 subunits.
When insulin binds to the receptor, several events occur: (1) There is a
conformational change of the receptor; (2) the receptors crosslink and form
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microaggregates; (3) the receptor is internalised; and (4) one or more signals are
generated. Within the cell, insulin is degraded in the lysosome, but the receptor may
be recycled to the cell surface. The number of insulin receptors on the cell surface is
tightly controlled, but may be up or down regulated. Factors known to influence
receptor concentration include insulin itself, physical exercise, and hormones such as
corticosteroids and growth hormone.
The exact nature of the intracellular mechanisms initiated by the binding of
insulin to its receptor remain obscure. Activation of tyrosine kinase leads to
activation of a receptor-associated serine kinase, and it is likely that the latter initiates
phosphorylation/dephosphorylation reactions leading to the generation of second
messengers. The nature of the second messenger(s) is poorly understood, but one
candidate is phospholipase C. Most other hormones exert their action through one of
two other second messenger systems, changes in the concentrations of cAMP or of
inositol triphosphate. While some of insulin's actions are associated with an increase
of cAMP, this does not account for the majority.
1.2 PHYSIOLOGICAL ACTIONS OF INSULIN
Although in clinical medicine the primacy of insulin is considered to be the
control of the blood glucose concentration, its actions are remarkably protean.
These include: (1) Metabolic effects - including carbohydrate, lipid and protein
metabolism; (2) effects on the autonomic nervous system; (3) haemodynamic effects;
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(4) effects on electrolyte balance; (5) effects on cell replication and cell death; and
(6) effects on gene transcription.
1.2.1 METABOLIC EFFECTS OF INSULIN
These may be usefully considered by the division into the postabsorptive state
and the postprandial state. The plasma insulin level depends upon the blood glucose
level, which in its turn depends upon three variables: (i) gastrointestinal absorption;
(ii) peripheral glucose uptake and utilisation; and (iii) hepatic glucose production by
glycogenolysis and gluconeogenesis. Excretion of glucose only occurs when the
renal threshold is exceeded, i.e. in diabetes mellitus and sometimes during
pregnancy. In the postabsorptive state, peripheral glucose uptake and hepatic glucose
production are equal and this balance is principally maintained by the combination of
insulin and glucagon. The plasma concentrations of glucose (low) and of non-
esterified fatty acids (high) are stable.
Postabsorptive state
The term postabsorptive state refers to the period 6-12 hours after a meal
during which the transition from the postprandial to the fasting state occurs. At this
time, glucose metabolism continues to be the main source of energy for tissues that
are obligate glucose metabolisers, principally the brain and erythrocytes, whose
uptake of glucose is independent of insulin. Plasma insulin levels are low, and the
insulin sensitive tissues (peripheral muscle, myocardium, liver and kidneys) generate
ATP from the P oxidation of non-esterified fatty acids. In these tissues, the
relationship between the metabolism of glucose and fatty acids is reciprocal; the
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glucose fatty acid cycle or Randle hypothesis operates (Randle et al 1963). Put
simply, this states that the oxidation of non-esterified fatty acid inhibits the uptake of
glucose by insulin sensitive tissue; thereby sparing glucose for metabolism by non-
insulin sensitive tissues.
Postprandial state
The postprandial response is obviously dependent upon the nature of the
ingested meal. In most studies, and those described in this thesis, the traditional
stimulus has been an aqueous solution of glucose. Following gastrointestinal
absorption, plasma glucose rises within 10 minutes and stimulates the islet (3 cells to
produce insulin, and suppresses release of glucagon from the a cells. Initially, when
portal venous concentrations are high, some ingested glucose is used to replenish
hepatic glycogen stores (insulin independent uptake), but most of the absorbed
glucose load is disposed of into peripheral muscle (insulin dependent uptake). Within
the muscle, glucose may undergo oxidative metabolism or non-oxidative
metabolism. Oxidative metabolism initially requires glycolysis, which produces 2
pyruvate molecules from one of glucose, after which the pyruvate is converted to
acetyl CoA, which undergoes complete oxidation in the tricarboxylic acid cycle.
Non-oxidative metabolism occurs either when only glycolysis takes place, or if
glucose is diverted into the muscle glycogen store (catalysed by glycogen synthase).
Insulin stimulates these processes at three main sites: (i) the transport of glucose
across the cell membrane; (ii) the activity of glycogen synthase; and, in adipose
tissue, (iii) the activity of pyruvate dehydrogenase, which catalyses the conversion of
pyruvate to acetyl CoA:
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(i) The effect of insulin on glucose transport involves a translocation of glucose
transporters from intracellular membrane to the plasma membrane, and then
activation of the transporter. These are 5 isoforms of transporter (GLUT 1-5) with
tissue specific expression: GLUT 1 (brain, erythrocyte); GLUT 2 (liver, pancreatic p
cell); GLUT 3 (gut, kidney); GLUT 4 (skeletal muscle, adipose tissue); and GLUT 5
(gut, kidney).
(ii) Glycogen synthase activity is regulated by phosphorylation and
dephosphorylation. Insulin activates the enzyme by activating glycogen synthase
phosphatase and inhibiting one of the glycogen synthase kinases, cAMP-dependent
kinase.
(iii) The pyruvate dehydrogenase complex in the mitochondria of adipocytes is
activated by insulin. Thus, it encourages the carbon atoms of glucose to venture
beyond "the point of no return" to become acetyl CoA (an irreversible reaction), from
where they must either enter the tricarboxylic acid cycle or, in adipose tissue in
particular, be used to synthesise fatty acids. Insulin also increases the rate of
triglyceride synthesis and inhibits lipolysis. Thus, by lowering the concentration of
circulating non-esterified fatty acids, the utilisation of glucose by peripheral muscle
is increased, as predicted by the glucose fatty acid cycle hypothesis.
Lastly, the effects of insulin upon protein metabolism have little effect on
glucose or fatty acid metabolism. In the short term (minutes) insulin stimulates
amino acid uptake, and in the longer term (hours) it alters protein synthesis via direct
effects on the generation and translation ofmRNA.
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1.2.2 NEURAL EFFECTS OF INSULIN
The modulation of insulin release by both a and p adrenergic stimulation has
been described. The possibility that insulin might alter sympathetic nervous system
activity has aroused interest, mainly as a possible link between raised insulin levels
and increased blood pressure. Augmented sympathetic nervous system activity may
also be important in ischaemic heart disease as recently reviewed by Kubler (Kubler
1992) and as witnessed in clinical practice by the widespread use of P adrenoceptor
antagonists.
Pereda was the first to report that intravenous administration of insulin to the
dog caused an increase in blood pressure prior to the onset of hypoglycaemia, and
that, if hypoglycaemia was prevented, the effect persisted (Pereda et al 1962). In
addition, it was found that smaller doses of insulin, which had no effect when
administered intravenously, elicited a pressor response when infused into the carotid
artery, suggesting that insulin may have a direct action on the brain. The response
was antagonised by phentolamine (an a adrenoceptor antagonist) and by
trimethidinium (a ganglion blocker). Further animal studies have revealed insulin-
specific binding sites in the hypothalamus (Van Houten et al 1983), and also shown
that intraventricular injections of insulin increase central nervous system
catecholamine turnover (Sauter et al 1983).
In a study very similar in concept to that of Pereda, Rowe reported the effects
of administering an intravenous infusion of insulin to 12 normal men (Rowe et al
1981). Blood glucose levels were maintained at fasting concentrations using the
hyperinsulinaemic euglycaemic clamp technique (De Fronzo et al 1979; see
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Chapter 2). A dose of insulin that maintained the plasma concentration in the high
physiological range (-150 mU/L) was associated with a 50% increase in plasma
noradrenaline, an increase in heart rate, but no change in blood pressure. A higher
dose of insulin that raised plasma concentrations of insulin to supraphysiological
levels (-600 mU/L), was associated with a 117% rise in noradrenaline and a
significant increase in mean blood pressure. The metabolic clearance of
noradrenaline was not altered by the insulin infusion.
Oral administration of 100 g glucose to 19 healthy subjects (which raised
plasma insulin levels to -50 mU/L) was associated with an increase of muscle nerve
sympathetic activity, measured by a microelectrode positioned in the peroneal nerve
(Berne et al 1989). Changes in muscle nerve sympathetic activity were apparent
within 15 minutes and there were concomitant increases in plasma noradrenaline, but
no change in plasma adrenaline. There was a small, but significant, increase in heart
rate, but no change in blood pressure. The sympathetic nerve activity to the skin was
examined in 3 subjects and showed no change, suggesting a selective augmentation
of sympathetic activity. There was no evidence of increased sympathetic outflow
when intravenous glucose was given in place of the oral load, and although the peak
plasma insulin level was similar, the duration of increase in circulating insulin was
very much less after intravenous glucose. This suggests that it was the
hyperinsulinaemia induced by the glucose load that was the stimulus, rather than an
increase in plasma glucose concentration.
In a study of 14 normotensive healthy young men, a two-step constant rate
intravenous infusion of insulin, which achieved steady state insulin concentrations at
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the upper end of the physiological range (-72 and -144 mU/L), increased muscle
nerve sympathetic activity, plasma noradrenaline level and heart rate, but there was
no change in systolic blood pressure and a fall in diastolic blood pressure (Anderson
etal 1991).
The most likely explanation for increased sympathetic activity induced by
insulin is a central action, although a baroreceptor mechanism cannot be excluded.
The fall in diastolic blood pressure in the latter study might be due to an unopposed
sympathetic vasodilator mechanism, although a direct vasodilator action of insulin is
possible and is discussed in the next section.
Lastly, there is evidence that insulin augments the pressor response to
noradrenaline but not to angiotensin II (Gans et al 1991a). In this study 9 healthy
males underwent a series of euglycaemic hyperinsulinaemic clamps (plasma insulin
-60 mU/L), and the pressor responses to noradrenaline and angiotensin II were
investigated. During hyperinsulinaemia, the plasma concentration of noradrenaline
required to raise diastolic blood pressure by 20 mm Hg was significantly reduced,
whilst there was no effect upon the pressor dose of angiotensin II. This provides
some evidence to support increased cardiovascular responsiveness to the sympathetic
nervous system during hyperinsulinaemia.
1.2.3 HAEMODYNAMIC EFFECTS OF INSULIN
The potential effect of insulin to increase blood pressure via an effect upon
the sympathetic nervous system was discussed in the preceding section, and an
alternative pressor mechanism, the antinatriuretic action, will be discussed in
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Section 1.2.4. Here I will discuss the vasodilator actions of insulin, which have
recently been reviewed by Anderson (Anderson et al 1993).
In the previous section, I described how raising the plasma insulin
concentration within the physiological range is associated with a rise in sympathetic
activity but often with no increase in blood pressure (Rowe et al 1981; Berne et al
1989), or even a fall in blood pressure (Anderson et al 1991). It was only when
plasma insulin was raised to supraphysiological levels that a rise in blood pressure
was produced (Rowe et al 1981). Evidence from animal (Liang et al 1982) and
human (Anderson et al 1991) studies have shown that the sympathetic
vasoconstrictor activation produced by insulin is opposed by vasodilation. This
provides an important mechanism by which insulin increases the supply of nutrients
to peripheral muscle in the postprandial state. The mechanism by which this is
achieved is unknown and there is evidence for both systemic and local dilator
mechanisms.
Systemic mechanisms
Sympathetic neural vasodilation to the skin occurs in insulin-induced
hypoglycaemia (Fagius et al 1989) and if this occurred in muscle it might provide an
explanation. Mitigating against this, however, is the observation that insulin produces
hypotension in patients with autonomic failure and presumed sympathetic
denervation (Mathius et al 1987).
A second systemic mechanism might be release of a substance known to
dilate the vascular bed in muscle. Adrenaline seems a likely candidate, but the
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vasodilator response to insulin has been shown in the absence of an increase in
circulating adrenaline (Liang et al 1982; Anderson et al 1991).
Local mechanisms
A number of potential local mechanisms have been suggested including:
(i) P adrenergic mechanisms; (ii) endothelium dependent relaxation; (iii)
stimulation of the sodium/potassium pump; (iv) increased CA2+-ATPase activity;
and (v) metabolic vasodilation.
(i) Studies both in animals (Liang et al 1982) and in humans (Creager et al 1985)
have shown that the skeletal muscle vasodilator effects of insulin are abolished by
pre-treatment with propranolol. In neither study did the insulin infusion cause an
increase in circulating adrenaline. The production of local p adrenergic receptor
stimulation in the absence of increased plasma adrenaline concentration raises the
possibility that an increase in insulin might augment the p adrenoceptor response to
adrenaline, as has been suggested for the a adrenoceptor response to adrenaline
(Gans et al 1991a).
(ii) In vitro studies have suggested a relaxing effect of insulin in canine arteries
(D'Orleans-Juste et al 1985), but this was present both in the presence and absence of
endothelium. Although preliminary studies in rat and guinea-pig did not support
insulin producing endothelium dependent vascular relaxation (Anderson et al 1993),
a recent study in 9 healthy volunteers has suggested that the vasodilator effects of
insulin in the forearm model are due to nitric oxide release (Scherrer et al 1994). In
this study, using a euglycaemic clamp to increase insulin concentrations to
~70 mU/L it was possible to show that the effects of hyperinsulinaemia in increasing
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forearm blood flow and decreasing forearm vascular resistance could be abolished by
pre-treatment with NG-mono-methyl-L-arginine (L-NMMA), a specific inhibitor of
the synthesis of endothelium derived nitric oxide (NO). Indeed, administration of the
glucose-insulin infusion was associated with a rise in blood pressure after pre-
treatment with L-NMMA. However, despite these haemodynamic changes, there was
no effect of treatment with L-NMMA on glucose uptake into muscle, indicating that
this is independent of NO. The NO synthase enzyme is constitutively expressed in
healthy endothelium and also exists in an inducible form in vascular smooth muscle
cells. Expression of the inducible form is stimulated by inflammatory mediators such
as interleukin-1 p and tumour necrosis factor-a which are released after vascular
injury. In vitro work has shown that insulin-like growth factor 1, and to a lesser
extent insulin itself, inhibit the release ofNO from vascular smooth muscle cells that
is stimulated by these mediators (Schini et al 1994). This suggests that insulin might
differentially affect the production ofNO by the constitutive and inducible forms of
NO synthase amongst vascular cells. Consequently, the effect of insulin might differ
from vasodilation in healthy vessels with intact endothelium to vasoconstriction in
diseased vessels with exposed intima-media components. In support of this, recent
data from subjects with vasospastic angina has suggested that fasting concentrations
of serum insulin correlate positively with the degree of abnormal coronary
vasoconstriction induced by intracoronary infusion of acetylcholine (Shimabukuro et
al 1995).
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(iii) The Na+-K+ pump and Na+-K+-ATPase are stimulated by insulin in many tissues
(Ferrannini et al 1988). In vascular smooth muscle, this can lead to hyperpolarisation
and relaxation, thus causing vasodilation.
(iv) It has been suggested that insulin may stimulate the Ca2 +-ATPase in the plasma
membrane, leading to vascular relaxation and blunting of vasoconstrictor response
(Zemel et al 1992).
(v) Insulin increases glycolytic flux and might cause metabolic vasodilation via net
extrusion of protons or other metabolic intermediates. This was investigated in 12
healthy subjects, in whom local administration of insulin to the forearm had no
haemodynamic action despite stimulation of glucose uptake and overall release of
protons, lactate and pyruvate (Natali et al 1990). The plasma concentration of insulin
attained in this study (-125 mU/L) was comparable to other studies (Anderson et al
1991) in which insulin was administered systemically and haemodynamic effects
were observed. This argues against a local vasodilator action of insulin.
In summary, there is conflicting evidence for both systemic and local
vasodilator actions of insulin. At present, the precise mechanisms remain obscure,
but the observation that insulin induced vasodilation can be blocked by L-NMMA in
man is most intriguing and points to endothelial release of nitric oxide as the final
effector pathway (Scherrer et al 1994).
1.2.4 INSULIN EFFECTS UPON ELECTROLYTE BALANCE
In 1933, Atchley reported the metabolic effects of the abrupt withdrawal of
insulin therapy from 2 diabetic patients. One of the most striking findings was a
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marked increase in urinary sodium excretion which commenced within 24 hours and
which reversed rapidly and completely on the resumption of therapy (Atchley et al
1933). The natriuresis commenced before hyperglycaemia and an osmotic diuresis
developed, and this may partly account for the profound loss of salt and water often
encountered in diabetic ketoacidosis.
De Fronzo demonstrated over 40 years later that an intravenous infusion of
insulin to healthy volunteers (steady state insulin concentration ~150 mU/L),
markedly reduced urinary sodium excretion whilst euglycaemia was maintained (De
Fronzo et al 1975). The decrease in sodium excretion was accompanied by a fall in
urinary potassium and phosphate, and by a rise in calcium excretion. These changes
occurred in the absence of a change in glomerular filtration rate and renal plasma
flow, and there was no change in plasma aldosterone. In a subsequent canine
experiment, De Fronzo showed that insulin enhances sodium reabsorption in the
distal tubule (De Fronzo et al 1976). The findings in humans were reproduced by
Skott, who also showed that the effect of insulin was located distally to the proximal
renal tubules, using lithium clearance as a measure of fluid output from the proximal
tubule (Skott et al 1989). In a study using 3 ascending doses of insulin, Gans et al
showed that the maximal reduction in fractional sodium excretion occurred within
the normal physiological range of insulin concentrations, and that supraphysiological
levels had no further effect (Gans et al 1991b).
It seems likely that the effect of insulin on sodium excretion in the distal
tubule is mediated via stimulation of Na+-K+-ATPase (Moore 1983), which is
abundant in the distal tubule (Jorgensen 1980). In an elegant study, Ferrannini et al
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demonstrated that the stimulation by insulin of Na+-K+ exchange in the human
forearm is independent of the effects of insulin on the stimulation of glucose
metabolism (Ferrannini et al 1988). In this study, an intra-arterial infusion of ouabain
abolished the stimulatory effect of insulin on potassium uptake, by inhibition of the
Na+-K+ pump, but had no significant effect on the rate of glucose uptake. This was a
very important observation, because it hints at a compartmentation of the actions of
insulin in vivo.
The influence of insulin on the renin-angiotensin-aldosterone system in
humans might be important when considering the possible effects of angiotensin
converting enzyme inhibition in hypertension or heart failure, but reports are
inconclusive. At circulating insulin concentrations well within the normal
physiological range (mean plasma insulin 66 mU/L) there was no effect upon plasma
aldosterone and plasma renin (Skott et al 1989). In another study, at a mean plasma
insulin concentration of 50 mU/L, there was a significant rise in plasma renin of
-50% compared to basal, but no change in aldosterone (Gans et al 1991b). A small
study which used an insulin infusion for only 40 minutes to raise plasma insulin to
160 mU/L (above the normal physiological range), found a significant increase in
plasma renin and angiotensin II, and a small fall in aldosterone (Trovati et al 1989).
These effects, however, could be attributed to the rapid insulin-induced decrease in
potassium encountered in this study, and they were abolished in a control study with
concomitant potassium replacement. There is some evidence from animal studies that
insulin may stimulate production of renin in the kidney and that this effect is
diminished in streptozotocin-induced diabetes (Jost-Vu et al 1992).
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Lastly, there is evidence that insulin stimulates renal Ca2+-ATPase activity in
several species (Levy et al 1989). Insulin also increases plasma membrane binding
and phosphorylation of calmodulin, which is an important regulator of Ca2+-ATPase
activity (Levy et al 1989). There is, however, much less evidence from human
studies to establish the important of insulin in calcium metabolism, although in De
Fronzo's study the infusion of insulin was associated with an increase in urinary
calcium excretion (De Fronzo et al 1975).
1.2.5 EFFECTS OF INSULIN ON SPECIFIC CELL TYPES
The general metabolic effects of insulin have been described. With regard to
arterial disease, 4 cell types are of particular importance, and the specific effects of
insulin on these cell types will be discussed. These 4 include endothelial and smooth
muscle cells from the arterial wall, and monocyte macrophages and platelets from the
circulation.
Regulation ofgene expression by insulin
After binding to its plasma membrane receptor, insulin can affect gene
expression in the eukaryotic cell and this has recently been reviewed (Castano 1991).
In general insulin seems to increase mRNA stability and its specific effect upon the
transcription of several genes has been investigated. There is evidence for increased
expression of some genes in the short term (minutes to 1 hour), and these include
hepatic glucokinase and the viral proto-oncogene c-myc. There are longer term delays
(1-24 hours) prior to increases in mRNA transcription for other genes, including
lipoprotein lipase in adipocytes and fatty acid synthetase in 3T3 cells. In contrast,
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insulin may reduce the transcription of certain mRNA including glucagon (short
term) and growth hormone (long term). These findings may be of importance in the
cellular proliferation which is characteristic of atheroma. Where there is information
on the effect of insulin upon DNA turnover in the individual cell types involved in
atheroma, it will be discussed below.
Endothelial cells
Human endothelial cells possess insulin receptors similar to those in other
tissues (Bar et al 1978). The effects of insulin upon endothelial cells from bovine
retinal artery and aorta were compared, and it was found that whilst insulin receptors
were present on both, endothelium of aortic origin was not sensitive to insulin, whilst
retinal artery endothelium responded with synthesis of glycogen and increased DNA
production (King et al 1983). This may be relevant to the pathogenesis of diabetic
retinopathy and in a broader sense might imply that the endothelium provides an
insulin resistant protective layer in parts of the arterial tree. More recently it was
shown that pathophysiological concentrations of insulin stimulate migration and
tube-forming activity of bovine carotid artery endothelial cells (Nakao-Hayashi et al
1992). This might suggest a role in endothelial repair but also might be relevant to
the neovascularisation which is a feature of the atherosclerotic plaque (Geiringer
1951).
Smooth muscle cells
Concentrations of insulin which are encountered in human subjects under
physiological and pathophysiological conditions have been shown to cause
proliferation of smooth muscle cells originating from primate (Stout et al 1975), rat
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(Weinstein et al 1981), bovine (King et al 1983) and human (Pfeifle et al 1981)
arteries. Although insulin receptors are present on the smooth muscle cell, there is
strong evidence that the mitogenic effects of insulin are mediated via the receptor for
insulin-like growth factor I (King et al 1980). Once again, this apparent support for a
compartmentation of the actions of insulin is a very important observation. This leads
to the suggestion that, in certain disease states, there may be defects in some, but not
all, of insulin's actions, such that there might, for example, be an ineffective
metabolic response but a normal proliferation response. It is also interesting that in
the experiments mentioned above, the maximal growth promoting effects of insulin
are often less than 50% those of bovine serum, which contains insulin-like growth
factors possessing much greater affinity than insulin at their own receptor (King et al
1985; Bornfeldt et al 1991). An observation from a situation which may be
analogous to insulin resistance being overcome by hyperinsulinaemia originated,
from a model of endothelial injury by balloon catheterisation in rats with
streptozotocin-induced diabetes who showed an impaired vascular smooth muscle
cell proliferative response to injury which could be overcome by chronic infusion of
either insulin or insulin-like growth factor I (Bornfeldt et al 1992).
Insulin stimulates DNA synthesis by arterial smooth muscle cells, even in the
absence of serum, and this may suggest that, in contrast to the endothelial cell, the
smooth muscle cell is particularly sensitive to insulin (Taggart et al 1980). More
recently, it has been shown that both insulin and insulin-like growth factor I cause an
increase in the expression of the proto-onocogene c-myc in human arterial smooth
muscle cells, although it was not clear which receptor was involved (Banskota et al
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1989a). The same group showed that insulin, insulin-like growth factor I and platelet
derived growth factor interact additively in the cellular proliferation and expression
of c-myc in bovine smooth muscle cell culture (Banskota et al 1989b). This raises the
intriguing possibility that insulin might be one of the agents that can modify the
phenotypic expression of the smooth muscle cell between contractile and synthetic as
reviewed recently by Ross (Ross 1993). However, some authors have suggested that
acute effects of insulin in enhancing vascular smooth muscle cell proliferation may
not persist in the presence of chronic stable hyperinsulinaemia (Ko et al 1993).
Two other effects of insulin may be of importance in the genesis of atheroma.
Firstly, the migration of smooth muscle cells into the subendothelial space in order to
release connective tissue proteins is central to their physiological role in repairing
damaged endothelium and, if it becomes unregulated, to the formation of the
atherosclerotic plaque. One of the chemoattractants released by activated platelets is
12-L-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE), and concentrations of
insulin in the physiological range (25-100 m/UL) stimulate the 12-HETE induced
smooth muscle cell migration in a manner dependent upon the prevailing glucose
concentration (Nakao et al 1985). An interesting finding of this study was that the
effect was only apparent when cells were pre-treated with insulin for several days
and there was no effect with acute exposure to insulin. The combination of a
relationship with glucose concentration and the need for long term incubation
implies that both an energy-dependent pathway and the synthesis of macromolecules
related to cell motility were necessary. A similar experiment using platelet derived
growth factor as a chemoattractant did not find evidence for augmentation of
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migration with insulin, but the lack of prolonged pre-exposure to insulin may be an
explanation (Grotendorst et al 1982).
Secondly, the exposure to insulin of human skin fibroblasts, which are very
similar to arterial smooth muscle cells, produces a downregulation of the number and
affinity of high density lipoprotein (HDL) receptors and an upregulation of the low
density lipoprotein (LDL) receptors (Oppenheimer et al 1989). In the same study it
was possible to show that HDL mediated cholesterol efflux from cholesterol loaded
cells was also significantly reduced. Thus, this study offered two mechanisms by
which insulin may increase the accumulation of cholesterol within the arterial wall.
One last observation that may have clinical relevance is that the insulin-
induced increases in RNA and protein synthesis in skeletal muscle cells are inhibited
by indomethacin (Palmer et al 1989). This suggests that eicosanoid metabolites of
arachidonic acid may play an important role in the long term control of myocyte
growth, and that this may be influenced by inhibition of cyclo-oxygenase.
Monocyte macrophages
There has been less work examining the effects of insulin on monocytes with
reference to arterial disease, although they are known to be rich in insulin receptors
(Gavin et al 1973). The synthesis of cholesterol within the monocyte is increased by
insulin via its effect upon the microsomal enzyme 3-hydroxy-3-methylgutaryl-CoA
(HMG-CoA) reductase, the rate-limiting step of sterol synthesis (Krone et al 1984).
More importantly, the same group have shown that physiological concentrations of
insulin stimulate the ability ofmonocytes to bind, accumulate and degrade LDL with
high affinity, probably via an influence on LDL receptor numbers (Krone et al 1988).
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Both of these observations may be relevant to the formation of foam cells from
monocyte macrophages in the atherosclerotic lesion.
Apoptosis
Apoptosis, or programmed cell death, is manifest in most animal tissues and
occurs when single cells die within otherwise healthy tissue (Wyllie 1993). There are
associated histological changes which are similar in different tissues, but the
molecular mechanisms involved are not known. Apoptosis differs fundamentally
from necrosis, the pathological form of cell death in which the cell swells and lyses,
because it is consistently characterised by cell shrinkage, condensation of
cytoplasmic and nuclear components, cleavage of chromosomal DNA into fragments
(-200 base pairs in length), and enhanced recognition of the cell by phagocytes.
There is increasing evidence that most animal cells contain cell suicide programmes
which may be activated or suppressed by signals from other cells, and that this
represents an anti-proliferative response. The most extreme view is that all cells
would undergo apoptosis in the absence of signals telling them not to (Raff 1992). As
discussed above, when fibroblasts are stimulated to proliferate in response to growth
factors, one response is increased expression of the proto-oncogene c-myc. There is
evidence that the cellular response to c-myc is critically dependent upon the
availability of certain growth factors, which may determine either proliferation or
apoptosis (Evan 1992). The most influential growth factor for fibroblasts seems to be
insulin-like growth factor I and it has been shown that insulin and insulin-like growth
factor I prolong survival, or inhibit apoptosis, in oligodendrocytes (Barres et al
1992). This raises the possibility that these agents are not proliferative factors, but are
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survival factors. Human umbilical vein endothelial cells undergo apoptosis if either
fibroblast growth factor or bovine serum albumin, which contains insulin-like growth
factor (Svrzic et al 1990), are removed from their medium (Araki et al 1990). Isolated
monocytes undergo apoptosis in the absence of exogenous stimuli (Mangan et al
1991) and this may be inhibited by cell adherence, microbial products, and some
cytokines, but is not inhibited by chemoattractants or other cytokines including
insulin-like growth factors (Mangan et al 1993).
Most interest in apoptosis has centred on its possible role in carcinogenesis,
although the possibility of an influence in chronic inflammatory disease has recently
been reviewed (Mangan et al 1993). A novel suggestion, if entirely speculative,
would be that a possible role for insulin in atherogenesis is in acting as a survival
factor for the cells involved in the "proliferation" of the atherosclerotic plaque by
preventing or delaying programmed cell death.
Platelets
Human platelets have been shown to possess insulin receptors (Hajek et al
1979), although the biological role of these receptors is largely unknown. Trovati et
al investigated the aggregatory response of platelets after incubation of platelet rich
plasma from normal volunteers with increasing doses of insulin for 5 or 30 minutes.
They observed a significant reduction of platelet sensitivity to all the aggregating
agents employed, including ADP, platelet-activating factor, adrenaline, collagen, and
arachidonate. This effect occurred at physiological concentrations of insulin (-40
mU/L), was reversible, and was time and dose-dependent (Trovati et al 1988). Kahn
et al showed that insulin increased binding of prostaglandin E, at the platelet
36
prostaglandin Ej/I2 receptor in platelet rich plasma from normal subjects, and that it
restored prostaglandin E( binding to normal level in platelets from 75% of patients
with acute coronary syndromes (Kahn et al 1991). This group found that the platelets
from 25% of patients with acute coronary syndromes appeared to be resistant to this
action of insulin. In a further study of patients suffering unstable angina or acute
myocardial infarction, they showed that intravenous boli of insulin increased
circulating levels of prostacyclin and decreased the minimum inhibitory
concentration of prostaglandin Ej for platelet aggregation to ADP. However, this
effect appeared to be abolished by the concurrent administration of aspirin (Kahn et
al 1992). Lastly, physiological concentrations of insulin increase intracellular
magnesium transport in human platelets, but have no effect upon calcium
concentrations (Hwang et al 1993). In the same study, insulin was shown to diminish
platelet aggregation to thrombin and to reduce production of thromboxane B2 and
12-HETE. These effects were abolished by a specific anti-insulin receptor
monoclonal antibody.
Thus, there is some evidence that concentrations of insulin in the postprandial
range inhibit platelet aggregation, although the teliological significance of this is not
clear. This effect is not present in some individuals with ischaemic heart disease and,
in addition, it may be blocked by administration of aspirin.
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1.3 EFFECTS OF INSULIN ON ARTERIES
Duff et al reported in 1954 that the failure of atheroma to develop in alloxan-
treated, cholesterol-fed rats was corrected when their insulin-deficient diabetic state
was treated with insulin replacement (Duff et al 1954). In a beautifully designed
study, Cruz et al observed in alloxan-treated diabetic dogs that the infusion of insulin
into the right femoral artery, compared to saline in the left femoral artery, was
associated with a significant increase in the cholesterol content of the artery (Cruz et
al 1961). In a series of studies, Stout showed that acute administration of insulin
stimulated lipogenesis and cholesterol synthesis in rat aorta, and then that chronic
treatment of chickens with insulin caused the development of atheromatous lesions in
the aorta (Stout 1968, 1969 and 1970). Almost 20 years later, Sato et al reported that
Wistar rats who were rendered hyperinsulinaemic by daily injections of insulin for
one year, developed atheromatous lesions in the aorta (Sato et al 1989). In particular,
the triglyceride content of the aorta was increased, and, at light microscopy, the
aortic intima of the insulin-treated rats, compared to saline-treated rats, was
significantly thickened and contained eosinophilic fibre bundles, amorphous ground
substances, and irregularly arranged cells. Electron microscopy confirmed that these
cells were of smooth muscle origin. Fasting concentrations of insulin were similar in
the 2 groups (27 v 26 mU/L) but the insulin injection caused an supraphysiological
peak (616 v 44 mU/L) and approximately 12 hours of hyperinsulinaemia. Despite
this, there was no effect upon plasma total cholesterol, triglyceride, phospholipid or
non-esterified fatty acids. Thus, this study supported the earlier work suggesting a
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role for insulin in the development of atheroma independent of any effect upon
circulating lipoproteins, and also demonstrated that the smooth muscle cell was
evident in these lesions.
Insight into the metabolic mechanisms that might be involved in these
changes was provided by a study in which a chronic hyperinsulinaemic state
associated with impaired glucose tolerance was induced in pigs by stimulating
production of antibodies to insulin (Falholt et al 1985a). In this study, the triglyceride
content of the aorta and of peripheral muscle was increased 10-15 fold compared to
control animals. Enzyme analysis showed increased activity of hydroxyacyl-CoA-
dehydrogenase, suggesting increased fatty acid oxidation, and higher concentrations
of glucose-6-phosphate dehydrogenase, possibly related indirectly to increased fatty
acid synthesis via a provision of NADPH. In general, the activity of enzymes
involved in glycolysis was decreased and there was evidence that the metabolic
derangement was more marked in the aorta than in muscle. Further studies from
Falholt et al using a canine model of chronic hyperinsulinaemia supported these
findings (Falholt et al 1985b).
Evidence for an influence of insulin on human arteries has recently been
provided from the ARIC study in which the mean thickness of the intima-media of
the carotid artery was measured in 7956 North American subjects using B-mode
ultrasound (Folsom et al 1994). In this study, fasting insulin showed a positive
correlation with artery wall thickness, with an estimated increase of 0.02 mm for an
increase of 14 mU/L plasma insulin. Unfortunately, no measure of stimulated insulin
response to glucose, or of insulin sensitivity, was made in this study.
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Not all studies have supported a role for insulin in the development of
atheroma. In general, the evidence suggests that it is chronic exposure to insulin
which leads to changes in the arterial wall. In one study, a single dose of insulin
failed to increase uptake of cholesterol into the aorta of rabbits (Christensen et al
1965). A more recent study of the acute proliferative response of the rat aorta to
balloon injury showed that exposure to increased insulin for 2-4 days after the injury
did not influence the acute proliferation response of the intima-media smooth muscle
cell (Ridray et al 1992).
1.4 PHYSIOLOGICAL EFFECTS OF INSULIN ON ENDOGENOUS
FIBRINOLYSIS
The ability of the blood to lyse intravascular thrombus using plasmin is
principally controlled by the balance between plasminogen activators and
plasminogen activator inhibitors. The observation that a positive correlation existed
in normal subjects between fasting insulin and plasminogen activator inhibitor type I
(PAI-1), the most physiologically important of the inhibitors (Vague et al 1986), led
to a number of studies which have attempted to explore the relationship between
these two.
In vitro studies
PAI-1 is synthesised in hepatocytes and endothelial cells in culture, and is
found in high concentrations in platelets. The effect of insulin on PAI-1 synthesis
was first studied in a comparison of hepatocytes from a human hepatocellular
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carcinoma cell line (Hep G2) and endothelial cells from human umbilical vein
(Alessi et al 1988). Using a range of insulin concentrations that remained within
physiological limits, Alessi et al showed a dose dependent increase of PAI-1 antigen
and activity in the culture medium of the hepatocytes, but there was no increase in
the endothelial cell culture. Using the same method they found no effect of human
proinsulin in either cell culture. The effect of insulin could be blocked by
cycloheximide and actinomycin D, indicating that it depended upon de novo protein
and RNA synthesis. Total protein synthesis was similar before and after stimulation
of the hepatocytes with insulin, suggesting that the increase in PAI-1 was a relatively
specific effect. Kooistra et al confirmed that insulin stimulated PAI-1 synthesis in
human hepatocytes using cells obtained from a liver transplant programme and they
showed that the increase in PAI-1 could be entirely explained by a concomitant
increase in PAI-1 mRNA levels (Kooistra et al 1989). A later study found no
influence of insulin on the production of tissue-type plasminogen activator (t-PA) in
hepatocyte culture (Seki et al 1990). More recently Anfosso et al showed that the
stimulating effect of insulin on PAI-1 synthesis by Hep G2 cells persisted even when
insulin receptor numbers were downregulated by prolonged exposure to insulin
(Anfosso et al 1993). In the same study, the stimulating effect of insulin on PAI-1
was inhibited by metformin, and although the exact mechanism of this is unknown, it




Attempts to show an acute influence of insulin on fibrinolysis in non-diabetic
humans have been much less revealing than the in vitro studies - probably because
of their short time scale and the difficulty in increasing circulating insulin
concentrations over a prolonged period in non-diabetic subjects.
Medvescek et al measured the PAI-1 response to a high calorie carbohydrate
meal in 10 lean and 11 obese individuals and suggested that there might be a
transient rise in PAI-1 antigen and activity at 1 hour, when insulin levels were at a
peak, and that this was superimposed upon the normal diurnal fall of PAI-1 seen over
the morning hours (Medvescek et al 1990). However, intravenous infusions of
insulin with glucose during a hyperinsulinaemic euglycaemic clamp in normal
subjects did not cause a rise in PAI-1 over 120 minutes (Grant et al 1990a), 6 hours
(Potter van Loon et al 1990) or over 3 hours (Vuorinen-Markkola et al 1992). One
study measured the response of both t-PA and PAI-1 to an intravenous glucose and
insulin infusion in 9 normal subjects and again failed to show any continuing
alteration of normal diurnal shift over a 2 hour period (Landin et al 1991).
Thus, whilst in vitro studies support a possible role for insulin in the
regulation of hepatic production of PAI-1, it is much more difficult to show an in
vivo effect in short term studies. Some indirect evidence is provided from studies in
which dietary changes to reduce calorie intake (Sundell et al 1989) or increasing
exercise (Williams et al 1980), both of which tend to reduce insulin levels, were
associated with improved fibrinolytic function, but actual insulin concentrations were
not measured in these studies.
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1.5 INSULIN IN ISCHAEMIC HEART DISEASE
The evidence for a role of insulin in patients with ischaemic heart disease can
be broadly divided into studies comparing populations with different levels of risk,
prospective longitudinal studies which have identified elevated insulin concentrations
to be a risk factor for developing ischaemic heart disease, and cross-sectional clinical
studies showing elevated concentrations of insulin to be a feature of patients with
established ischaemic heart disease.
1.5.1 POPULATION STUDIES
Epidemiological studies have shown that different populations have different
levels of risk for developing ischaemic heart disease. One approach to identifying
potential risk factors is to compare their in populations at different levels of risk and
extrapolate from this their possible influence. A few studies have used this approach
for insulin, but the Edinburgh-Stockholm study deserves special mention as it was
performed on our own population and because it was one of the major stimuli to
undertaking this thesis (Logan et al 1978). Twenty years ago the mortality from
ischaemic heart disease for 40 year old men was three times greater in Edinburgh
than in Stockholm. A study was designed to compare the prevalence of classical and
some potential new metabolic risk factors in matched cohorts of normal 40 year old
men from the two cities. Over a 6 month period, 107 Edinburgh men and 82
Stockholm men were studied. Edinburgh men were shorter, more obese, had higher
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blood pressure, smoked more cigarettes, drank more alcohol, had more resting
electrocardiographic abnormalities and lower exercise tolerance. Edinburgh men had
a more adverse lipid profile, lower levels of plasma and adipose tissue linoleic acid
and a lower polyunsaturated/saturated fatty acid ratio. However, and most
importantly for this thesis, in response to an oral glucose tolerance test, for an
identical glucose response, Edinburgh men had a much greater insulin response.
Although it was recognised that this implied insulin resistance, and this was 10 years
before Reaven's landmark lecture (Reaven 1988), amongst all the other findings of
the study, this one did not receive a great deal of attention.
A 12 year follow up of the Edinburgh cohort was undertaken and 11 men
were found to have suffered a cardiovascular event, which included the development
of angina, myocardial infarction, coronary artery surgery or sudden cardiac death
(Hargreaves et al 1992). There was no significant difference in baseline insulinogenic
indices between the men who developed one of the endpoints and men who remained
free of cardiovascular events. However, only 4 men suffered myocardial infarction in
this group (RA Riemersma, personal communication) and this makes it difficult to
draw any firm conclusion about insulin as a risk factor for myocardial infarction
within the Edinburgh population.
Four studies have sought abnormalities of insulin response in populations of
Asian origin within the United Kingdom and compared with subjects of European
ancestry. McKeigue et al described stimulated hyperinsulinaemia in 253 Bangladeshi
men and women living in London but they did not measure fasting insulin
(McKeigue et al 1988). In a subsequent and much larger study, both fasting and
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stimulated hyperinsulinaemia were a feature of 1421 South Asian men, and these
were also associated with electrocardiographic evidence ofpremature ischaemic heart
disease (McKeigue et al 1993). Stimulated hyperinsulinaemia was confirmed in a
different population of Asian men living in Bradford (Knight et al 1992). In a study
of patients surviving myocardial infarction, Hughes et al compared the 2 hour insulin
response in British Asian and white men and found even greater hyperinsulinaemia
in the Asian survivors (Hughes et al 1989).
1.5.2 PROSPECTIVE STUDIES
In the Helsinki Policemen Study, 982 men aged 35-64 years underwent a
baseline oral glucose tolerance test (glucose load 75 g or 90 g dependent on body
surface area) with measurement of plasma insulin at baseline fasting, 1 and 2 hours.
The major endpoints were fatal and non-fatal myocardial infarction, and after 5 years
these were more common in those with the highest insulin concentrations at each of
the above time points (Pyorala 1979). A further follow up after 9i/2 years showed
that these relative risks had persisted (Pyorala et al 1985). Other classical risk factors
that were also measured included blood pressure, total cholesterol and triglyceride
levels, smoking, body mass index, physical activity score and blood glucose. When
these factors were included in multivariate analysis, a significant independent excess
risk for those in the highest decile for 60 and 120 minutes insulin values persisted,
although the adjusted relative risk for fasting plasma insulin was not significant (p =
0.09). One interesting finding of this study in view of a recent suggestion that
cigarette smoking is associated with hyperinsulinaemia and insulin resistance
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(Facchini et al 1992) was that those who were current smokers (n = 426) had similar
fasting plasma insulin concentrations and significantly lower 2 hour insulin values
when compared with non-smokers.
In the Paris Prospective Study, 7246 men aged 43-54 years underwent a
baseline 75 g oral glucose tolerance test with measurement of plasma insulin
concentrations at fasting baseline and at 2 hours. The major endpoints were fatal and
non-fatal myocardial infarction, and after 5 years these were more common in those
with the highest insulin values (Ducimetiere et al 1980). In multivariate analysis
which also included total cholesterol, systolic blood pressure, cigarette consumption
and plasma glucose, only fasting plasma insulin concentration remained a significant
independent predictor of risk.
In the Busselton, Western Australia Study, 3390 men and women
representing 91% of the adult population of Busselton underwent a non-fasting 50 g
oral glucose tolerance test and a single blood sample was taken at 60 minutes. The
major endpoints were the 6 year incidence of ischaemic heart disease, including
stable angina, and the 12 year mortality from ischaemic heart disease. Men in the
highest quintile for plasma insulin were at significantly greater risk for all major
endpoints, but there was no apparent risk associated with hyperinsulinaemia in
women (Welborn et al 1979). A subsequent multivariate analysis of the 13 years
mortality in a subgroup of 1654 subjects from this study suggested that total
mortality in men aged 60-74 years was positively related to the 60 minute insulin
level, but that total mortality was negatively related to insulin in men aged 40-59
years (Cullen et al 1983).
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Thus, although these studies provide support for an aetiological role of insulin
in the development of ischaemic heart disease in men, they do not present a
consistent picture, with emphasis not resting clearly on either fasting insulin
concentrations or the stimulated insulin response to an oral glucose load. One
problem is that the inter-relationships which exist between insulin, blood pressure,
plasma lipids, body mass index, and possibly cigarette smoking, make the
interpretation of multivariate analysis suspect. As with many risk factors for
ischaemic heart disease, the importance of insulin for women is less clear, but what
evidence there is, recently reviewed by Fontbonne, suggests that hyperinsulinaemia
may not be a risk factor for ischaemic heart disease in women (Fontbonne 1991).
1.5.3 CROSS-SECTIONAL STUDIES
The initial report that plasma insulin concentrations were elevated in patients
with ischaemic heart disease was made by Peters and Hales in 1965. Seven patients
underwent an oral glucose tolerance test at a mean of 12 months from the time of
myocardial infarction and were found to have significant fasting and stimulated
hyperinsulinaemia when compared to controls. Since then there have been a number
of studies examining the glucose and insulin response to an oral glucose load and
some details of these are given in Table 1. Important factors to consider in the
interpretation of this data include:
(1) Sample size - from 7 patients (Peters and Hales 1965) to 499 patients
(Lichtenstein et al 1987, fasting blood sample only).
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(2) Many studies have exclusively included patients with prior myocardial
infarction, often at different times in their convalescence, and others have also
included patients with stable angina. No study has included an assessment of
ventricular function.
(3) Most studies have excluded diabetics but many have included patients with
abnormal or impaired glucose tolerance.
(4) Most studies have not excluded patients with a previous history of
hypertension.
Other than the sample size, the above considerations are important because
they may affect the expression of hyperinsulinaemia. The pathogenesis of episodes of
chronic stable angina and myocardial infarction are different. Whereas the presence
of atheroma is important for both, acute myocardial infarction develops as a
consequence of acute occlusive intracoronary thrombus, although episodes of
haemorrhage into a fissured plaque without luminal obstruction may contribute to the
progression of atheroma (Fuster et al 1992a, 1992b). The preceding discussion of the
actions of insulin has shown how it may influence either atheroma progression or
risk of thrombosis. The potential confounding effect upon hyperinsulinaemia of
impaired ventricular function and heart failure has not been addressed in any of these
studies. The neurohumoral response to chronic ventricular impairment (Bayliss J et al
1987) which leads to increased secretion of catecholamines, Cortisol and growth
hormone might have an important influence in antagonising the effects of insulin
(Brindley and Rolland 1989).
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Three conditions which are more prevalent amongst patients with ischaemic
heart disease than in the general population are hypertension, impaired glucose
tolerance and non-insulin dependent diabetes mellitus. All of these are associated
with hyperinsulinaemia and peripheral insulin resistance (Reaven 1988). Many
previous studies have included patients with these conditions and have failed to
address their potentially confounding influence.
Table 1 gives an overview of the published work and reveals that the most
consistent feature of patients with ischaemic heart disease is stimulated
hyperinsulinaemia in response to an oral glucose load. Three studies did not find
post-load hyperinsulinaemia. In one study which included patients without prior
myocardial infarction, insulin concentrations were lower in those with only angina,
and stimulated hyperinsulinaemia was only present in those with impaired glucose
tolerance (Gertler et al 1972). The study of Bergstrand et al examined male survivors
ofmyocardial infarction, but who were studied at a mean of 3 years from the time of
infarction, and who were matched by age and plasma lipids to controls (Bergstrand et
al 1979). Both the long delay from the time of infarction and the matching for plasma
lipids, which are often abnormal in the hyperinsulinaemia syndrome, may account for
the absence of a difference in insulin response between patients and controls. Lastly,
Jackson et al studied 7 men with myocardial infarction under the age of 40 years and
did not find hyperinsulinaemia to be a feature (Jackson et al 1983). Despite the small
size of this study, and in conjunction with the previous study, this might suggest that
hyperinsulinaemia was not important in young people with ischaemic heart disease.
However, this hypothesis is refuted by the larger series of Anders Hamsten, which
49
did find hyperinsulinaemia in 104 male survivors of myocardial infarction aged less
than 45 years (Hamsten et al 1987).
Three studies have described fasting hyperinsulinaemia in patients with
ischaemic heart disease. The studies of Peters (Peters and Hales 1965) and Larsen
(Larsen et al 1981) included only 7 and 10 subjects respectively. However, the very
large Caerphilly study suggested that fasting plasma insulin concentrations were 29%
higher amongst 499 patients with ischaemic heart disease compared to 1526 controls,
and because of its size this study had by far the greatest power of any to detect such a
difference (Lichtenstein et al 1987).
In summary, previous studies suggest that stimulated post-glucose load
hyperinsulinaemia is a feature of patients with ischaemic heart disease and possibly
fasting hyperinsulinaemia also. Analysis of these studies is hampered by
heterogeneous patient groups, the timing of studies with relation to myocardial
infarction, and failure to exclude subjects with other important conditions associated
with hyperinsulinaemia.
1.5.4 HYPERINSULINAEMIA AND THE METABOLIC SYNDROME
In trying to establish the significance of hyperinsulinaemia in the
pathogenesis of ischaemic heart disease it is difficult to dissociate the links between
insulin and other individual coronary risk factors. In particular a clustering of several
of these risk factors occurs in many individuals (Zavaroni et al 1987 and 1989). The
1988 Banting Lecture from Gerald Reaven was a very good introduction to the
possible role of insulin and this risk factor syndrome in human disease
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(Reaven 1988), and De Fronzo and Ferrannini have produced a more recent review of
the mechanisms which may be involved (De Fronzo and Ferrannini 1991).
Hyperinsulinaemia has been associated with hypertension, dyslipidaemia, upper-
body obesity, decreased physical activity, impaired glucose tolerance and non-insulin
dependent diabetes mellitus.
Young non-obese subjects with untreated moderately severe essential
hypertension have been shown to have stimulated hyperinsulinaemia and peripheral
insulin resistance (Ferrannini et al 1987). Most studies have described a positive
relationship between the degree of hyperinsulinaemia and blood pressure in
hypertensives, but several have not found such a relationship in normotensives. The
chicken and egg argument is difficult to resolve but possible aetiological mechanisms
for insulin include sodium retention at the kidney, effects on autonomic balance, and
direct haemodynamic effects.
In large population-based studies, hyperinsulinaemia has been associated with
a dyslipidaemic profile including raised levels of plasma very low density lipoprotein
(VLDL) cholesterol and triglyceride, raised levels of low density lipoprotein (LDL)
cholesterol and triglyceride, and low levels of high density lipoprotein HDL)
cholesterol (Modan et al 1988). Whilst the relationship between insulin, VLDL and
HDL cholesterol is strikingly consistent, there are discrepancies for the relationship
with total and LDL cholesterol. A recent study has suggested that individuals who
are hypercholesterolaemic but who have normal triglyceride levels do not have
abnormalities of glucose and insulin metabolism (Sheu et al 1993). The likely
mechanism by which insulin influences lipid profile is by stimulating hepatic VLDL
synthesis, which would explain the elevated total triglycerides, but the exact
mechanism for the reduction in HDL levels remains unclear.
It was assumed for many years that patients with impaired glucose tolerance
or non-insulin dependent diabetes mellitus were suffering from an absolute
deficiency of insulin. It is now clear that for the vast majority with impaired glucose
tolerance, and for those with non-insulin dependent diabetes mellitus who have not
reached an advanced stage of the disease, absolute concentrations of immunoreactive
insulin are greater than in normal controls both for fasting and stimulated, and that
this is due to the presence of peripheral insulin resistance (Reaven et al 1989).
Recently it has been suggested that conventional insulin assays may overestimate the
concentrations of insulin because of cross-reactivity with abnormally elevated levels
of pro insulin and proinsulin split products in non-insulin dependent diabetes (Temple
et al 1990). However, in subjects with diet-controlled diabetes (Clark et al 1992) and
in impaired glucose tolerance (Davies et al 1993) these do not seem to comprise a
significant proportion of the total.
Several groups have proposed a clustering of risk factors including
hypertension, dyslipidaemia, impaired glucose tolerance, obesity, hyperinsulinaemia
and insulin resistance. These have been referred to as the GOH conditions (Modan et
al 1985), Syndrome X (Reaven 1988) or the metabolic cardiovascular syndrome
(Hjermann 1992).
This metabolic syndrome was well illustrated in a study in which 32 healthy,
normotensive, non-obese subjects were identified as having hyperinsulinaemia on the
basis of having a fasting or post-glucose load insulin more than 2 standard deviations
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higher than the mean of a total group to 247 volunteers, all with normal glucose
tolerance (Zavaroni et al 1989). The hyperinsulinaemic group were matched for age,
sex and body mass index with 32 controls and were shown to have higher plasma
triglyceride levels, lower HDL cholesterol levels, higher systolic and diastolic blood
pressures, and higher post-load plasma glucose levels.
1.6 HYPERINSULINAEMIA AND INSULIN RESISTANCE
The terms hyperinsulinaemia and insulin resistance are often used
interchangeably but whilst the two conditions frequently coexist, the terms have
different meanings. Hyperinsulinaemia implies either abnormally elevated fasting
concentrations of insulin, or an increased insulin response to a stimulus - usually an
orally or intravenously administered glucose load. Insulin resistance describes a state
in which the biological effect of insulin on glucose metabolism is less than it should
be, and this usually leads to a chronic compensatory hyperinsulinaemia. However,
the ability of the pancreas to maintain this response may wane as islet cells become
exhausted and thus lead to the combination of insulin resistance with low circulating
levels of insulin. Such changes are thought to occur in many individuals as they
develop non-insulin dependent diabetes mellitus and glycaemic control deteriorates
(Saad et al 1989). The biological defect in most insulin resistant states is fairly tissue
specific (mostly involving skeletal muscle), selective (mostly involving insulin-
stimulated glucose uptake), pathway specific (mostly involving non-oxidative
pathways e.g. glycogen metabolism), and partial (i.e. a reduction in function but not
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a complete loss). However, some differences in the expression of insulin resistance
according to the clinical presentation are shown in Table 2. To what extent the
defects in insulin action extend to effects of insulin other than on glucose, such as
potassium balance, has not been clearly defined as yet. There is some preliminary
evidence that in obesity and in hypertension, insulin-mediated vasodilation may also
be impaired (Feldman and Bierbrier 1993).
In this thesis I do not use the terms hyperinsulinaemia and insulin resistance
interchangeably, and when insulin resistance is used it implies that a method of
quantifying insulin resistance has been used. The most widely accepted and "gold
standard" technique is the euglycaemic hyperinsulinaemic clamp described by De
Fronzo (De Fronzo et al 1979), its major advantage being that measurements are
made at steady state concentrations of glucose and insulin. A number of other
methodologies have been described, and are briefly reviewed in Chapter 2, but none
have usurped the primacy of the "clamp." The euglycaemic clamp has been used to
quantify insulin resistance in subjects with obesity, impaired glucose tolerance,
insulin dependent and non-insulin dependent diabetes mellitus, and essential
hypertension (Reaven 1988; De Fronzo and Ferrannini 1991). Whilst it has been
inferred that patients with ischaemic heart disease are insulin resistant, no studies as
yet have employed the euglycaemic clamp to evaluate this. Recently, two studies
have used alternative methods to suggest the presence of insulin resistance. Young et
al used the insulin suppression test in 20 patients with angiographically verified
coronary artery disease to show insulin resistance compared to controls, but failed to
exclude patients with impaired glucose tolerance and did not describe the presence of
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previous infarction or heart failure (Young et al 1993). Ley et al used a frequently
sampled intravenous glucose tolerance test combined with a mathematical model to
show insulin resistance in 37 non-obese men with angina and abnormal coronary
angiograms (Ley et al 1994). The complexity and time-consuming nature of the
euglycaemic clamp preclude its use in large scale clinical studies, but it nevertheless
remains the least controversial of the different methods for measuring insulin
sensitivity.
1.7 EFFECTS OF DRUG THERAPY ON HYPERINSULINAEMIA AND
INSULIN RESISTANCE
The vast majority of work investigating the pharmacological manipulation of
insulin responses has been carried out in subjects with either hypertension or diabetes
mellitus or both. Very few studies have addressed the effects of commonly
prescribed drugs in patients with ischaemic heart disease, and for compounds
including (3 adrenoceptor antagonists, calcium antagonists, angiotensin converting
enzymes (ACE) inhibitors, and diuretics, it tends to be assumed that their effects
would be the same in hypertension and ischaemic heart disease. The possible effects
on insulin resistance of presently available and new agents which are under
development was recently reviewed by Donnelly and Morris (Donnelly and Morris
1994).
The effect of p blockers on glucose tolerance and insulin response in patients
with ischaemic heart disease was studied in a comparison of the effects of
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propranolol and acebutolol (Birnbaum et al 1983). There was no change in insulin
secretion in this study. Other chronic studies have employed only hypertensive
subjects and no clear effect has been demonstrated (Ekberg et al 1977; Day et al
1979; Berglund et al 1981; Lehtonen 1984; Cressman et al 1985). One study, which
used the euglycaemic clamp to measure insulin sensitivity, suggested that chronic
administration of atenolol and metoprolol was associated with a decrease in insulin
sensitivity (Pollare et al 1989a). However, this study is difficult to interpret because
of a significant weight gain in both groups over the study period. In a recent review it
was concluded that there is no evidence for an adverse effect of (3j -selective (3
blokers on glucose and insulin parameters (Sawicki and Berger 1992).
There is no compelling evidence for an adverse metabolic effect of calcium
antagonists, and in particular no support for an influence of these agents on glucose
and insulin responses, despite an extensive literature which has been reviewed by
Trost (Trost 1987).
An overview of studies which have explored the possible influence of ACE
inhibitors on hyperinsulinaemia and insulin resistance appears in Table 3. Although
a large number of such studies have been reported in the last few years, it is striking
how few have employed adequate experimental design with, for example, double-
blind conditions and placebo control. One of the earliest and most influential reports
appeared from Pollare et al and compared the effect of captopril and
hydrochlorothiazide in 50 hypertensive subjects who underwent metabolic
investigations after a placebo run-in period, after 4 months treatment with one drug
followed by a 4 week washout phase and then 4 months treatment with the other drug
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(Pollare et al 1989b). Unfortunately, analysis was hampered by a hangover effect of
thiazide treatment and therefore results were presented as a parallel group study of
the first treatment period only. There was no hangover effect with captopril.
Captopril was shown to increase glucose disposal, the measure of insulin sensitivity,
from 5.7 to 6.3 mg/kg/min (p < 0.05), whereas hydrochlorothiazide caused a decrease
from 6.4 to 5.7 mg/kg/min (p < 0.01). Captopril had no effect upon fasting glucose,
insulin or lipoproteins, but did cause a significant decrease in the stimulated insulin
response to an intravenous glucose load. This group recently reported a follow up
after 2-3 years treatment with captopril in a minority subgroup of the original cohort
and found that the initial improvement in insulin sensitivity appeared to be
maintained, although differences between baseline and 2 years were no longer
statistically significant (Lind et al 1994).
Since the original study there have been many others which have looked at
normal subjects, hypertensives, diabetics, and hypertensive diabetics, and which have
investigated a variety of ACE inhibitors. No consistent picture has emerged, with the
strongest evidence of an effect being for captopril. No study has found an effect on
fasting insulin and only two have suggested a fall in stimulated hyperinsulinaemia.
Four studies using the euglycaemic clamp have reported an increase in insulin
sensitivity, three after treatment with captopril and one after enalapril, and with
durations of treatment ranging from a single dose to 4 months. Eight studies of
various ACE inhibitors using a variety of methods to measure insulin sensitivity have
found no effect. One recent study which included both animal and clinical
experiments and which compared an ACE inhibitor with a sulphydryl group
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(captopril) to two without (enalapril and delapril), found that only captopril was
associated with an increase in insulin sensitivity (Uehara et al 1994). Also in this
study, only captopril was associated with an increase in plasma bradykinin; and
infusion of a bradykinin antagonist abolished the effect of captopril on insulin
sensitivity. This lead to the conclusion that ACE inhibitors with a sulphydryl group
may have the most potent effects on insulin action and that one possible mechanism
is via an effect on bradykinin. This view is supported by earlier evidence that
captopril enhanced forearm uptake of glucose in diabetic patients in association with
a rise in kinin levels (Jauch et al 1987). The same group later showed that in post
operative subjects an infusion of bradykinin increased glucose disposal (Hartl et al
1990).
Other mechanisms by which ACE inhibitors might enhance insulin action
include the inhibition of the formation of angiotensin II and their vasodilator action.
As discussed earlier (Section 1.2.4), there is no strong evidence to show an effect of
insulin upon the renin-angiotensin system, and likewise there is little evidence for a
direct effect of components of the renin-angiotensin system at physiological
concentrations on insulin action (Morris et al 1993). There is much stronger evidence
that skeletal muscle blood flow is important in determining muscle glucose uptake
(Ganrot 1993), which is one of the main defects in the insulin resistance syndrome,
and thus improved muscle blood flow secondary to ACE inhibition might explain
improved insulin action. Furthermore, one study has shown that prazosin, another
vasodilator, improves insulin sensitivity in hypertensive subjects (Pollare et al 1988).
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Two recent studies which infused pressor doses of angiotensin II (Buchanan
et al 1993; Townsend et al 1993) to normal volunteers showed an increase in insulin-
mediated glucose disposal, and in patients with Type 2 diet-controlled diabetes
mellitus Morris found that both subpressor and pressor doses of angiotensin II
improved glucose uptake (Morris et al 1994). It remains unclear as to whether these
effects can be wholly accounted for by alterations in muscle blood flow caused by
the haemodynamic effects of angiotensin II, or whether it may perhaps have some
unsuspected metabolic effect, but the former seems most likely.
It is widely known that the thiazide diuretics are associated with a
deterioration in glucose tolerance which may sometimes be clinically important and
Pollare et al confirmed that hydrochlorothiazide caused a decrease in insulin
sensitivity as discussed above (Pollare et al 1989b). These drugs tend to be used in
the management of hypertension, but in normotensive patients with ischaemic heart
disease the need for diuretics arises when cardiac failure develops and in this
situation loop diuretics are usually employed. Although there are case reports of
these being associated with deterioration of glucose tolerance (Toivenen and Mustala
1966), in studies which examined their effect upon glucose tolerance and insulin
response when given for hypertension (Jackson and Nellen 1966) or for heart failure
after myocardial infarction (Efendic et al 1984) there was no evidence of an effect on
hyperinsulinaemia.
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1.8 ENDOGENOUS FIBRINOLYSIS AND THE RISK OF THROMBOSIS
After a prolonged period of controversy, it is now accepted that the cause of
acute myocardial infarction in the overwhelming majority of cases is the formation of
occlusive thrombus within a coronary artery (De Wood et al 1980). Thrombosis
results from the deposition of abnormal quantities of fibrin and platelets within the
vessel lumen. Initially platelets adhere to the vessel wall, a further platelet
aggregation takes place, and then the platelets discharge their contents locally. The
crucial point after activation of the coagulation cascade from either the intrinsic or
extrinsic pathway is the development of thrombin. Thrombin stimulates the
formation of soluble fibrin monomer from circulating fibrinogen, and thereafter
insoluble fibrin polymer precipitates and fibrin crosslinking takes place. Platelets, red
blood cells and other circulating components are adsorbed onto the thrombus and it
becomes established. However, a system exists which, in the basal state, is equal and
opposite in action to the forces of coagulation, the fibrinolytic system. This system
ensures the formation of plasmin, which is generated locally from plasminogen, and
this digests the fibrin component of the thrombus leading to its partial or complete
dissolution. Over the last quarter century there has been a great increase in the
understanding of the molecular basis of this system, which in combination with the
development of recombinant DNA technology, has lead to the enormous clinical
benefit derived from the use of therapeutic thrombolytic agents. Thus, occlusive
thrombus forms within a vessel when circumstances within the vessel allow the
equilibrium between the pro-thrombotic and fibrinolytic systems to be disturbed in
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favour of thrombosis. At the same time, by either using pharmacological
thrombolytic agents, or possibly by enhancing endogenous fibrinolysis, it is possible
to restore that equilibrium, and with it, vessel patency.
Plasminogen is a circulating proenzyme which is only converted to plasmin
within the circulation in the presence of fibrin. Plasmin is able to digest fibrin and
also fibrinogen, factor V and factor VIII. To ensure that fibrinolysis remains a local
phenomenon, plasmin is rapidly inactivated by circulating alpha-2 antiplasmin, and
to a lesser extent by alpha-2 macroglobulin and CI esterase inhibitor.
The conversion of plasminogen to plasmin is brought about by plasminogen
activators, of which 2 have been identified and these are presently available as
commercially produced pharmacological agents. Named according to their initial site
of identification, these are tissue-type plasminogen activator (t-PA) and urokinase-
type plasminogen activator (u-PA). Although both are found within the circulation, it
is t-PA which appears to be the more important generator of plasmin within the
intravascular space, particularly as its activity is greatly enhanced in the presence of
fibrin. Both t-PA and u-PA may exist as single chain (sc) or two chain (tc) molecules
and t-PA is most active in its sc form.
The plasminogen activators are inhibited by 2 specific inhibitors,
plasminogen activator inhibitor type 1 (PAI-1) and plasminogen activator inhibitor
type 2 (PAI-2). PAI-1 is synthesised in the liver and by vascular endothelium, and is
found in low free circulating concentrations but high concentrations within platelets
(Booth et al 1988). PAI-2 was first identified in the placenta and can be detected in 2
molecular forms in the plasma of pregnant women, but is not normally detectable in
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the plasma of healthy, non-pregnant individuals. Alpha-2 macroglobulin and CI
esterase inhibitor may also play a small role in inhibiting the plasminogen activators.
Thus, the two most important components in the control of the fibrinolytic system
appear to be t-PA and PAI-1. The overall activity of the endogenous fibrinolytic
system is governed by a number of factors including:
(i) the presence of fibrin. Plasminogen and t-PA bind to fibrin polymer where they
are favourably juxtaposed to generate plasmin in a site where it is to an extent
protected from antiplasmin by the fibrin structure.
(ii) the endothelium. The endothelium is a site of production for both t-PA and PAI-
1, and may respond to different stimuli for each of these. Local production of t-PA is
likely to be of crucial importance in ensuring successful endogenous fibrinolysis
(reviewed by Emeis in 1992). An important observation is that t-PA which is present
prior to thrombus formation both impedes the formation of thrombus and accelerates
the dissolution of thrombus by the addition of further t-PA in vitro, and in an animal
model subthrombolytic doses of t-PA could prevent thrombus formation (Fox et al
1985). The endothelium may also play an important role in governing intravascular
flow and other pro- or anti-thrombotic influences such as activating protein C, which
binds and inactivates PAI-1, or prostacyclin, which inhibits further platelet
aggregation.
(iii) the presence of inhibitors. Within the circulation, alpha-2 antiplasmin is the most
important inhibitor and rapidly inactivates free plasmin. However, within an
intravascular thrombus the concentrations of PAI-1 are much higher, probably
because of the large platelet component, and in this setting PAI-1 may be the more
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important. PAI-1 is found in the endothelial cells and smooth muscle cells of healthy
human arteries but in diseased arteries there is increased expression of PAI-1 mRNA
within the cellular component of the atheromatous plaque which may promote
thrombus function at the site of plaque rupture (Lupu et al 1993).
(iv) The clearance of fibrinolytic components. Hepatic clearance of t-PA is rapid but
the exact mechanism is unclear (Brommer et al 1988). PAI-1 is probably cleared as a
complex with t-PA in the liver, but this is difficult to quantitate because the liver also
produces PAI-1.
1.9 PHYSIOLOGICAL CONTROLS OF TISSUE-TYPE PLASMINOGEN
ACTIVATOR AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE I
The physiological pathways which control the activity of the endogenous
fibrinolytic system are incompletely understood. Although a number of influences
have been identified, it is difficult to place these in any hierarchical order.
It has long been recognised that there is a marked diurnal variation in
endogenous fibrinolysis, with a peak activity in the afternoon and a nadir in the early
morning hours (Fearnley et al 1957). It is of note that this mirrors the known
circadian variation in the incidence ofmyocardial infarction (Muller et al 1986). This
rhythm has now been shown to be mainly due to large variations in PAI-1, which
peaks in the early morning, and much smaller variations in t-PA. This has been
confirmed in normal subjects (Andreotti et al 1988; Grimaudo et al 1988) and in
patients with stable (Angleton et al 1989) and unstable (Huber et al 1988) coronary
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artery disease. The diurnal pattern does not appear to follow changes in insulin,
Cortisol or catecholamines (Chandler et al 1990).
Adopting upright posture is associated with an increase in overall fibrinolytic
activity, a rise in t-PA antigen level, and no change in PAI-1 (Winther et al 1992).
Physical exercise is associated with a rise in fibrinolytic activity (Hamouratidis et al
1988), and recently it has been shown that this is only partially accounted for by the
exercise induced increase in circulating adrenaline (Chandler et al 1992). The role of
adrenergic mechanisms in influencing fibrinolysis was investigated in Edinburgh by
Cash, who showed that the rise in plasminogen activator caused by an intravenous
infusion of adrenaline was unaffected by practolol and only partially antagonised by
propranolol (Cash et al 1970). The possible effects of p adrenoceptor antagonism on
fibrinolysis were recently reviewed (Teger-Nilsson 1991) but in a previous study of
20 patients with stable angina treated for 6 months with either metoprolol or epanolol
(a pi selective antagonist with intrinsic sympathomimetic activity) I was unable to
show any effect upon either t-PA or PAI-1 (Wright et al 1994). Other possible
hormonal influences on haemostasis have been reviewed by Grant and Medcalf
(Grant and Medcalf 1990) but I would like to concentrate on 2 which may be of
clinical relevance - for one, angiotensin II, there is only preliminary evidence; and for
the other, insulin, there is a large body of evidence. The most important issues here
are which components of the fibrinolytic system are modulated by these hormones
and to what extent they exert either an acute modifying action or a chronic influence
on fibrinolytic balance, and whether this is direct or via secondary effects.
64
In a study of 10 volunteers, 4 normotensives and 6 with essential
hypertension, Ridker et al investigated the effect of an intravenous infusion of
angiotensin II upon t-PA and PAI-1 antigen concentrations (Ridker et al 1993a).
Compared to only 4 controls who received a control infusion of dextrose, the
infusion of angiotensin II was associated with a small fall in t-PA but caused a
significant increase in PAI-1 concentrations, which occurred against the normal
diurnal fall of PAI-1. This study was important because it suggested a potentially
important relationship between the renin-angiotensin system and risk of thrombosis.
The time course of the experiment suggests a direct effect of angiotensin II on PAI-1
but does not identify the site of release - most probably from liver but possibly from
endothelium or platelets. It also suggested the possibility that ACE inhibitors might
influence fibrinolysis and risk of thrombosis. Two in vitro studies have investigated
this further; in one angiotensin I and angiotensin II were shown to stimulate
expression of mRNA for t-PA and PAI-1 in cultured rat aortic smooth muscle cells
and the effect of angiotensin I was abolished by the addition of captopril (van
Leeuwen et al 1994), and in the other angiotensin I and angiotensin II stimulated
PAI-1 mRNA production in cultured bovine aortic endothelial cells and the effect of
angiotensin I could be abolished by captopril (Vaughan et al 1995). These studies
support an effect of angiotensin II upon fibrinolysis within the vascular tree and also
hint at the potential importance of the local renin-angiotensin system.
The evidence for a role of insulin in the physiological control of fibrinolysis
was discussed earlier in this chapter and here I will discuss the possible influence of
insulin on fibrinolysis in various pathological conditions. Vague and colleagues first
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reported a significant positive correlation between fasting insulin and PAI-1 in
normal and obese subjects (Vague et al 1986) and then went on to describe the same
relationship in 2 groups of patients, 67 patients with angina pectoris, of whom only
15 had suffered previous myocardial infarction (Juhan-Vague et al 1989a), and
38 patients with non-insulin dependent diabetes mellitus (Juhan-Vague et al 1989b).
Recently a study of 1484 patients with angina pectoris who were undergoing
coronary angiography reported on the associations between fasting insulin
concentrations and components of the fibrinolytic system (Juhan-Vague et al 1993a).
The strongest relationships were between insulin and PAI-1 antigen and activity (r =
0.44, p < 0.0001) and between insulin and t-PA antigen (r = 0.36, p < 0.0001). The
evidence for a link between hypofibrinolysis and insulin resistance was reviewed by
Juhan-Vague who made two important points, firstly that the strength of the
association between insulin and PAI-1 was very similar in all patient groups that had
been studied, and secondly that the relationship was consistent only for fasting
insulin concentrations, with less evidence for the importance of stimulated insulin
responses (Juhan-Vague 1991). A positive correlation between PAI-1 and insulin
resistance measured by the euglycaemic clamp has been shown in obese subjects
(Landin et al 1990) and in non-insulin dependent diabetes (Potter van Loon et al
1993) but has not been studied in other patient groups.
The in vitro evidence for insulin increasing hepatic secretions of PAI-1 was
reviewed earlier (Section 1.4). An alternative mechanism is that the
hypertriglyceridaemia that is also a feature of the hyperinsulinaemic syndrome may
be important, and this was supported by an experiment that showed that the very low
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density lipoprotein (VLDL) particles from hypertriglyceridaemic subjects are a
potent stimulus to PAI-1 secretions from endothelial cells in culture (Stiko-Rahm et
al 1990). In a more recent study of hypertriglyceridaemic and normotriglyceridaemic
men from the same investigators, they confirmed that hypertriglyceridaemic men had
significantly higher PAI-1 activity, fasting insulin and stimulated hyperinsulinaemia
(Asplund-Carlson et al 1993). In univariate analysis the usual relationship between
fasting insulin and PAI-1 was present, but in multivariate analysis only VLDL
triglyceride concentrations remained a significant predictor. However, the problems
of performing multivariate analysis with variables that are so closely linked must be
borne in mind.
Most information regarding the hyperinsulinaemic-hypofibrinolytic
relationship has been gained from studies in subjects with non-insulin dependent
diabetes mellitus and some interesting observations may be worthy of note. In a
study of 51 fasting diabetics, Nagi et al found that a significant correlation was only
present between PAI-1 and fasting levels of 32-33 split proinsulin, and not with total
immunoreactive insulin (as measured in the standard assays) or total insulin (by
specific IRMA assays) or proinsulin (Nagi et al 1990). However, the link between
PAI-1 and both fasting immunoreactive insulin and a derived insulin resistance score
has since been confirmed (Gough et al 1993).
Two studies have examined the effect on PAI-1 of chronic treatment of
insulin resistant Type 2 diabetic patients with exogenous insulin, which might
worsen the situation if hyperinsulinaemia is important or alternatively might improve
it if overcoming insulin resistance is important. After 16 weeks of insulin treatment
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in 19 patients with secondary failure to sulphonylureas there was no change in either
t-PA or PAI-1 antigen concentrations, despite as improvement in glycaemic control
(Vukovich et al 1992). However, in a crossover comparison of sulphonylureas or
insulin in 11 Type 2 diabetics, there was a significant decrease in PAI-1 activity after
8 weeks treatment with insulin (Jain et al 1993), suggesting that overcoming insulin
resistance might be important. Other therapeutic strategies may also have an
influence. In a study in which insulin was not measured, the standard dietary advice
issued to 14 newly diagnosed Type 2 diabetics was responsible for a significant fall
in PAI-1 activity over 12 weeks (Bahru et al 1993), but there was no association
between this and concomitant changes in glycaemic control, body mass index and
serum triglycerides. Lastly, a number of studies in diabetic subjects have suggested
that the biguanide oral hypoglycaemic agent metformin, which increases insulin
sensitivity, improves fibrinolytic function in association with a suppression of PAI-1
(Grant 1991).
Thus, there is good evidence for basal insulin levels having a modulating
influence on endogenous fibrinolysis via an effect on PAI-1, and possibly t-PA also.
There is some evidence to suggest that this may, at least in part, reflect the
disturbances of triglyceride metabolism associated with hyperinsulinaemia. There is
no evidence to support an acute effect of exogenous insulin, and conflicting evidence
of a chronic effect of exogenous insulin administration in non-insulin dependent
diabetes mellitus.
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1.10 CLINICAL STUDIES OF FIBRINOLYTIC PARAMETERS IN
ISCHAEMIC HEART DISEASE
Disturbances of t-PA and PAI-1 have been described in many disease states
(Kruithof et al 1988). Three recent reviews have specifically addressed their role in
the pathogenesis of ischaemic heart disease (Hamsten 1993; Juhan-Vague and Alessi
1993b; de Bono 1994). The idea that fibrinolysis might be important in
atherosclerotic disease is far from new (Astrup 1956) and early studies showed
fibrinolytic function to be impaired both around the time of acute myocardial
infarction (Ogston and Fullerton 1965) and in the convalescent phase after
myocardial infarction (Chakrabarti et al 1968). These initial studies relied on tests of
global fibrinolytic function, such as the euglobulin clot lysis time, and did not
measure specific fibrinolytic components. Before reviewing more recent studies
which have included assays of t-PA and PAI-1, two prospective studies are worthy of
mention. Between 1972 and 1978, 1511 healthy white men aged between 40 and 64
years were recruited into the Northwick Park Heart Study. Initial results after a mean
follow up of 10 years suggested that plasma fibrinogen and factor VII were the most
important predictors of major ischaemic heart disease events (Meade et al 1986).
However, after a mean follow up of 16 years, dilute blood clot lysis time was the
most important predictor of a fatal or non-fatal events in men who were aged 40-
54 years at enrolment (Meade et al 1993). In this study the haemostatic variables
were consistently stronger predictors of events than plasma cholesterol. It only
became apparent that fibrinolysis was important in the younger group after extended
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follow up because it took that length of time for enough events to accrue in a group
initially at lower risk. However, in the Goteborg study (Wilhelmsen et al 1984),
which established fibrinogen as a risk factor for primary cardiovascular events,
fibrinolytic activity, measured by euglobulin lysis on a fibrin plate, failed to
distinguish those who had events during 13.5 years follow up. This population had a
mean age of 54 years, but events were not specifically analysed with respect to age
and therefore it is possible that impaired fibrinolysis is a risk factor for younger age
groups only.
A large number of studies have now addressed the possible importance of t-
PA and PAI-1 in patients with established ischaemic heart disease. An overview of
these is represented in Tables 4, 5, and 6. Table 4 gives the results from studies of
patients with stable ischaemic heart disease, the majority of whom were studied when
they were attending for routine coronary angiography. A consistent observation from
these studies was a lack of any relationship between the extent of coronary artery
stenoses and fibrinolytic parameters. The principal finding was of elevation PAI-1
activity. PAI-1 antigen was usually increased when it had been measured, and
interestingly, t-PA antigen levels also were higher than in controls. Measurements of
t-PA activity in these groups did not reveal differences from controls. Three studies
suggested that PAI-1 levels were higher in patients with a previous history of
myocardial infarction than in those with stable angina (Aznar et al 1988; Juhan-
Vague 1989a; The ECAT Angina Pectoris Study Group 1993).
Table 5 shows the results from studies of patients in the convalescent phase
of myocardial infarction at times from 8 weeks to 3 years. The work of Anders
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Hamsten was the most important in drawing attention to the possible relevance of
PAI-1. He recruited male survivors ofmyocardial infarction who had been aged less
than 45 years at the time of presentation and undertook a prospective cohort study.
He initially identified that this group had elevated levels of the recently recognised
PAI-1, accompanied by decreased t-PA activity in the presence of raised levels of t-
PA antigen (Hamsten et al 1985). Subsequently he showed that elevated PAI-1
activity was a marker for increased risk of reinfarction, but did not report the
relationship with baseline t-PA measurements (Hamsten et al 1987b). An interesting
observation from other studies was that depressed t-PA activity and increased PAI-1
activity may be implicated in subjects who suffer myocardial infarction but have
relatively trivial coronary artery disease (Verheught et al 1987).
Table 6 displays data from studies in which t-PA and PAI-1 were measured
around the time of presentation, and sometimes during follow up, in patients with the
acute coronary syndromes of either unstable angina or acute myocardial infarction.
Once again the most frequent finding was of elevated PAI-1 activity and in many
studies t-PA antigen concentrations were also increased. Several studies suggested
that PAI-1 activity was higher in those with acute myocardial infarction, and
therefore with presumed occlusive thrombosis, than in those with unstable angina. A
very interesting suggestion, first proposed by Lucore, was that in patients treated
with t-PA thrombolytic therapy, there may be a rebound increase in PAI-1 at the end
of the infusion which might be associated with an increased risk of failure to achieve
vessel patency or for reocclusion to occur (Lucore et al 1988). Evidence has been
provided from a number of angiographic studies to support this (Barbash et al 1989;
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Andreotti et al 1990; Sane et al 1991) and in a prospective study using non-invasive
markers to assess reperfusion (Gray et al 1993c).
The most damaging criticism ofmuch of this work, however, is that the case-
control design of most of these studies does not answer the question of whether the
disorders of fibrinolytic parameters encountered in patients with established disease
represents cause or effect. The important early studies which outlined that these
factors might indicate risk of subsequent events were those of Hamsten showing that
greater PAI-1 activity predicted risk of reinfarction (Hamsten et al 1987b), and of
Gram, which received much less attention and which suggested that decreased t-PA
activity and, counter-intuitively, increased t-PA antigen also predicted risk of
reinfarction (Gram et al 1987a and 1987b). Later, two studies found that in patients
with unstable or severe stable angina pectoris baseline levels of t-PA antigen, and
not PAI-1, predicted the likelihood of future myocardial infarction (Munkvad et al
1990a; Jansson et al 1991). These studies helped to underline that disturbances of
endogenous fibrinolysis might play a causal role in the future development of
myocardial infarction, but two pieces of stronger evidence were to be published in
1993.
In the US Physicians' Health Study, designed to investigate the place of
aspirin in primary prevention, baseline blood samples were taken and plasma stored.
After a mean of 5 years, 231 individuals had developed myocardial infarction and
they were matched for controls from within the same study who remained free of
disease (Ridker et al 1993b). Plasma concentrations of t-PA antigen, but not of PAI-
1, were significant predictors of the risk of infarction. This suggested that disorders
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of endogenous fibrinolytic precede the development of acute syndromes associated
with occlusive thrombosis by many years. Further support for this hypothesis came
from the same study when Ridker reported that the risk of stroke was similarly
predicted by baseline levels of t-PA antigen (Ridker et al 1994). A recent study has
supported a role for altered fibrinolysis in the early stages of atherosclerosis in
asymptomatic individuals in whom those with increased intima-media thickness of
the carotid artery had elevated plasma concentrations of tPA and PAI-1 antigen
(Salomaa et al 1995). Furthermore, in a follow up of their study first published in
1991, Jansson et al reported that in 213 patients who had presented with severe
angina pectoris, baseline concentrations of t-PA antigen, and not PAI-1, predicted
mortality at a mean follow up of 7 years (Jansson et al 1993). Of special note, this
finding also applied to the 78% of patients in this group who had undergone coronary
artery bypass grafting shortly after their initial presentation. These findings have now
been confirmed in a large cohort study of 3043 patients with chronic stable angina
followed up for 2 years in whom an increased risk of myocardial infarction or sudden
death was associated with higher baseline concentrations of t-PA antigen (Thompson
et al 1995).
Thus, although initial impressions were that it was measurements of PAI-1
activity which were indicative of the importance of endogenous fibrinolysis, the
pendulum has now swung in favour of the assay of t-PA antigen. This apparent
paradox is perhaps not too difficult to explain. Firstly, t-PA and PAI-1 can either be
measured in terms of their total mass concentration by measuring their antigenicity in
plasma, or in terms of their functional ability. The majority of t-PA and PAI-1 in the
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circulation exists in a 1:1 complex which is functionally inert but has maintained
antigenicity. Short term variations in fibrinolytic activity seem to be governed by
changes in the release of PAI-1, and there is good evidence that thrombosis induces
both the secretion of PAI-1 (Fujii et al 1991) and the expression of PAI-1 mRNA
(Fujii et al 1992). The majority of t-PA that is secreted becomes quickly bound to
PAI-1 and therefore exists in the functionally inactive complexed form, whilst the
minority exists in a free, functionally active form. This explains the positive
correlation that is reported between PAI-1 antigen and activity, and between PAI-1
activity and t-PA antigen, but the negative correlation between t-PA antigen and
activity (Olofsson et al 1989; Chandler et al 1994). Perhaps because of the marked
diurnal variation in PAI-1, it appears that plasma concentrations of t-PA antigen
more accurately reflect the overall activity of the fibrinolytic system and, by
implication, the overall pro-thrombotic tendency. The recent evidence suggests that
both of these may be abnormally elevated for many years prior to a failure of the
fibrinolytic system leading to a clinical thrombotic event.
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1.11 SUMMARY
This review has attempted to present the evidence for hyperinsulinaemia and
endogenous fibrinolysis being implicated in the pathogenesis of ischaemic heart
disease. In addition, the possible links between the two have been discussed. The
most important points are:
(1) Insulin has many diverse actions mediated through more than one type of
receptor and these include effects upon metabolism, the autonomic nervous
system, vascular tone, electrolyte balance, cell growth and arterial structure,
thrombosis and fibrinolysis.
(2) There is evidence to support an aetiological role for hyperinsulinaemia in the
development of myocardial infarction and hyperinsulinaemia is a feature of
patients with established ischaemic heart disease.
(3) Hyperinsulinaemia usually reflects underlying resistance to the effects of
insulin on glucose metabolism. To what extent insulin resistance extends to
other actions of insulin is unclear.
(4) It is possible to modify hyperinsulinaemia in patients with hypertension and
diabetes mellitus using drugs and/or non-pharmaceutical intervention.
(5) Occlusive vascular thrombosis occurs when there is an imbalance between
the pro-thrombotic forces and the endogenous fibrinolytic system.
(6) Disturbances of tissue plasminogen activator and plasminogen activator
inhibitor type 1 are a feature of patients with ischaemic heart disease and may
be used to predict prognosis.
(7) Insulin appears to be an important modulator of endogenous fibrinolysis. An
association between hyperinsulinaemia and impaired endogenous fibrinolysis
has been shown in subjects with obesity, non-insulin dependent diabetes
mellitus, and ischaemic heart disease.
Rationale for the work performed for this MD Thesis
I have attempted to extend previous observations relating to the nature of
hyperinsulinaemia in ischaemic heart disease and to further investigate the
relationship between insulin resistance and endogenous fibrinolysis in patients with
ischaemic heart disease. When seeking to discover whether it was possible to modify
either or both of these I was influenced by the recent studies suggesting that
angiotensin converting enzyme inhibitors improve prognosis in patients with mild
left ventricular dysfunction following myocardial infarction (Pfeffer et al 1992; The
SOLVD Investigators 1991 and 1992) and by the unexpected reduction in the
incidence of acute coronary syndromes in these studies (Pfeffer et al 1992; Yusuf et
al 1992). I have sought to answer the following questions:
(1) Is the extent of hyperinsulinaemia in patients with ischaemic heart disease
influenced by the extent of left ventricular impairment or by a history of
myocardial infarction as opposed to chronic stable angina.
(2) Impaired glucose tolerance is a risk factor for developing ischaemic heart
disease and is associated with hyperinsulinaemia and insulin resistance. The
incidence of impaired glucose tolerance is high in patients with ischaemic
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heart disease and I sought to answer whether this further increased degree of
hyperinsulinaemia.
(3) Insulin resistance in patients with ischaemic heart disease has not been
quantified using the hyperinsulinaemic euglycaemic clamp. Insulin resistance
may be favourably modified by angiotensin converting enzyme inhibitors in
some patient groups. I have quantified insulin resistance in patients with
previous uncomplicated myocardial infarction and investigated whether it is
modified by the angiotensin converting enzyme inhibitor captopril.
(4) In this same patient group I have investigated the relationship between
hyperinsulinaemia, insulin resistance, and components of the endogenous
fibrinolytic system. The effect of captopril on tissue-type plasminogen
activator and plasminogen activator inhibitor type 1 was defined.
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TABLE 2. Defects in insulin-mediated glucose metabolism assessed
by the euglycaemic clamp (adapted from de fronzo and ferrannini
1991)
Obesity NIDDM Hypertension




Suppression of hepatic glucose
production
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CHAPTER 2
A REVIEW OF METHODS USED IN THIS THESIS
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2.1 INTRODUCTION
In this chapter I shall review briefly some aspects of the methods which have
been employed in the studies described in this thesis. Where relevant I shall describe
any validation work that I have performed.
2.2 ORAL GLUCOSE TOLERANCE TEST
The cornerstone of the data presented in Chapters 3 and 4 is the 75 g oral
glucose tolerance test (OGTT) as described by the World Health Organisation
(World Health Organisation 1985). Important factors in the performance of this test
include asking the subjects to (i) fast for 10-12 hours; (ii) take an unrestricted diet
including at least 150 g of carbohydrate for 3 days prior to the test; and (iii) not
smoking on the day of the test and avoiding alcohol consumption for 24 hours prior
to the test. I routinely performed the tests with subjects seated and I placed an
intravenous cannula for blood sampling 30 minutes prior to commencing the test.
The cannula was flushed between samples with normal saline or "Hepsal," a solution
of 10 U/mL heparin. Prior to sampling, 5 mL of blood was withdrawn and discarded
to exclude the "deadspace."
The standard 75 g of glucose monohydrate in 200 mL water was administered
over less than 3 minutes. Further blood samples were taken at 30 minute intervals for
at least 2 hours. Samples for measurement of plasma glucose were taken into fluoride
oxalate anticoagulant to prevent glucose uptake into red cells, and samples for
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measurement of plasma insulin were taken into lithium heparin, placed on melting
ice and plasma separated within one hour by centrifugation and stored at -40°C.
Plasma glucose was measured by the hexokinase method (Schmidt 1973) on a Cobas
Bio analyser. Plasma insulin was measured by radioimmunoassay using the double
antibody technique (Soeldner and Slone 1965) by kind arrangement with Professor
George Alberti at the Department of Medicine at the University of Newcastle Upon
Tyne. Important aspects of the insulin assay are discussed later.
The OGTT has many advantages in clinical research. It is easily understood
by the subject and is widely acceptable by being minimally invasive. It provides the
simplest, although crude, estimation of insulinogenic indices in terms of the fasting
insulin concentration, the 2 hour insulin concentration or the area under the insulin
curve. In addition all of these may be corrected for the prevailing glucose
concentration. It is probably best to use the OGTT to quantify fasting and stimulated
insulin responses and not to infer from these tissue insulin sensitivity because that is
inevitably derived from the former. The validity of using the OGTT in non-diabetic
subjects to infer estimates of insulin secretion and insulin resistance was recently
confirmed for studies comparing different patient populations (Phillips et al 1994).
However, it must be remembered that under circumstances where insulin secretion is
altered (e.g. non-insulin dependent diabetes mellitus or by certain drugs) then it is
difficult to interpret, and it also fails to give direct information on tissue sensitivity to
insulin. It is interesting to note that it is only in the last 10 years that it has become
firmly established that the majority of glucose disposal (-75%) after an oral glucose
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load is into insulin-sensitive peripheral muscle and that this is associated with an
~50% reduction in hepatic glucose output (Ferrannini et al 1985).
2.3 INSULIN ASSAYS
The principle of the radioimmunoassay used in Newcastle is the competition
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between a constant amount of I-labelled insulin and the sample insulin for the
available binding sites on a fixed amount of guinea-pig anti-insulin serum (Soeldner
and Slone 1965). Separation of soluble antibody-bound insulin is facilitated by using
an antibody raised in rabbits to guinea-pig globulin (the double antibody technique).
Important features of this assay are its coefficient of variation which is 6.8-7.5%, and
that it shows less than 20% cross reactivity with proinsulin and 32,33-split
proinsulin. There has been considerable concern recently that many
radioimmunoassays may significantly overestimate plasma insulin concentrations
because of a combination of high cross-reactivity of the assay with abnormally high
circulating levels of proinsulin and its split products (see Temple et al 1992, for a
review). However, it now seems that it may only be in non-insulin dependent
diabetics who exhibit poor glycaemic control that concentrations of these
components are high (Temple et al 1990) and obscure a real insulin deficiency
(Temple et al 1989). In diet-controlled diabetics (Clark et al 1992), in subjects with
impaired glucose tolerance (Davies et al 1993), and in subjects with normal glucose
tolerance who are at high risk of developing non-insulin dependent diabetes (Haffner
et al 1994), these molecules comprise < 20% of the total immunoreactive insulin
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measured by radioimmunoassay. Because the insulin assay used for my studies has
< 20% cross reactivity with proinsulin and its split products, and because only non-
diabetic subjects have been included in my studies, that implies that < 5% of the total
immunoreactive insulin measured in my studies could be accounted for by proinsulin
or its split products.
2.4 ASSESSMENT OF INSULIN SENSITIVITY
A number of approaches to quantifying insulin sensitivity have been
developed by many different investigators but it is interesting to note that the
conclusions of a review of these methods written over a decade ago (Reaven 1983)
and of several more recent ones (Starke 1992; Groop et al 1993; Donnelly and Morris
1994) are not very different; the majority of investigators favour the euglycaemic
hyperinsulinaemic clamp (De Fronzo et al 1979). Briefly, the main requirement of
any of these techniques is that they reveal a measurable relationship between the
plasma concentration of insulin and some quantifiable action of insulin on glucose
metabolism. The tests employed should ideally fulfil a number of additional
specifications which include (i) that the plasma insulin concentration is sufficient to
suppress hepatic glucose production, so that the rate of glucose uptake is not
underestimated; (ii) that a steady state condition is produced during which
measurements can be made; (iii) that the plasma glucose concentration during the
measurement of insulin sensitivity does not itself influence the result because,
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particularly at low insulin concentrations, glucose uptake is partly dependent upon
plasma glucose concentration.
The two most commonly used alternative methods to the clamp are the
frequently sampled intravenous glucose tolerance test (FSIVGTT) in combination
with a mathematical model, and the insulin suppression test (1ST) using a combined
infusion of insulin and glucose with or without the addition of somatostatin or
adrenaline and propranolol. Each of these has their own merits, and in particular both
are less laborious than the clamp, but there are some drawbacks. The mathematical
model usually used with the FSIVGTT (Bergman 1989) inevitably makes
assumptions about the compartments in which events take place, such that insulin
action is in a "remote" compartment, but it does provide detailed information on the
early and late phases of insulin secretion. The 1ST involves a continuous constant
rate infusion of glucose and insulin, with either somatostatin (Harano et al 1977) or
adrenaline and propranolol (Greenfield et al 1981) to suppress insulin secretion, and
the steady state plasma glucose which is achieved after 2-3 hours is used as a
measure of insulin sensitivity. The disadvantages of this technique are that the steady
state plasma glucose concentration is often high and thus might influence its own
uptake, that a true steady state is difficult to achieve, and that both intravenous
infusion of somatostatin and of adrenaline are not without hazard or side effects.
2.4.1 THE EUGLYCAEMIC HYPERINSULINAEMIC CLAMP
For the studies reported in Chapter 5 of this thesis I used this technique as
originally described in 1979 by De Fronzo. The essence of this method is that the
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plasma insulin concentration is raised to a level at the upper end of the physiological
range and the plasma glucose concentration is "clamped" at the basal level by a
variable rate glucose infusion. The rate of the glucose infusion is adjusted according
to frequent blood glucose determinations and when a steady state has been achieved,
the glucose infusion rate is equal to the rate of whole body glucose disposal (M
value, expressed in mg/kg.min). The M value should be corrected for the prevailing
plasma insulin concentration to provide the most accurate measure of insulin
sensitivity.
Clamp protocol
Subjects attended the department at 08.30 hours having observed the same
restrictions as for the oral glucose tolerance test. They lay recumbent on a couch for
the whole procedure and were asked to place their left hand within a heated water
jacket in the shape of an open-ended cylinder which allows the hand to be entered to
beyond the wrist and a thermometer to enter from the opposite end before the ends of
the cylinder were sealed with foam and surgical dressing. The temperature inside the
arm heater was kept between 55 and 65°C by altering the thermostatic control on the
water heater. The purpose of heating the hand is to "arterialise" the blood in the veins
of the dorsum of the hand. Recently, possible problems with this technique have been
raised (Anstrup et al 1988; Gallen and MacDonald 1990) depending on the method of
heating and I therefore undertook a validation of my method which is presented in
the next section.
After 10 minutes a 21 G intravenous cannula was inserted retrogradely into a
vein on the dorsum of the left hand and connected to a 3-way tap and continuous
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(2 mL/hr) saline flush system. An 18 G cannula was inserted into a large antecubital
vein and connected via a 3-way tap to both the 20% glucose solution (with 20 mmol
KCL added to 500 mL 20% glucose), which was delivered via an IMED Gemini
infusion pump, and the insulin infusion, given via a Graseby 50 mL syringe driver.
The insulin solution was made of 20 units Human Actrapid insulin (Novo) in 45 mL
of normal saline with 5 mL of the subjects own blood added to prevent absorption of
the insulin onto plastic surfaces. The subjects rested for 30 minutes and 2 arterialised
venous blood samples were taken 15 minutes apart to confirm that the blood glucose
level was stable (< 0.2 mmol difference) prior to commencing the study. The mean of
these two results was used as the target blood glucose concentration for clamp studies
in that subject.
The insulin infusion was given at a constant rate of 40 mU/m body surface
area min after a 10 minute priming infusion given according to the schedule in
Table 7. The aim of this regime is to raise the plasma insulin concentration to -100
mU/L during the period of the clamp.
The glucose infusion was commenced after 4 minutes at a rate of
2 mg/kg.min, and increased at 10 minutes to 2.5 mg/kg.min. Thereafter the rate is
adjusted according to the formula described by De Fronzo which is dependent upon
measurements of blood glucose made at 5 minute intervals.
S; - SVj + SMj
where for time i:-
Si = the glucose infusion rate (mL/hr) at time i
SVj = that portion of the glucose needed for the volume component
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SMj = that portion of the glucose needed for the metabolic component
SVj = (Gd-Gi) x (0.684 x body weight)
where
Gd = desired blood glucose concentration
G; = blood glucose concentration at time i
SM; = SMj.2 x (Gd/Gj) x (Gd/Gj.j)
where
SMj.2 = SM; from 10 minutes earlier
Gi_! = Gj from 5 minutes earlier
These calculations can be performed very quickly on a pocket calculator,
despite their appearance, and all calculations were recorded on a custom form for
each individual. In practice, and after personal discussion with Professor Alberti and
Dr Ferrannini, the investigator may override the result of these equations in order to
achieve a steady state more quickly once he becomes familiar with the technique, but
the results from the calculations provide a good estimate of the correct infusion rate.
The target for the investigator was to maintain the blood glucose level at Gd
(or within 0.1 mmol/L) for at least the last 60 minutes of the clamp. The blood
glucose level was measured every 5 minutes using an autoanalyser based on the
glucose oxidase method (Yellowsprings Institute, Yellowsprings, Ohio). This
provides a result within 90 seconds of the sample being presented.
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Samples for blood glucose were taken into 2 mL tubes containing fluoride
oxalate anticoagulant. Samples for plasma insulin determination were taken into 5mL
lithium heparin tubes and placed onto melting ice and treated as described for the
oral glucose tolerance test. Samples for insulin assay were taken at -15, 0, 60, 70, 80,
90, 100, 110, and 120 minutes, in order to know the prevailing plasma insulin
concentration during the last hour of the clamp.
At the end of the study, the insulin infusion was switched off and the 20%
glucose infusion was continued for 30 minutes to prevent rebound hypoglycaemia
which occurs as a result of the inhibition of hepatic glucose production. A
measurement of plasma potassium was taken at the end of the study to ensure that
adequate potassium replacement had been given over the course of the clamp, which
proved to be so in every case.
The measure of insulin sensitivity used for my studies was the quotient of the
whole body glucose disposal over the last hour and the prevailing plasma insulin
concentration over the last hour.
2.4.2 "arterialised" venous blood sampling
For all of the methods ofmeasuring insulin sensitivity it has been emphasised
that arterial blood glucose monitoring is to be preferred because, under the conditions
of these methods, the circulating insulin concentration is elevated and the extraction
of glucose across the capillary bed will be increased. However, the insertion of intra¬
arterial cannulae is regarded as unacceptable for routine studies by most investigators
and instead they opt to heat the hand to open up arterio-venous channels and make
95
the venous blood "arterialised." A cannula inserted retrogradely in the dorsum of the
hand then samples blood which has undergone very little extraction of oxygen or
nutrient molecules. Recently the use of warmed electric blankets to heat the arm has
been criticised (Anstrup et al 1988) and other techniques to heat the air around the
hand in a closed box have been developed (Gallen and MacDonald 1990). I opted to
design my own system, partly for reasons of economy. With the help of Dr
Riemersma, we constructed a cylindrical water jacket inside which the hand could
rest to beyond the wrist and was supported so as to avoid direct contact with the wall.
A thermometer was placed next to the hand, but not in contact with any surface, and
the temperature inside the cylinder was kept at 60°C (range 55-65°C) by altering the
thermostat on the water heater which was incorporated into the pump system
ensuring circulation of the water.
In order to validate this new system we studied 8 patients who were
undergoing elective cardiac catheterisation and who had an indwelling femoral artery
sheath through which arterial samples could be obtained. After their investigation
they were taken to the clinical investigation area where they placed their arm in the
arm heater for 120 minutes. In order to obtain results over a range of glucose values,
the subjects received a constant rate infusion of 20% glucose (360 mg/kg.hr) and
insulin (50 mU/kg.hr) over the course of 120 minutes. "Arterialised" venous and true
arterial samples were taken every 30 minutes or analysis of plasma glucose. Taking a
mean of 40 samples, "arterialised" venous blood glucose levels were 1.9% lower
than true arterial samples (Table 8). After 120 minutes, the mean "arterialised"
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venous oxygen saturation was 2.3% lower than true arterial blood (Table 9). These
results are very comparable to those achieved with other methods (Liu et al 1992).
Fibrinolyticparameters
Details of the commercial kits used for the measurement of tissue-type
plasminogen activator (t-PA) antigen and plasminogen activator inhibitor 1 (PAI-1)
antigen and activity are given in Chapter 6.
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Table 7. Insulin prime during the euglycaemic clamp
Time Insulin infusion rate













Table 8. Plasma glucose concentrations in 8 subjects
Time (min) 0 30 60 90 120
Femoral artery glucose 5.8(0.6) 10.8(0.8) 11.9(1.0) 12.6(1.5) 11.5(2.3)
(mmol/L
"Arterialised" glucose 5.7(0.6) 10.5(0.8) 11.8(0.7) 12.2(1.5) 11.4(2.3)
(mmol/L)
Data are mean (SD)
Table 9. Arterial and "arterialised" venous oxygen saturations
Subject 1 2 3 4 5 6 7 8 Mean (SD)
Femoral artery (%) 91 94 93 89 91 92 92 91 91.6(1.5)
"Arterialised" (%) 88 93 89 89 87 88 91 89 89.3 (1.9)
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CHAPTER 3
HYPERINSULINAEMIA IN ISCHAEMIC HEART DISEASE:
THE IMPORTANCE OF MYOCARDIAL INFARCTION
AND LEFT VENTRICULAR FUNCTION
100
3.1 SUMMARY
Elevated circulating insulin levels have been reported in ischaemic heart
disease and may be of aetiological importance. Previous studies have not considered
the potential influence of heart failure or of previous myocardial infarction as
opposed to stable angina. I therefore measured the insulin response to a 75 g oral
glucose tolerance test in 5 groups with normal glucose tolerance, comparing normal
male controls to men with chronic stable angina, men with recent myocardial
infarction assessed either at 3 weeks or 3 months after the acute event, and men with
chronic severe heart failure. Only patients with chronic heart failure had fasting
hyperinsulinaemia and this probably reflected the associated neuroendocrine
abnormalities. Stimulated hyperinsulinaemia was present in all patient groups but
was less pronounced and of shorter duration in patients with angina. At 120 minutes,
only patients with heart failure or previous myocardial infarction were
hyperinsulinaemic. The degree of stimulated hyperinsulinaemia was not influenced
by the presence of heart failure or by the length of time from infarction.
Hyperinsulinaemia is associated with impaired peripheral muscle glucose uptake and
metabolism and might contribute to the development ofmuscular fatigue on exertion
in patients with previous myocardial infarction or with heart failure.
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3.2 INTRODUCTION
Hyperinsulinaemia has been described in obesity, impaired glucose tolerance
(IGT), non-insulin dependent diabetes mellitus, hypertension and ischaemic heart
disease (IHD) (Reaven 1988). Insulin may have a direct role in the development of
atherosclerosis or may influence other risk factors for IHD, such as blood pressure
and lipoproteins (Stout 1990). The relationship of fasting and stimulated
hyperinsulinaemia to IHD has not been clearly defined. Previous studies in which an
oral glucose load was given to patients with IHD have frequently reported stimulated
hyperinsulinaemia (Peters and Hales 1965; Nikkila et al 1965; Tzagournis et al 1967;
Tzagournis et al 1968; Kashyap et al 1970; Malherbe et al 1971; Gertler et al 1972;
Berchthold et al 1972; Sorge et al 1976; Larsen et al 1981; Hamsten et al 1987a;
Lichtenstein et al 1987), less often fasting hyperinsulinaemia (Peters and Hales 1965;
Larsen et al 1981; Lichtenstein et al 1987) and two studies have failed to show
fasting or stimulated hyperinsulinaemia (Bergstrand et al 1979; Jackson et al 1983).
Earlier studies were limited as they frequently involved only patients with previous
myocardial infarction and they failed to differentiate the importance of heart failure.
Often patients with IGT or diabetes mellitus were not excluded (Nikkila et al 1965;
Tzagournis et al 1967; Tzagournis et al 1968; Kashyap et al 1970; Malherbe et al
1971; Gertler et al 1972; Berchthold et al 1972; Sorge et al 1976; Hamsten et al
1987a; Lichtenstein et al 1987; Bergstrand et al 1979) and patients and controls were
not matched for other important confounding variables including age, body mass
index (BMI) or blood pressure (Peters and Hales 1965; Nikkila et al 1965;
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Tzagournis et al 1967; Tzagournis et al 1968; Malherbe et al 1971; Gertler et al 1972;
Berchthold et al 1972; Sorge et al 1976; Larsen et al 1981; Hamsten et al 1987a;
Lichtenstein et al 1987; Bergstrand et al 1979; Jackson et al 1983). The administered
glucose load has not been the standard 75 g in all studies and the subsequent blood
sampling has sometimes been limited to 60 minutes.
The immunoreactive insulin (IRI) response to a 75 g oral glucose tolerance test
was measured over 120 minutes in 5 groups with normal glucose tolerance matched
for age, BMI and blood pressure. I have compared normal male controls to men with
chronic stable angina, men with myocardial infarction assessed either at 3 weeks or
3 months after the acute event and men with severe chronic heart failure.
3.3 METHODS
Subjects
Normal control subjects (n = 22) were identified at random from the Lothian
Health Board register and they had no previous history of hypertension, IHD or
family history of diabetes mellitus. They were taking no regular medication and had
a normal 12 lead electrocardiogram. Patients with stable angina (n = 15) were
identified on the basis of a typical history of exertional chest pain and the
development of significant electrocardiographic changes (> 1 mV ST segment
depression 0.06 seconds after the J point) during treadmill exercise testing. None had
any clinical evidence of heart failure. At the time of study they were receiving
nifedipine and none were taking (5 blockers. The 2 groups of patients with recent
myocardial infarction had an initial diagnosis based upon World Health Organisation
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criteria. One group was studied 3 weeks after the acute event (MI Group I, n = 26)
and one group was studied 12 weeks after the acute event (MI Group II, n = 15).
None of these patients had symptomatic heart failure and all were taking aspirin.
Twenty (77%) of the patients in MI Group I and all those in MI Group II were taking
a cardioselective p blocker. Patients with chronic heart failure (n = 16) were free of
oedema but remained severely restricted (all NYHA grade III). At the time of study
the heart failure group were all receiving a loop diuretic with potassium supplements
and none were taking an angiotensin converting enzyme inhibitor.
I screened 93 patients attending the out patient department with established
IHD and with fasting plasma glucose < 6.7 mmol/L using a 75 g oral glucose
tolerance test. Twenty-one (23%) patients were found to have IGT or diabetes
mellitus according to World Health Organisation criteria (2 hour glucose > 11
mmol/L = diabetes, > 7.8 mmol/L = IGT) (World Health Organisation 1985) and
were excluded from this analysis because both of these conditions have previously
been associated with hyperinsulinaemia (Reaven 1988).
Data from 72 patients and 22 normal controls are presented. Details of age,
BMI (weight/height2), blood pressure, smoking habit and left ventricular ejection
fraction are given in Table 10. The 5 groups were well matched for age, BMI and
blood pressure. Ten (63%) of the patients with chronic heart failure were smokers
compared to less than 10% in the other groups. Measurement of left ventricular
function was made by radionuclide ventriculogram in patients with a history of
myocardial infarction or heart failure. MI Group I and MI Group II had similar and
well preserved left ventricular function, whereas the group with NYHA grade III
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heart failure had significantly decreased left ventricular ejection fraction by
comparison with those groups.
The study received the approval of the Lothian Health Board Ethical
Committee for medical research.
Oral glucose tolerance test
Patients and controls attended the department after a 12 hour overnight fast.
An indwelling 16 G intravenous cannula was inserted into an antecubital vein and
they rested for 30 minutes. After a baseline blood sample they took 75 g glucose
monohydrate in 200 mL water. Further blood samples were taken at 30, 60, 90 and
120 minutes. Samples were placed on ice and plasma separated within one hour and
stored at -40°C. Each sample was assayed for glucose and IRI. Glucose was
measured using a Cobas Bio analyser by the hexokinase method (Schmidt 1973) with
an interassay coefficient of variation of 1.7%. IRI was measured by
radioimmunoassay (Soeldner and Slone 1965) with a coefficient of variation of 6.8 to
7.5%. This assay does not differentiate between insulin, proinsulin and proinsulin
split-products.
Statistical analysis
Descriptive data are expressed as mean (SEM). Areas under the curve (AUC)
were calculated using the trapezium rule. Glucose values are expressed as arithmetic
mean (95% CI ofmean). Values for insulin and insulin/glucose ratio were compared
after logarithmic transformation and are expressed as geometric mean (95% CI of
mean). Analysis of variance (ANOVA) was used to assess differences among the
means of the groups. Where ANOVA revealed a significant difference between the
105
5 groups, further pairwise comparisons were made using Fisher's least-significant-
difference test. Data was stored on a Dell 486P/33 personal computer and statistical
analyses were performed using SYSTAT for Windows, Version 5 (Systat Inc. 1992,
Evanston, Illinois). The level of significance was taken to be p < 0.05.
3.4 RESULTS (Table 11)
Glucose response to oral glucose (Figure 1)
There was no significant difference between the 5 groups for glucose levels
either fasting, or at 120 minutes or AUC. Despite all patients having normal glucose
tolerance, glucose levels at 120 minutes tended to be higher compared to controls in
patients with previous MI or heart failure.
Insulin response to oral glucose (Figure 2)
Plasma insulin levels were significantly different between the 5 groups for
fasting (p = 0.012), at 120 minutes (p = 0.002) and for AUC (p = 0.011). Follow up
pairwise comparisons for fasting insulin showed significant differences between
patients with heart failure v normal controls (p = 0.002), v MI Group I (p = 0.006),
and v MI Group II (p = 0.003), and borderline significant difference between patients
with heart failure v stable angina (p = 0.06). Follow up pairwise comparisons for 120
minute levels showed significant differences between normal controls v MI Group I
(p = 0.001), v MI Group II (p = 0.02), and v chronic heart failure (p = 0.001). In
addition, patients with stable angina were significantly different from MI Group I
(p = 0.03) and from chronic heart failure (p = 0.02). Follow up pairwise comparisons
for AUC showed significant differences between normal controls and all patient
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groups, controls v stable angina (p = 0.03), v MI Group I (p = 0.005), v MI Group II
(p = 0.01), and v chronic heart failure p = 0.001, but there were no significant
differences between patient groups.
Insulin/glucose ratio response to oral glucose (Figure 3)
The ratio of plasma insulin/glucose was significantly different between the 5
groups for fasting (p = 0.007), at 120 minutes (p = 0.004) and for AUC (p = 0.004).
Pairwise comparisons for fasting ratios showed significant differences between
patients with heart failure v normal controls (p = 0.001), v stable angina (p = 0.04), v
MI Group I (p = 0.005) and v MI Group II (p = 0.001). Pairwise comparisons
revealed significant differences for values at 120 minutes between normal controls v
MI Group I (p = 0.0012), v MI Group II (p = 0.03) and v chronic heart failure
(p = 0.001), and between stable angina v chronic heart failure (p = 0.03). Pairwise
comparisons between the groups for AUC showed significant differences between
normal controls v stable angina (p = 0.05), v MI Group I (p = 0.003), v MI Group II
(p = 0.005) and v chronic heart failure (p < 0.001).
3.5 DISCUSSION
The most important finding of this study was to suggest that the presence and
nature of hyperinsulinaemia in patients with IHD may be crucially influenced by
previous myocardial infarction or the extent of left ventricular dysfunction. Unlike
previous studies (Nikkila et al 1965; Tzagournis et al 1967; Tzagournis et al 1968;
Kashyap et al 1970; Malherbe et al 1971; Gertler et al 1972; Berchthold et al 1972;
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Sorge et al 1976; Larsen et al 1981; Hamsten et al 1987a; Lichtenstein et al 1987;
Bergstrand et al 1979; Jackson et al 1983) I have taken care to minimise the influence
of other conditions known to influence insulin sensitivity by excluding patients with
impaired or abnormal glucose tolerance and by matching patient groups and controls
for age, BMI and blood pressure (Reaven 1988). Fasting hyperinsulinaemia was only
a feature of patients with chronic heart failure. Stimulated hyperinsulinaemia was
present in chronic stable angina, for at least 3 months following recent acute
myocardial infarction without clinically significant left ventricular impairment, and
in chronic heart failure. Although patients with angina or recent infarction had
similar fasting levels of insulin, at 120 minutes patients with recent infarction had
persistently elevated insulin, similar in magnitude to that of the heart failure group
and significantly higher than controls, whilst at 120 minutes patients with angina did
not differ significantly from controls but were significantly lower than MI group I or
patients with chronic heart failure. It may be that the persistent elevation of insulin at
120 minutes in those with recent myocardial infarction, as opposed to a return to
normal insulin levels in those with stable angina, is associated with an increased
tendency to occlusive thrombus formation in addition to atheroma. This hypothesis is
supported by evidence linking hyperinsulinaemia to impaired endogenous
fibrinolysis (Juhan-Vague et al 1991). Alternatively, stimulated hyperinsulinaemia
may occur as a response to the presence of left ventricular dysfunction, irrespective
of the presence of symptoms. If this were the case, then the degree of the stimulated
response is not critically dependent upon the extent of ventricular impairment, as the
120 minute and AUC values were similar in those with a well preserved left
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ventricular ejection fraction and those with severely impaired ejection fraction. The
degree of stimulated hyperinsulinaemia in those with recent myocardial infarction
did not differ between Group I, studied 3 weeks after the acute event, and Group II,
studied 3 months after. This implies that, in the absence of heart failure, the acute
phase response to acute myocardial infarction does not influence hyperinsulinaemia
after 3 weeks from the time of infarction. It is impossible to say whether stimulated
hyperinsulinaemia was present prior to infarction or developed as a consequence.
Three large longitudinal population studies have suggested that hyperinsulinaemia is
a risk factor for subsequent myocardial infarction (Welborn et al 1979; Ducimetiere
et al 1980; Pyorala et al 1985). My data would support this hypothesis but would also
suggest that fasting hyperinsulinaemia is a late development confined to patients with
moderate or severe heart failure.
No previous study has specifically addressed the importance of insulin in heart
failure secondary to ischaemic heart disease but low fasting insulin levels and an
impaired response to intravenous tolbutamide were found in a previous study in
8 patients with heart failure secondary to rheumatic heart disease (Sharma et al
1970). The effect of an oral glucose load was not tested and the patients studied were
severely ill and bedridden despite treatment with digoxin and diuretics. In a study of
8 patients with congestive heart failure (Paolisso et al 1991), of whom only one had
ischaemic heart disease, impaired insulin sensitivity was shown to be a feature and
the degree of insulin resistance appeared to correlate positively with plasma
noradrenaline concentrations. In end-stage disease it is conceivable that pancreatic
hypoperfusion might lead to reduced insulin secretion, but in less severe heart failure
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there are a number of possible influences on insulin action which might lead to
insulin resistance and hyperinsulinaemia. The neuroendocrine response in heart
failure leads to increased secretion of catecholamines, Cortisol and growth hormone
(Bayliss et al 1987) all ofwhich antagonise the peripheral action of insulin. Physical
inactivity is associated with hyperinsulinaemia and insulin resistance and this may be
of relevance to patients with ischaemic heart disease and particularly those with heart
failure (Rosenthal et al 1983). Although there is no evidence from studies in man to
support a primary role for hyperinsulinaemia or insulin resistance in the development
of heart failure, impaired ventricular function associated with prolonged insulin
resistance has recently been described in a rat model of streptozocin-induced diabetes
(Schaffer et al 1993). This would be of particular importance because of evidence
that angiotensin converting enzyme inhibitors may favourably modify insulin
resistance (Pollare et al 1989b).
Hyperinsulinaemia is an important finding in IHD because it is associated with
dyslipidaemia, hypertension, impaired fibrinolysis and sodium retention by the
kidney (Reaven 1988; Stout 1990). In addition, hyperinsulinaemia, particularly in the
presence of normal glucose levels, suggests a defect in utilisation of substrate by
peripheral muscle, as has been shown in diabetes mellitus (Shulman et al 1990), and
this may be relevant to the symptoms of fatigue and diminished effort tolerance
which are prevalent in patients with heart failure or after myocardial infarction.
Secondly, studies in patients with hypertension have illustrated the potential adverse
effects of (3 blockers (Pollare et al 1989a) and beneficial effects of angiotensin
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converting enzyme inhibitors on insulin resistance (Pollare et al 1989b) and these are
classes of drug widely prescribed to patients with IHD.
Limitations ofthis study
It should be noted that nearly all current insulin immunoassays cross react with
proinsulin and 32-33 split proinsulin and these molecules may form a considerable
part of total insulin immunoreactivity after a glucose stimulus in subjects with non-
insulin dependent diabetes mellitus (Sobey et al 1989; Clark et al 1992). However,
there is no information to suggest that insulin precursor levels are increased in non-
diabetic subjects with IHD, and even amongst those with non-insulin dependent
diabetes, it appears that those with mild or diet controlled disease do not show excess
secretion of insulin precursor molecules (Clark et al 1992). The stimulated
hyperinsulinaemia in some groups may in part reflect relative hyperglycaemia. The
elevated ratio of insulin/glucose in those with heart failure or recent myocardial
infarction does not support this, however, and suggests that the available insulin was
not acting normally to increase glucose uptake, which indicates the presence of
insulin resistance.
Although there are no studies of the effect of chronic [1 blockade on insulin
resistance in patients with IHD, in patients with hypertension p blockers have been
associated with impaired insulin sensitivity and hyperinsulinaemia (Pollare et al
1989a). In this study, the groups taking p blockers were those with a recent history of
myocardial infarction and without heart failure. In MI Group I and MI Group II,
fasting levels of insulin were similar to both normal controls and men with stable
angina who were not taking a p blocker. Stimulated levels of insulin in MI Group I
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and MI Group II were similar to those with heart failure who were not taking a P
blocker. This suggests that P blockers were not responsible for hyperinsulinaemia in
this study.
All of the patients in the group with chronic heart failure were taking loop
diuretics with potassium supplements and there are case reports of these being
associated with IGT (Toivenen et al 1966). However, the proposed mechanism is not
through increased insulin release but through inhibition of insulin secretion and this
has been confirmed in an animal study (Sandstrom and Semlin 1988). In studies
which have examined the effect of frusemide on glucose tolerance and insulin
response in patients with hypertension (Jackson and Nellen 1966) and following
myocardial infarction (Efendic et al 1984) there was no effect on fasting or
stimulated insulin.
In this study the group of patients with heart failure was the only group to
contain a high proportion of smokers (10/16) and cigarette smoking has been
associated in normal volunteers with stimulated hyperinsulinaemia in response to an
OGTT and increased insulin resistance (Facchini et al 1992). However, a comparison
of the smokers and non-smokers in the heart failure group (Table 12) showed no
significant difference between smokers and non-smokers. This is also supported by
data from the Helsinki Policeman Study in which 426 of 982 men were smokers and
in whom there was no difference in fasting or stimulated insulin response (Pyorala et
al 1985). Unpublished data from the Edinburgh-Stockholm Study also failed to find




In patients with ischaemic heart disease, fasting hyperinsulinaemia is only
present in severe heart failure, whereas stimulated hyperinsulinaemia is prominent
amongst those with previous myocardial infarction and those with heart failure, and
is also present, but less marked, in those with chronic stable angina.
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Table 12. Plasma insulin response to a 75 g oral glucose tolerance
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CHAPTER 4
IMPAIRED GLUCOSE TOLERANCE, HYPERINSULINAEMIA
AND INSULIN RESISTANCE IN PATIENTS
WITH ISCHAEMIC HEART DISEASE
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4.1 SUMMARY
To compare the extent of hyperinsulinaemia during a 75 g oral glucose
tolerance test in ischaemic heart disease patients with either normal or impaired
glucose tolerance, 72 patients with normal glucose tolerance and 18 with impaired
glucose tolerance were compared. Patients with impaired glucose tolerance had both
fasting (11.6 v 7.2 mU/L, p = 0.04) and stimulated (120 minute insulin, 118.3 v 55.5
mU/L, p < 0.001) hyperinsulinaemia.
A subgroup of 56 patients also underwent radionuclide ventriculography.
There was a significant correlation between left ventricular ejection fraction and
fasting insulin (r = -0.392, p = 0.003), but there was no relationship with the
stimulated insulin response. Left ventricular ejection fraction, body mass index and
fasting glucose were entered into a multiple linear regression model with fasting
insulin as the dependent variable. Left ventricular ejection fraction remained a
significant predictor of fasting plasma insulin.
The prevalence of impaired glucose tolerance amongst non-diabetic men with
ischaemic heart disease was 20%. Both fasting and stimulated hyperinsulinaemia
were significantly greater in patients with impaired glucose tolerance. In a subgroup
of 56 patients, there was an inverse relationship between left ventricular ejection
fraction and fasting insulin concentration, but there was no relationship between
ejection fraction and glycaemia or stimulated hyperinsulinaemia.
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4.2 INTRODUCTION
Hyperinsulinaemia has been described in patients with ischaemic heart
disease (Peters and Hales 1965) and is also known to occur in obesity, impaired
glucose tolerance, non-insulin dependent diabetes mellitus and hypertension (Reaven
1988). Insulin may have a direct role in the development of atherosclerosis, or may
influence other risk factors for ischaemic heart disease, such as blood pressure,
lipoproteins and endogenous fibrinolysis (Stout 1990; Savage 1993). Impaired
glucose tolerance was previously known as "borderline diabetes," and the current
definition was produced by the World Health Organisation in 1985. Impaired glucose
tolerance is an intermediate state in which glucose tolerance is abnormal but there is
no risk of the microvascular complications of diabetes, although the risk of
subsequently developing non-insulin dependent diabetes is increased (Yudkin et al
1990). Impaired glucose tolerance is, however, a risk factor for developing
macrovascular disease in subjects without known cardiac disease (Fuller et al 1980;
Fontbonne et al 1989; McKeigue et al 1993) and is also more prevalent amongst
young patients with myocardial infarction than matched controls (Hamsten et al
1987a). Hyperinsulinaemia and insulin resistance are features of impaired glucose
tolerance in subjects who are otherwise healthy (Reaven et al 1989). It has been
suggested that impaired glucose tolerance and obesity only convey independent
excess risk of cardiovascular disease in men who are hyperinsulinaemic (Modan et al
1991). Previous studies in selected groups of patients with ischaemic heart disease in
which the results for those with abnormal glucose tolerance were described
122
separately have shown conflicting results regarding the presence of fasting or
stimulated hyperinsulinaemia (Hamsten et al 1987a; Gertler et al 1972; Sorge et al
1976; Efendic et al 1984) but these studies were carried out prior to the recent and
widely accepted definition of impaired glucose tolerance (World Health
Organisation, 1985) and generally with insulin assays of poor specificity.
The purpose of this study was to examine the immunoreactive insulin
response to a 75 g oral glucose tolerance test amongst a broad range of patients with
ischaemic heart disease and compare those with impaired glucose tolerance
(120 minute plasma glucose > 7.8 and <11.0 mmol/L) to those with normal glucose
tolerance (120 minute glucose < 7.8 mmol/L).
4.3 METHODS
Patients
Ninety-three patients attending the Department of Cardiology as out patients
and with a principal diagnosis of ischaemic heart disease who were in a stable
condition and who gave their informed consent to undergo an oral glucose tolerance
test were recruited. The study received the approval of the Lothian Health Board
Ethical Committee for medical research. The diagnosis of ischaemic heart disease
was based upon a history of previous myocardial infarction meeting World Health
Organisation criteria or a combination of a history of typical stable angina pectoris
and recent positive exercise tolerance test (> 1 mV ST segment depression
0.06 seconds after the J point in at least one of 12 standard electrocardiographic
leads). All patients had a fasting plasma glucose of less than 6.7 mmol/L and none
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were suspected of having abnormal glucose tolerance. Patients with diabetes mellitus
or with a history of diabetes in a first degree relative were excluded from this study.
A formal measurement of left ventricular function by radionuclide angiography was
made as part of the routine assessment of 56 (70%) patients.
Oral glucose tolerance test
Subjects attended the department at 08.00 hours after a 12 hour overnight
fast. An indwelling 16 G intravenous cannula was inserted into an antecubital vein,
and they rested sitting for 30 minutes. Prior to blood sampling on each occasion 5
mL of blood was withdrawn and discarded. After a baseline blood sample they took
75 g glucose monohydrate in 200 mL water. Further blood samples were taken at 30,
60, 90 and 120 minutes. Samples were placed immediately onto melting ice. Plasma
was separated within 1 hour, and stored at -40°C. Each sample was assayed for
immunoreactive insulin. Glucose was measured using a Cobas Bio analyser by the
hexokinase method (Schmidt 1973) with an interassay coefficient of variation of
1.7%. Immunoreactive insulin was measured by radioimmunoassay (Soeldner and
Slone 1965) with a coefficient of variation of 6.8-7.5%. This assay shows less than
20% cross-reactivity with proinsulin and 32,33 split proinsulin. This means that even
if proinsulin and its split products were present in 30% of the molar concentration of
insulin they would represent less than 6% of the measured immunoreactive insulin.
In a recent study of subjects with impaired glucose tolerance, these molecules were
found to represent only 15% of the total immunoreactive insulin measured by the
assay (Davies et al 1993).
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Statistical analysis
Descriptive data are given as mean (SD). Areas under the curve were
calculated using the trapezium rule. Body mass index was calculated as
weight/height2.
Glucose values are given as the arithmetic mean (95% CI of mean). Values
for insulin and insulin/glucose ratio were compared after logarithmic transformation
to normalise their distribution, and are expressed as the geometric mean (95% CI of
mean). The data have been expressed in this form (mean [95% CI ofmean]) because
a consequence of the need for logarithmic transformation of insulin data is that CI of
the difference between the impaired glucose tolerance and normal glucose tolerance
groups represent CI of the ratio between groups rather than absolute values (Gardner
and Altman 1989). Statistical testing of the differences between the 2 groups was by
Student's t test for unpaired observations assuming unequal variances. Pearson linear
correlation coefficients and multiple linear regression were performed using
SYSTAT for Windows Version 5 (Systat Inc. 1992, Evanston, Illinois). The two-
tailed level of significance was p < 0.05.
4.4 RESULTS
Baseline characteristics
The clinical characteristics of the 2 groups are shown in Table 13. There were
no significant differences between the 2 groups in their baseline characteristics and in
particular the groups were well matched for previous myocardial infarction, heart
failure and the prescription of drug therapy.
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Oral glucose tolerance test
(A summary of the principal results is shown in Table 14)
Fasting plasma glucose did not differ between the 2 groups. The expected
response (by definition) to the oral glucose load is shown in Figure 4.
Fasting insulin concentrations were significantly higher in the impaired
glucose tolerance group (p = 0.044). Figure 4 shows that insulin levels were
persistently higher throughout the test for the impaired glucose tolerance group with
no evidence of a failure of early insulin release in those with impaired glucose
tolerance. There were significant differences between the 2 groups for both area
under the curve (p = 0.022) and 120 minute insulin (p < 0.001).
The influence of left ventricular function on insulin and glucose in ischaemic
heart disease
In order to gain further information about the possible influence of left
ventricular function on glycaemia and hyperinsulinaemia in patients with ischaemic
heart disease, I considered the 56 patients (44 with normal glucose tolerance, 12 with
impaired glucose tolerance) in whom measurement of left ventricular function had
also been made. Table 15 shows a Pearson correlation matrix for these 56 patients
including both fasting and 120 minute glucose and insulin concentration with body
mass index and left ventricular ejection fraction. There were no significant
correlations between glucose concentration and either body mass index or left
ventricular ejection fraction. There were significant correlations between fasting
insulin and body mass index, 120 minute insulin and ejection fraction (in descending
order of significance) but not with fasting glucose. Figure 5 shows a plot of log
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fasting insulin against left ventricular ejection fraction and Figure 6 a plot of log
fasting insulin against body mass index. There were significant correlations between
120 minute insulin and 120 minute glucose, fasting insulin and body mass index (in
descending order of significance) but not with left ventricular ejection fraction.
Table 16 shows the results of a multiple regression model with fasting insulin as the
dependent variable and including fasting glucose, body mass index and left
ventricular ejection fraction as independent variables; both body mass index
(p < 0.001) and left ventricular ejection fraction (p = 0.013) were significant
predictors. Table 17 shows the results of a multiple regression model with 120
minute insulin as the dependent variable and including body mass index, left
ventricular ejection fraction, 120 minute glucose and fasting glucose and insulin;
only 120 minute glucose (p < 0.001) and fasting insulin (p = 0.008) remained
significant predictors.
4.5 DISCUSSION
This study showed that impaired glucose tolerance was present in 20% of
patients with ischaemic heart disease who were not suspected of abnormal glucose
tolerance. Impaired glucose tolerance was associated with significant fasting and
stimulated hyperinsulinaemia over and above that which occurs in patients with
ischaemic heart disease who have normal glucose tolerance. The results also showed
that body mass index and left ventricular ejection fraction were important
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determinants of fasting insulin concentrations but did not have a major influence on
either glycaemia or the stimulated insulin response.
These results confirm previous observations in healthy subjects that
circulating insulin levels are increased in impaired glucose tolerance compared to
normal glucose tolerance (Reaven et al 1989). This was also suggested in earlier
studies in selected patients with ischaemic heart disease which used differing
definitions of abnormal glucose tolerance (Hamsten et al 1987a; Gertler et al 1972;
Sorge et al 1976) although one study reported a diminished insulin response to an
intravenous glucose tolerance test in patients who had abnormal glucose tolerance
following myocardial infarction (Efendic et al 1984). In my study there was no
evidence of a diminished early insulin response in patients with impaired glucose
tolerance as has recently been suggested in otherwise healthy subjects with impaired
glucose tolerance (Mitrakou et al 1992; Davies et al 1993). The relative specificity of
the insulin assay in Newcastle suggests that for true hypoinsulinaemia to be present
at 30 minutes, proinsulin and its split products would have had to contribute well
over 50% of total insulin immunoreactivity. Recent results from healthy subjects
with impaired glucose tolerance have suggested that the proportion of fasting
proinsulin-like molecules is 15% compared to 12% in subjects with normal glucose
tolerance (Davies et al 1993) and therefore it is unlikely that they represented a
significant part of the difference in immunoreactive insulin levels found in my study.
There is no information on insulin precursor levels in non-diabetic patients with
ischaemic heart disease. The absence of a failure of early insulin secretion suggests
that in patients with ischaemic heart disease the persistent hyperglycaemia of
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impaired glucose tolerance is primarily due to reduced peripheral insulin sensitivity.
Reduced insulin-mediated glucose uptake, measured by the insulin suppression test,
has recently been shown in a group of men with ischaemic heart disease in a study
which included patients with impaired glucose tolerance but did not differentiate
their results (Young et al 1993). My results in the basal and stimulated state suggest
that peripheral insulin resistance is greater in ischaemic heart disease patients with
impaired glucose tolerance than normal glucose tolerance, and that frank
deterioration to diabetic glucose tolerance is prevented by a compensatory increase in
insulin secretion. This may well be relevant to prognosis in ischaemic heart disease,
since hyperinsulinaemia has been associated with several important risk factors
(Stout 1990; Savage 1993) and with increased cardiovascular morbidity in three large
prospective studies (Welborn et al 1979; Ducimetiere et al 1980; Pyorala 1985).
There is little information on the prognostic importance of impaired glucose
tolerance or hyperinsulinaemia for patients with established ischaemic heart disease.
Studies in patients with acute myocardial infarction have shown that elevated glucose
levels on admission may predict pre-existing diabetes (Husband et al 1983) and a
poorer prognosis (Oswald et al 1984; Oswald et al 1986; Bellodi et al 1989).
However, glucose concentrations on admission reflect in part the neurohumoral
disturbance associated with infarction, and this is proportional to the extent of left
ventricular damage (Oswald et al 1986). The longer term risk due to
atherothrombosis, rather than left ventricular dysfunction, may be more accurately
predicted by risk factor assessment in the convalescent period. None of the above
studies included a measurement of insulin.
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Another important consequence of my study is to emphasise that when
describing hyperinsulinaemia and insulin resistance in ischaemic heart disease it is
crucial to fully define the glucose tolerance status of subjects (World Health
Organisation 1985).
The analysis of patients with ischaemic heart disease who had normal
glucose tolerance has suggested that fasting hyperinsulinaemia is most prominent in
patients with heart failure (Chapter 3). This is supported by the inverse correlation
between fasting insulin and left ventricular ejection fraction found in the combined
groups. Insulin resistance in non-ischaemic heart failure has been ascribed to the
neurohumoral response to heart failure (Paolisso et al 1991) much ofwhich would be
expected to antagonise insulin action. My own results suggest that impaired left
ventricular function is an important determinant of fasting, but not stimulated,
hyperinsulinaemia. This is consistent with observations that there is skeletal muscle
metabolic dysfunction in heart failure (Wilson and Mancini 1993) and that muscle
blood flow is an important determinant of whole body insulin sensitivity (Ganrot
1993). This study has also emphasised the recognised importance of body mass index
in determining insulin levels (Reaven 1988).
In patients with normal glucose tolerance 120 minute insulin concentrations
were elevated in those with prior myocardial infarction or chronic heart failure
(Chapter 3). It is noteworthy that 120 minute insulin levels were considerably
increased in patients with impaired glucose tolerance in this comparison, despite the
groups being matched for the presence of heart failure and for previous myocardial
infarction. It is impossible to say to what degree the stimulated hyperinsulinaemia
130
was due to higher glucose concentrations or to impaired insulin action. There was no
relationship between stimulated insulin response and left ventricular ejection fraction
in this study and a much weaker relationship with body mass index than for fasting
insulin. This suggests that the influences on basal insulin secretion and the insulin
response to glucose stimulation are different, which may be important if the risk of
myocardial infarction is associated more with the stimulated insulin response.
Study limitations
It is well established from studies in hypertensive patients that glucose and
insulin metabolism may be altered by both (3 blockers (Pollare et al 1989a) and
angiotensin converting enzyme inhibitors (Pollare et al 1989b). The 2 groups in this
study contained similar proportions of patients receiving these drugs, but I cannot
exclude the possibility that the glucose or insulin response of some subjects was
altered by their medication. However, no subject had undergone a change in their
regular medication in the 4 week period prior to this study.
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4.6 CONCLUSION
Impaired glucose tolerance was present in 20% of non-diabetic patients with
ischaemic heart disease, none of whom were suspected of having abnormal glucose
tolerance. Compared to patients with normal glucose tolerance, those with impaired
glucose tolerance had significant fasting hyperinsulinaemia and significant
stimulated hyperinsulinaemia in response to a 75 g oral glucose load. Fasting insulin
concentrations were related to both body mass index and left ventricular ejection
fraction, but these parameters did not significantly influence stimulated
hyperinsulinaemia or glycaemia.
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Age (years) 61 (8) 57 (10)
Previous hypertension 6 (8%) 3 (17%)
Previous myocardial infarction 58 (81%) 15 (83%)
Chronic heart failure 18 (25%) 5 (28%)
Never smoked 20 (28%) 5 (28%)
Ex-smoker 35 (49%) 9 (50%)
Current smoker 17 (24%) 4 (22%)
P blocker 33 (46%) 9 (50%)
ACE inhibitor 9 (13%) 3 (17%)
Loop diuretic 18 (25%) 5 (28%)
Body mass index (kg/m ) 25.6 (3.0) 27.2 (3.4)
Systolic BP (mm Hg 125 (21) 125 (17)
Diastolic BP (mm Hg) 78 (12) 79 (13)
Left ventricular ejection fraction (%) 33 (12) [n=44] 34 (10) [n=12]
Total cholesterol (mmol/L) 6.2 (1.2) 6.7 (1.2)
Total triglyceride (mmol/L) 1.7 (0.7) 2.5 (1.3)
HDL cholesterol (mmol/L) 1.0 (0.2) 1.0 (0.3)
ACE = angiotensin converting enzyme, HDL = high density lipoprotein
Figures in parentheses are SD or % of the relevant group as appropriate. There
were no significant differences between the 2 groups
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Table 14. Plasma glucose and insulin responses to a 75 g oral
glucose tolerance test
NGT (n=72) IGT (n=18) p value
Fasting
Glucose 5.1 5.1 0.836
(mmol/L) (5.0 to 5.2) (4.6 to 5.5)
Insulin 7.2 11.6 0.044
(mU/L) (6.0 to 8.6) (7.5 to 17.9)
Insulin/Glucose 1.4 2.3 0.063
(mU/mmol) (1.2 to 1.7) (1.4 to 3.8)
30 minute
Glucose 7.9 8.8 0.006
(mmol/L) (7.5 to 8.2) (8.2 to 9.3)
Insulin 62.3 83.3 0.098
(mU/L) (54.6 to 71.1) (60.5 to 114.8)
Insulin/Glucose 8.1 9.5 0.331
(mU/mmol) (7.1 to 9.1) (6.9 to 13.2)
120 minute
Glucose 5.8 8.9 < 0.001
(mmol/L) (5.5 to 6.1) (8.3 to 9.4)
Insulin 55.5 118.3 <0.001
(mU/L) (46.7 to 66.0) (96.2 to 145.3)
Insulin/Glucose 9.9 13.4 0.023
(mU/mmol) (8.5 to 11.4) (10.7 to 16.7)
AUC
Glucose 852 1080 <0.001
(min.mmol/L (822 to 882) (1022 to 1137)
Insulin 8071 11861 0.022
(min.mU/L) (7155 to 9104) (8901 to 15806)
Insulin/Glucose 9.6 11.0 0.388
(mU/mmol) (8.6 to 10.6) (8.2 to 14.8)
AUC = area under the curve calculated from samples at 0, 30, 60, 90 and 120
minutes, NGT = normal glucose tolerance, IGT = impaired glucose tolerance,
Values are arithmetic mean (95% CI) for glucose and geometric mean (95% CI)
for insulin and insulin/glucose ratio, p value from Student's t-test for unpaired
observations
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Figure 4. The glucose and insulin response to a 75 g oral glucose load in
patients with ischaemic heart disease, 72 with normal glucose
tolerance (NGT) and 18 with impaired glucose tolerance (IGT).
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Figure 5. Plot of log fasting insulin against left ventricular ejection fraction
(LYEF) with the regression line (r = -0.392, p = 0.003) and 95%
CI of the regression line (n = 56). The equation for the regression
line was y = -2.9x + 3.03. Patients with normal glucose tolerance
are shown as open circles and those with impaired glucose
tolerance as filled circles
5 -i
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Figure 6. Plot of log fasting insulin against body mass index (BMI) with the
regression line (r = 0.522, p < 0.001) and 95% CI of the regression
line (n = 56). The equation for the regression line was y = 0.17x -
2.46. Patients with normal glucose tolerance are shown as open




EFFECTS OF CAPTOPRIL ON HYPERINSULINAEMIA AND




Angiotensin converting enzyme inhibitors have been shown to improve
prognosis in patients with chronic heart failure and in patients with recent myocardial
infarction. Captopril has been shown to increase insulin sensitivity in patients with
essential hypertension. The study reported in this chapter examined the effect of
captopril upon hyperinsulinaemia and insulin resistance in patients who had made an
uncomplicated recovery from a recent myocardial infarction. Patients were
randomised to receive 4 weeks placebo and 4 weeks captopril in a double-blind
crossover study design. Hyperinsulinaemia and insulin sensitivity were assessed at
the end of each treatment period using a 3 hour oral glucose tolerance test and a
2 hour euglycaemic hyperinsulinaemic clamp performed 48 hours apart. The use of
captopril had no significant effect upon fasting or stimulated hyperinsulinaemia, or
insulin sensitivity. This suggests that there may be differences in the mechanisms of
insulin resistance in essential hypertension and ischaemic heart disease.
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5.2 INTRODUCTION
Captopril has been shown to improve insulin sensitivity in patients with
essential hypertension (Pollare et al 1989b) but, as discussed in Chapter 1, there have
subsequently been conflicting reports for both captopril and other angiotensin
converting enzyme (ACE) inhibitors which have been studied in subjects with
essential hypertension (Santoro et al 1992; Egan 1993; Baba 1993; Uehara 1994;
Oksa 1994), or diabetes mellitus (Seefeldt 1990; Uehara 1994), or both (Torlone
1991; Seghieri 1992; Bak 1992; Torlone 1993; Uehara 1994). The effect of ACE
inhibitors upon insulin resistance has not been studied in patients with ischaemic
heart disease.
Several very large studies of patients with acute myocardial infarction have
suggested that the use ofACE inhibitors is associated with improved prognosis either
in an unrestricted short term protocol (Gruppo Italiano per lo Studio della
Sopravvivenza nell'Infarcto Miocardico 1994), or over long periods in patients with
either depressed left ventricular function assessed by radionuclide ventriculography
(Pfeffer et al 1992), or with clinical evidence of heart failure (The Acute Infarction
Ramipril Efficacy (AIRE) Study Investigators 1993). The most likely mechanisms by
which ACE inhibitors bring about their benefit is by an attenuation of left ventricular
remodelling (Sharpe et al 1988; Pfeffer et al 1988), possibly by modulating the
neurohumoral response to acute myocardial infarction (Rouleau et al 1993; Ray et al
1993).
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The purpose of the studies presented in this and the next chapter was to
investigate the effect of captopril on insulin resistance (this chapter) and endogenous
fibrinolysis (Chapter 6) in a group of men who had recovered from an acute
myocardial infarction without developing any complications such as heart failure or
significant arrhythmia. To minimise the possible interference of other drug therapy,
but yet to still investigate a group representative of a large number of patients with
myocardial infarction, I elected to include only patients who were taking a
cardioselective (3 adrenoceptor antagonist and aspirin, without other therapy. Thus I
enrolled a group of patients who, at the time of study, did not have any conventional
indications to undergo ACE inhibitor therapy and who were also taking those agents
which had been shown to improve prognosis after myocardial infarction, aspirin (The
ISIS-2 Collaborative Group 1988) and p blockade (The Norwegian Multicenter
Group 1981; The Beta Blocker Heart Attack Research Group 1982).
5.3 METHODS
Subjects
Eighteen men younger than 75 years and suffering from their first myocardial
infarction were recruited 6 weeks after their admission to the Coronary Care Unit at
the Royal Infirmary of Edinburgh. In addition to a typical history, subjects had to
have developed pathological Q waves on the 12 lead electrocardiogram or to have
had a peak creatine kinase of > 800 iu/L, or both. All patients had been taking a
cardioselective p adrenoceptor blocking agent and aspirin 300 mg daily from the
time of their admission to hospital, and no other medication was allowed. None of
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the patients who entered the study had previously taken an ACE inhibitor. Patients
with a history of hypertension or diabetes mellitus, or with a family history of
diabetes mellitus, were excluded because of the known association of these
conditions with hyperinsulinaemia and insulin resistance. At the time of recruitment
a full clinical assessment was made and a chest radiograph, symptom limited
treadmill exercise test and radionuclide ventriculogram performed. Any patient with
clinical or radiological signs of heart failure, or evidence of ischaemia or arrhythmia
requiring additional therapy was excluded. Thus, the study population consisted of a
group considered to have made an entirely uneventful recovery from their myocardial
infarction and without any other significant illness.
Of the 18 patients who were initially entered into the study, 3 patients were
subsequently excluded from analysis, one patient whose compliance with study
medication was less than 90% by tablet count (75%), one patient whose P blocker
was withdrawn by his general practitioner during the study because of mild
dyspnoea, and one patient who moved to England during the study and was unwilling
to continue to take part. Details of the index hospital admission for the 15 remaining
patients are given in Table 18.
To provide data on values for insulin sensitivity in an age and body mass
index matched healthy population, 12 men were identified at random from the
Lothian Elealth Board register. None of these men gave a history of ischaemic heart
disease, hypertension or diabetes mellitus, and none were taking any medication.
None had a family history of diabetes mellitus. All of these healthy subjects had a
normal physical examination and a normal 12 lead electrocardiogram.
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All of the subjects who took part in this study gave fully informed oral and
written consent to participate. In addition, their general practitioners were approached
to ensure that they knew of no reason why their patients should not take part. The
study was approved by the Lothian Health Board Ethical Committee.
Study design
The study was designed as a randomised, double-blind, placebo-controlled,
crossover study. Entry into the study was 8 weeks after the onset of myocardial
infarction in order to avoid any acute phase response or metabolic derangement
around the time of infarction. A stable insulin response between weeks 3 and 12 after
myocardial infarction is suggested by the data on oral glucose tolerance tests
presented in Chapter 3.
At the beginning of each treatment period, patients received a test dose of
placebo or 6.25 mg captopril under medical supervision and this was followed by one
tablet of placebo or 25 mg captopril three times daily. After 4 weeks of therapy the
patients crossed over to the other treatment arm for a further 4 weeks. No patient
suffered a significant hypotensive response.
At the end of each treatment period, but separated by 48 hours, patients
underwent an oral glucose tolerance test and a euglycaemic hyperinsulinaemic clamp
study, thus each investigation was made at 12 and 16 weeks from the time of
infarction. The healthy normal men underwent a euglycaemic clamp on one occasion
only. Before each of these investigations subjects were asked to fast from
22.00 hours the previous night, but patients were asked to take their (3 blocker,
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aspirin and captopril/placebo with a glass of water at 07.00 hours prior to attending
the out patient department at 08.30 hours.
Oral glucose tolerance test
The patients were seated and a 16 G intravenous cannula was inserted into a
large antecubital vein after which they rested for 30 minutes. Two baseline blood
samples were taken 15 minutes apart before the patients took 75 g glucose
monohydrate in 200 mL water. Further blood samples were taken at 30, 60, 90, 120,
150 and 180 minutes in an extended version of the standard test. Samples taken into
fluoride oxalate for plasma glucose measurement were stored at room temperature
and plasma separated within 1 hour prior to analysis within 3 hours. Glucose was
measured using a Cobas Bio analyser by the hexokinase method (Schmidt 1973) with
an interassay coefficient of variation of 1.7%. Samples taken into lithium heparin for
immunoreactive insulin measurement were placed on ice and plasma was separated
within 1 hour after centrifugation (20 minutes at 2000 g and 4°C). Plasma samples
were stored at -40°C before analyses for the whole study were performed in
Newcastle. Immunoreactive insulin was measured by radioimmunoassay (Soeldner
and Slone 1965) with a coefficient of variation of 6.8-7.5%. Further details of this
assay have been discussed in Chapter 2.
Euglycaemic hyperinsulinaemic clamp
The patients lay recumbent and two intravenous cannulae were inserted after
which they rested for 30 minutes. An 18 G cannula was inserted into a large
antecubital vein for infusion of insulin and 20% dextrose. A 21 G cannula was
inserted retrogradely into a vein on the dorsum of the left hand and connected to a
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continuous flush system to ensure patency. The left hand was placed inside a
plexiglass heated water jacket maintained at an internal temperature of 55-65°C
throughout the study to facilitate sampling of "arterialised" venous blood as
discussed in Chapter 2. After 2 baseline "arterialised" blood samples taken 15
minutes apart, the euglycaemic hyperinsulinaemic clamp was performed according to
the method of De Fronzo (De Fronzo et al 1979; see Discussion in Chapter 2).
Essentially this consists of a 10 minute priming infusion of insulin followed by a
continuous infusion of 40 mU/m body surface area min, whilst after 4 minutes a
variable infusion of 20% glucose solution (with added potassium chloride) is
commenced and the rate varied in order to maintain the whole blood glucose
concentration at the mean of the 2 baseline fasting samples. Measurements of whole
blood glucose are made every 5 minutes using a glucose analyser (Yellowsprings
Instruments, Yellowsprings, Ohio). Adjustments to the rate of infusion were guided
according to the algorithm described by De Fronzo. The clamp was performed over
at least 120 minutes and the aim was to achieve steady state blood glucose levels
within 0.1 mmol/L of the target for the last 60 minutes. Additional blood samples
were taken at 10 minute intervals over the last 60 minutes for measurement of plasma
insulin by radioimmunoassay. Samples for insulin assay were handled exactly as
described above. The measurement of insulin sensitivity was taken as the quotient of
the whole body glucose intake (disposal) over the last 60 minutes and the prevailing
plasma insulin concentration. This is a more true reflection of insulin sensitivity than
merely the glucose disposal figure with no correction for the prevailing insulin
concentration, although many investigators do only quote glucose disposal.
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At the end of the study, the insulin infusion was stopped whilst the 20%
glucose solution was continued for 30 minutes to prevent rebound hypoglycaemia.
The plasma potassium was checked to see that it remained within normal range.
Subjects received their lunch prior to leaving the hospital.
Statistical analysis
Descriptive data are given as mean (SEM). Incremental areas under the curve
were calculated using the trapezium rule. Glucose data are given as arithmetic means
(95% CI of the mean). Values for insulin data and insulin/glucose ratios were
compared after logarithmic transformation to normalise their distribution and are
presented as geometric mean (95% CI of the mean). The effect of captopril versus
placebo was analysed by Student's t test for paired observations. Where comparisons
are made between patients and healthy men, Student's t test for unpaired
observations was used. Statistical analyses were made using SYSTAT for Windows,




There were no significant differences in the baseline characteristics of the
12 normal men and the 15 patients (Table 19).
Captopril v placebo - oral glucose tolerance test
Nine patients received placebo first and 6 received captopril first in the
crossover design. There was no evidence of an order effect and therefore results are
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presented combined. The main results are given in Table 20 and the glucose and
insulin curves for each treatment period are shown in Figure 7. Captopril had no
effect upon glucose tolerance or fasting or stimulated hyperinsulinaemia.
Captopril v placebo - hyperinsulinaemic euglycaemic clamp
The main results are given in Table 21 and the plots of whole blood glucose,
glucose infusion rate, and the plasma insulin concentration over the 120 minute
period of the study are shown in Figure 8. The plot of blood glucose in Figure 8
confirms that identical blood glucose levels were maintained during the last
60 minutes of the two clamp studies. There was a significant decrease in whole body
glucose disposal after 4 weeks treatment with captopril (323 v 299 mg/hr.kg,
p = 0.016) but also a tendency for the mean plasma insulin concentration over the last
60 minutes to be lower (95.1 v 89.6 mU/L, p = 0.124). When the insulin sensitivity
index was calculated, correcting whole body glucose disposal for the prevailing
plasma insulin concentration, there was no difference between captopril and placebo
effects (3.56 v 3.58 mg/hr.kg.mU/L plasma insulin, p = 0.889).
Captopril v placebo - other variables
The effect of 4 weeks therapy with captopril and placebo on blood pressure,
plasma electrolytes and lipids is shown in Table 22. There were no significant
differences.
Insulin sensitivity in patients v healthy normal subjects
The results for the hyperinsulinaemic euglycaemic clamp study in the
12 healthy normal men are given with those of patients taking a (3 blocker and aspirin
with placebo only in Table 23. These are mainly intended to provide an indication of
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the normal range of insulin sensitivity in age and body mass index matched controls.
This group are not true controls for the patients because they were not taking aspirin
or a (3 blocker. Taking heed of this caveat, statistical comparison between the healthy
men and patients at the end of the placebo period revealed no significant difference in
mean whole body glucose disposal (360 v 323 mg/hr.kg, p = 0.439) but with
significantly lower prevailing plasma insulin in healthy subjects (76.7 v 95.1 mU/L,
p = 0.002), and therefore a tendency to a higher insulin sensitivity index in healthy
subjects (4.89 v 3.56 mg/hr.kg.mU/L plasma insulin, p = 0.094).
5.5 DISCUSSION
This study, performed on patients with previous uncomplicated myocardial
infarction, has shown no evidence to support the hypothesis that captopril might
improve hyperinsulinaemia and/or insulin resistance. The results of the oral glucose
tolerance tests showed no influence of captopril on glucose tolerance or fasting
insulin concentrations or the stimulated insulin response to an oral glucose load up to
180 minutes. The results of the euglycaemic hyperinsulinaemic clamp studies
suggested that captopril might even have decreased whole body glucose disposal,
although when this was corrected for the prevailing plasma insulin concentration to
provide the insulin sensitivity index, there was no overall effect of captopril on
insulin sensitivity. The similar plateau insulin level in response to a constant dose of
insulin during the clamp and the identical insulin response to oral glucose also
151
suggest that neither the pattern of insulin clearance nor the secretory response of the
pancreas were altered by captopril.
A number of studies have investigated the possible effect of ACE inhibitors
on hyperinsulinaemia and insulin resistance in other patient groups and these were
discussed in Chapter 1 and detailed in Table 3, Chapter 1. Including only studies in
which captopril was given for more than 2 days, then there are three which merit
consideration. In 24 patients with essential hypertension, after 4 months treatment
with captopril 100 mg daily, there was a reduction in the stimulated insulin response
to intravenous glucose and an increase in insulin sensitivity assessed by the
euglycaemic clamp compared to baseline values (Pollare et al 1989b). In contrast,
14 hypertensive non-insulin dependent diabetic patients treated for 3 months with
captopril 50-100 mg daily, showed no change in their insulin response to oral glucose
or glucose disposal assessed by the insulin suppression test compared to baseline
(Seghieri et al 1992). In neither of these studies was there a placebo control group. A
single-blind, placebo controlled crossover study was performed in 16 hypertensive
non-insulin dependent diabetic subjects who received captopril 50-100 mg daily or
placebo for 3 months (Torlone et al 1993). Although a glucose tolerance test was not
performed in this study, there was a significant fall in glycosylated haemoglobin, and
euglycaemic clamp studies revealed improved insulin sensitivity, although there was
no change in fasting insulin concentrations.
One problem in trying to compare with these other studies is that the nature of
insulin resistance may differ in hypertension, ischaemic heart disease and non-insulin
dependent diabetes; and thus the influence of ACE inhibition may not be the same
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(reviewed by Donnelly 1992). In addition, an important difference between my study
and the others cited is that the patients in my study maintained concomitant treatment
with a p blocker and aspirin.
Although cardioselective P blockers are not thought to have a significant
influence on glucose-insulin homeostasis (Sawicki and Berger 1992), they have been
shown to influence insulin sensitivity in some studies (Pollare et al 1989a) and I
cannot exclude the possibility that p, adrenoceptor antagonism obscured an effect of
captopril in this study. A more intriguing possibility is that the use of aspirin may
alter the response to ACE inhibition. This has recently been suggested with regard to
the vasodilator effects of enalapril in heart failure (Hall et al 1992) although I am not
aware of data regarding the effect of aspirin on the neurohumoral response to ACE
inhibition.
Limitations of this study
It is possible that the duration of treatment in this study was too short,
although some workers have reported an effect of ACE inhibition after only a few
days or less (Torlone et al 1991; Gans et al 1991c; Uehara et al 1994). Acute
myocardial infarction is known to be associated with a metabolic disturbance (Vetter
et al 1974) and this might still influence glucose and insulin responses in the
convalescent period. Against this hypothesis is the lack of a difference in
hyperinsulinaemic response between patients with myocardial infarction studied at
3 weeks and 3 months presented in Chapter 3, and from this study, the lack of an
order effect on glucose, insulin and lipid parameters within the crossover design. It is
unlikely that there was any hangover effect for patients receiving captopril in the first
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treatment period because of the described endocrine response to the withdrawal of
captopril (Maslowski et al 1981), and specifically the findings of Pollare on the lack
of a hangover effect of captopril on insulin sensitivity (Pollare et al 1989b). I
purposely chose to study patients who had made an uncomplicated recovery from
myocardial infarction without symptomatic left ventricular impairment. This was
likely to minimise the neurohumoral disturbance associated with myocardial
infarction, but at the same time may have reduced the likelihood of captopril having a
beneficial effect. This was a deliberate strategy, prompted by the desire to explore
possible new indications for the use of ACE inhibitors in patients following
myocardial infarction rather than investigating patients for whom there were already
good indications for their use.
Insulin sensitivity in patients with myocardial infarction and healthy men
Although the results of the euglycaemic hyperinsulinaemic clamp in the
healthy subjects were intended to provide a normal range, and they were not controls
because they were not taking a p blocker or aspirin, a number of interesting
observations can still be made. Firstly, although cardioselective p blockers have been
shown to worsen insulin resistance in essential hypertension (Pollare et al 1989a), the
patients were not significantly more insulin resistant than the healthy men, even
though the trend was in that direction. Secondly, for a given dose of intravenous
insulin (40 mU/m body surface area min), the healthy men had a significantly lower
plateau plasma insulin concentration. This suggests that insulin clearance is impaired,
either as an effect of p blockade, which has been suggested before (Pollare et al
1989a), or due to impaired insulin clearance as a feature of ischaemic heart disease.
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Impaired insulin clearance has been described in hypertension (Salvatore et al 1992).
Overall it is perhaps surprising that there was no difference in glucose
disposal or insulin sensitivity index between the patients and healthy mean, although
the trend was in that direction. This reflects the limited power of the study to detect a
difference because of the large variance of the observation. In addition, the nature of
the patients studied made them less likely to be insulin resistant because of the
absence of heart failure. In a study of 8 patients with chronic congestive heart failure,
of whom only one had ischaemic heart disease, the patients were shown to have
impaired insulin sensitivity which correlated strongly with plasma concentrations of
noradrenaline (Paolisso et al 1991). Two recent studies of insulin sensitivity amongst
patients with ischaemic heart disease have shown insulin resistance using either the
insulin suppression test (Young et al 1993) or an intravenous glucose tolerance test
and mathematical model (Ley et al 1994). However, formal measurement of left
ventricular function was not made in these studies, the subjects contained a mixture
of those with and without previous myocardial infarction, and patients with impaired
glucose tolerance did not appear to be excluded.
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5.6 CONCLUSION
This study has shown no evidence to support the hypothesis that captopril
might improve insulin resistance in patients with uncomplicated myocardial
infarction taking a (3 blocker and aspirin.
156
Table 18. Details of the index myocardial infarction in the
15 patients
n or mean (range)
Cigarette smokers





Peak creatine kinase (iu/L)
Cardiothoracic ratio







0.37 (0.28 - 0.42)
IHD = ischaemic heart disease
LVEF = left ventricular ejection fraction
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Table 19. Baseline characteristics of the normal men and patients
with recent myocardial infarction
Normals (n=12) Patients (n=15)
Age (years) 57 (2) 63 (2)
Height (m) 1.77 (0.02) 1.78 (0.01)
Weight (kg) 79.5 (2.2) 79.5 (2.2)
BMI (kg/m2) 25.4 (0.6) 25.2 (0.6)
Pulse (bpm) 67 (2) 60 (2)
Systolic BP (mm Hg) 120 (4) 124 (5)
Diastolic BP (mm Hg) 80 (3) 77 (3)
Cholesterol (mmol/L) 6.2 (0.3) 6.9 (0.2)
Triglyceride (mmol/L) 1.5 (0.2) 2.0 (0.2)
HDL Cholesterol (mmol/L) 1.3 (0.1) 1.1 (0.1)
Glucose (mmol/L) 4.9 (0.1) 5.2 (0.1)
Insulin (mU/L) 7.3 (1.8) 7.7 (2.3)
BMI = body mass index, HDL = high density lipoprotein
Data are presented as mean (SEM)
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Table 20. Plasma glucose and insulin responses to a 75 g oral
glucose tolerance test in 15 patients with recent uncomplicated
myocardial infarction after 4 weeks treatment with placebo and
after 4 weeks treatment with captopril



































































AUC = incremental area under the curve from 0 to 180 minutes
Results are arithmetic mean (95% CI) for glucose and geometric mean (95%
CI) for insulin and insulin glucose ratios
Statistical testing was by Student's t test for paired observations using the raw
data for glucose results and log transformed data for insulin and insulin/glucose
ratios
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Table 21. Principal results of the hyperinsulinaemic euglycaemic
clamp studies in 15 patients with recent uncomplicated myocardial
infarction after 4 weeks treatment with placebo and after 4 weeks
treatment with captopril.
Placebo Captopril p value
Rate of infusion of 129 120 0.015
20% glucose in the (104 to 154) (95 to 144)
last hour(1)
(mL/hr)
Whole body glucose 323 299 0.016
disposal in the last (266 to 381) (245 to 353)
hour(2)
(mg.hr"1.kg"1)
Mean plasma insulin 95.1 89.6 0.124
in the last hour (86.4 to 103.8) (80.3 to 98.9)
(niU/L)
Insulin sensitivity 3.56 3.58 0.889
index(3) (2.72 to 4.40) (2.61 to 4.56)
(mg.hr"1 .kg"1 .mU"1.1)
Results are arithmetic mean (95% CI)
Statistical testing was by Student's t test for paired observations
Notes
(1) Rate of 20% glucose infusion (mL/hr) is raw data not corrected for body
weight.
(2) Whole body glucose disposal in the last hour (mg.hr"1.kg"1) is corrected for
body weight but not corrected for the prevailing plasma insulin concentration.
(3) The insulin sensitivity index (mg.hr"1.kg"1.mU"1.!) represents the whole body
glucose disposal in the last hour corrected for body weight and the prevailing
plasma insulin concentration.
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Table 22. Effect of 4 weeks placebo and 4 weeks captopril on other
parameters
Placebo Captopril
Systolic BP (mmHg) 117 (4) 114 (4)
Diastolic BP (mm Hg) 69 (3) 68 (4)
Urea (mmol/L) 6.3 (0.3) 6.5 (0.4)
Sodium (mmol/L) 141 (1) 141 (1)
Potassium (mmol/L) 4.1 (0.1) 4.1 (0.1)
Creatinine (pmol/L) 105 (3) 105 (3)
Cholesterol (mmol/L) 6.9 (0.2) 6.8 (0.2)
Triglyceride (mmol/L) 2.0 (0.2) 2.2 (0.3)
HDL cholesterol (mmol/L) 1.1 (0.1) 1.1 (0.1)
HDL = high density lipoprotein
Values are mean (SEM)
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Table 23. Principal results of the hyperinsulinaemic euglycaemic
clamp studies in 12 healthy men and in 15 patients with recent
uncomplicated myocardial infarction after 4 weeks treatment with
placebo
Healthy Men Patients p value
Rate of infusion of 140 129 0.535
20% glucose in the (113 to 166) (104 to 154)
last hour(1)
(mL/hr)
Whole body glucose 360 323 0.439
disposal in the last (278 to 442) (266 to 381)
hour(2)
(mg.hr"1 .kg"1)
Mean plasma insulin 76.7 95.1 0.002
in the last hour (69.1 to 84.3) (86.4 to 103.8)
(mU/L)
Insulin sensitivity 4.89 3.56 0.094
index(3) (3.52 to 6.26) (2.72 to 4.40)
(mg.hr"1 .kg"1 .mU"1.1)
Results are arithmetic mean (95% CI)
Statistical testing was by Student's t test for unpaired observations
Notes
(1) Rate of 20% glucose infusion (mL/hr) is raw data not corrected for body
weight.
(2) Whole body glucose disposal in the last hour (mg.hr"1.kg"1) is corrected for
body weight but not corrected for the prevailing plasma insulin concentration.
(3) The insulin sensitivity index (mg.hr"1.kg"1.mU"'.l) represents the whole body
glucose disposal in the last hour corrected for body weight and the prevailing
plasma insulin concentration.
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Figure 7. Plasma glucose and insulin response to a 75 g oral glucose
tolerance test in 15 patients with recent uncomplicated
myocardial infarction after 4 weeks placebo (x) and 4 weeks
captopril (o). Values are mean (SD)
Plasma Glucose (mmol/l)
0 30 60 90 120 150 180
Time (min)
Plasma Insulin (mLI/l)
0 30 60 90 120 150 180
Time (min)
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Figure 8. The whole blood glucose concentration, infusion rate of 20%
glucose solution, and plasma insulin concentrations during a
euglycaemic clamp performed in 15 patients with recent
uncomplicated myocardial infarction after 4 weeks placebo (x)
and after 4 weeks captopril (o). Values are mean (SD)






EFFECTS OF CAPTOPRIL ON ENDOGENOUS FIBRINOLYSIS IN MEN
WITH RECENT UNCOMPLICATED MYOCARDIAL INFARCTION
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6.1 SUMMARY
Increased plasma concentrations of tissue-type plasminogen activator (t-PA)
antigen and plasminogen activator inhibitor type 1 (PAI-1) activity have been
associated with an adverse prognosis in patients with ischaemic heart disease. The
use of angiotensin converting enzyme inhibitors has been shown to improve
prognosis after myocardial infarction. The study in this chapter examined the effect
of captopril on t-PA antigen and PAI-1 antigen and activity in patients who had made
an uncomplicated recovery from recent myocardial infarction. Patients were
randomised to receive 4 weeks placebo and 4 weeks captopril in a double-blind
crossover design. Treatment with captopril was associated with a significant
reduction in t-PA antigen and PAI-1 activity. This may help to explain the




Data from three large placebo controlled studies have indicated that the
administration of angiotensin converting enzyme inhibitors to patients with mild left
ventricular dysfunction following myocardial infarction results in a reduced
incidence of acute coronary syndromes (The SOLVD Investigators 1991; The
SOLVD Investigators 1992; Pfeffer et al 1992). The mechanism by which this is
achieved is not clear, but suggestions have included effects upon blood pressure,
angiotensin II, or the arterial intima (Yusuf et al 1992).
Impaired endogenous fibrinolysis is associated with an increased risk of
intravascular thrombosis (Astrup 1956). The activity of the fibrinolytic system is
reflected in circulating levels of tissue-type plasminogen activator and its most
physiologically important inhibitor, plasminogen activator inhibitor type 1 (Kruithof
et al 1988). Raised levels of tissue-type plasminogen activator antigen have been
shown to be a marker of risk for coronary thrombosis in healthy men (Ridker et al
1993b), in patients with angina (Munkvad 1990, Jansson et al 1991) and in patients
with myocardial infarction (Gram et al 1987b), and most recently to predict long
term mortality in patients with coronary artery disease (Jansson et al 1993). Elevated
levels of plasminogen activator inhibitor type 1 activity have been identified in
young survivors of myocardial infarction (Hamsten 1985) and were also shown to be
associated with an increased risk of reinfarction (Hamsten et al 1987b). Studies in
normal subjects (Vague et al 1986) and patients with angina (Juhan-Vague et al
1989a) have shown a correlation between fasting insulin and both tissue-type
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plasminogen activator and plasminogen activator inhibitor type 1. This is supported
by in vitro evidence that insulin increases the production of plasminogen activator
inhibitor type 1 by hepatocytes (Alessi et al 1988, Kooistra et al 1989). Angiotensin
converting enzyme inhibitors have been shown to improve hyperinsulinaemia in
hypertensive patients (Pollare et al 1989b), and thus might influence endogenous
fibrinolysis via this pathway. Recently it has been shown that an intravenous infusion
of angiotensin II results in an increase in plasma levels of plasminogen activator
inhibitor type 1 (Ridker et al 1993a), providing a link between the renin-angiotensin
system and risk of thrombosis, and an alternative path by which angiotensin
converting enzyme inhibitors might influence fibrinolysis.
The hypothesis that the angiotensin converting enzyme inhibitor captopril
might modify endogenous fibrinolysis was investigated in men following myocardial




Eighteen men younger than 75 years and suffering from their first myocardial
infarction were recruited 6 weeks after their admission to hospital. In addition to a
typical history, subjects had to show pathological Q waves in the ECG or have had a
peak creatine kinase of > 800 iu/L, or both. Patients with a history of hypertension or
diabetes mellitus were excluded. All patients had been taking a cardioselective
P adrenoceptor blocking agent and 300 mg of aspirin daily from the time of
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admission to hospital, and no other medication was permitted. None had previously
taken an angiotensin converting enzyme inhibitor. At the time of recruitment a full
clinical assessment was made and a chest radiograph, symptom limited treadmill
exercise test and radionuclide ventriculogram performed. Any patient with clinical or
radiological signs of heart failure, or evidence of ischaemia or arrhythmia requiring
additional therapy was excluded, and only those considered to have made an
uncomplicated recovery from their infarction and without other significant illness
were admitted to the study. Three patients were excluded from analysis, one patient
whose compliance was less than 90% by tablet count (75%), one patient whose
(3 blocker was withdrawn by his general practitioner during the study and one who
moved to England during the study and was unwilling to continue with study
medication. Details of the index admission to hospital for the 15 patients are given in
Table 18, Chapter 5.
To provide comparison for fibrinolytic parameters, 12 normal men of similar
age to the patients were identified at random from the Lothian Health Board register.
None of these men gave a history of ischaemic heart disease, hypertension or
diabetes mellitus and none were taking any medication. They all had a normal
physical examination and normal 12 lead ECG.
All subjects gave their oral and written consent to participate in the study and
the study was approved by the Lothian Health Board Ethical Committee.
Study design
The study was designed as a randomised, double-blind, placebo-controlled
crossover study. Entry into the study was 8 weeks after the onset of myocardial
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infarction in order to avoid any acute phase response or short term fluctuation in
fibrinolytic function (Gram et al 1987a). Patients received a test dose of placebo or
6.25 mg captopril under medical supervision at the beginning of each treatment
period and this was followed by one tablet of placebo or 25 mg captopril three times
daily. After 4 weeks of therapy the patients crossed over to the other treatment arm
for a further 4 weeks. No patient suffered a significant hypotensive response.
Measurements of fibrinolytic and other parameters were made on one occasion only
for normal subjects and at the end of each 4 week treatment period for patients, thus
at 12 and 16 weeks from the onset of myocardial infarction. Patients fasted from
22.00 hours the previous night, took their (3 blocker, aspirin and placebo/captopril
with a glass of water at 07.00 hours and attended the out patient department at 08.30
hours. The patients lay recumbent, a 16 G intravenous cannula was inserted into a
large antecubital vein and flushed with saline. Thirty minutes later 5 mL of blood
was drawn and discarded, a further 10 mL of blood was taken into potassium citrate
anticoagulant for fibrinolytic assays, 10 mL into lithium heparin for immunoreactive
insulin, urea and electrolytes, 2.5 mL into fluoride oxalate for glucose and 10 mL
into a plain glass tube for serum lipoproteins. Ten minutes later a further 5 mL of
blood was drawn and discarded, and an additional 10 mL sample for fibrinolytic
assays was taken into potassium citrate. The samples for fibrinolytic assays and
insulin were placed into melting ice. Within 1 hour, plasma was separated by




All fibrinolytic assays were performed at the same time after completion of
the study. Assays for tissue-type plasminogen activator and plasminogen activator
inhibitor type 1 antigen were by a two-site enzyme-linked immunosorbent assay
(Biopool AB, Umea, Sweden) and were performed as instructed by the manufacturer.
This follows the method of Ranby (Ranby et al 1986) in which plasma samples are
incubated in microtitre plates coated with monoclonal antibodies against the relevant
antigen, unbound antigens are washed off and bound antigen detected by addition of
a second specific antibody conjugated to horseradish peroxidase. Standard curves
were constructed using purified antigen diluted in plasma to known concentrations.
The amount of tissue-type plasminogen activator and plasminogen activator inhibitor
type 1 antigen in samples was deduced by comparing absorbence with the standard
curve. The coefficients of variation for repeated measures of tissue-type plasminogen
activator antigen and plasminogen activator inhibitor type 1 antigen in our laboratory
were 9.2% and 5.5% respectively. Plasminogen activator inhibitor type 1 activity was
measured by chromogenic assay (Biopool AB, Umea, Sweden) according to the
manufacturer's instructions and according to the principle first presented by
Chmielewska (Chmielewska et al 1983). Briefly, a fixed amount of tissue-type
plasminogen activator is added to the plasma sample and allowed to react with the
plasminogen activator inhibitor type 1 present. The residual tissue-type plasminogen
activator activity is measured by its ability to catalyse the conversion of plasminogen
to plasmin assessed colorimetrically and compared to standard curves. The
plasminogen activator inhibitor type 1 activity is defined as the difference between
171
the amount of tissue-type plasminogen activator added and the amount of tissue-type
plasminogen activator found. The coefficient of variation for repeated measures of
plasminogen activator inhibitor type 1 activity in our laboratory was 5.9%. Total
immunoreactive insulin was measured by radioimmunoassay (Soeldner and Slone
1965). Urea and electrolytes were measured on an autoanalyser. Total plasma
cholesterol and triglycerides were determined enzymatically and HDL cholesterol
using magnesium dextran. Plasma glucose was measured using the hexokinase
method (Cobas Bio analyser).
Statistical analyses
For fibrinolytic parameters the mean of 2 samples taken 10 minutes apart was
calculated and the values are presented as median (range) because of their skewed
distribution. Other parameters are given as mean (SE). Comparison of fibrinolytic
parameters between the normal subjects and myocardial infarction patients taking
placebo was by Mann Whitney U test. Comparison of fibrinolytic parameters
between the myocardial infarction patients at the end of each treatment period was by
Wilcoxon rank sum test and the estimated median and 95% CI were calculated using
Minitab Release 7 (Minitab Inc. 1989, Pennsylvania) on a personal computer.
Comparison of other parameters between the groups was by paired or unpaired
Student's t test as appropriate. To examine relationships between haemostatic
variables and metabolic parameters for all subjects (normals and myocardial
infarction patients on placebo) a Pearson correlation matrix using log transformed
data for variables which were not normally distributed (insulin, tissue-type
plasminogen activator, plasminogen activator inhibitor type 1 antigen, plasminogen
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activator inhibitor type 1 activity) was constructed with SYSTAT for Windows
Version 5 (Systat Inc. 1992, Evanston, Illinois) on a personal computer. The
significance level for correlations is given after applying the Bonferroni correction
for multiple comparisons. All reported p values are two-tailed.
6.4 RESULTS
Baseline characteristics (Table 19, Chapter 5)
There were no significant differences in the baseline characteristics of the
12 normal men and the 15 patients.
Fibrinolytic parameters (Results are summarised in Table 24)
NormalMen vMyocardial Infarction Patients
Tissue-type plasminogen activator antigen levels at the end of the placebo
period were significantly elevated in patients compared to normal men (p = 0.001).
Plasminogen activator inhibitor type 1 antigen tended to be higher in patients and
plasminogen activator inhibitor type 1 activity was significantly increased (p = 0.04).
Myocardial Infarction Patients - Placebo v Captopril
Nine patients received placebo first and 6 received captopril first in the
crossover design. There was no evidence of an order effect and therefore summary
results are presented combined in Table 24, individual results are given in the figures.
Tissue-Type Plasminogen Activator Antigen (Figure 9)
After 4 weeks therapy with captopril compared to 4 weeks placebo, there was
a highly significant fall in tissue-type plasminogen activator (p = 0.001) with a
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median reduction of 46% (95% CI, -29 to -64%). Fourteen patients showed a
reduction and one showed a small rise.
Plasminogen Activator Inhibitor Type 1 Antigen (Figure 10)
After captopril compared to placebo, 10 patients showed a fall in
plasminogen activator inhibitor type 1 antigen, one patient no change, and 4 patients
showed a rise. There was no overall significant effect, although there was a median
reduction of 18% (+9 to -49%, p = 0.17).
Plasminogen Activator Inhibitor Type 1 Activity (Figure 11)
After captopril there was a significant reduction in plasminogen activator
inhibitor type 1 activity (p = 0.02) with a median reduction of 17% (-8 to -29%),
13 patients showed a reduction in plasminogen activator inhibitor type 1 activity and
2 showed a rise.
Other parameters (Table 22, Chapter 5)
Myocardial Infarction Patients - Placebo v Captopril
After 4 weeks therapy with placebo compared to 4 weeks captopril, there was
no significant effect upon blood pressure or plasma urea, electrolytes, lipoproteins,
glucose and insulin.
Relationship between metabolic and haemostatic parameters for all subjects
Using combined results from normal men and patients with myocardial
infarction treated with P blocker, aspirin and placebo, Table 25 shows the Pearson
correlation coefficients between fibrinolytic parameters and plasma glucose, insulin
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and lipids. After adjustment for multiple comparisons, the correlations between
tissue-type plasminogen activator antigen and plasminogen activator inhibitor type 1
activity (r = 0.61, p = 0.027), and between plasminogen activator inhibitor type 1
antigen and plasminogen activator inhibitor type 1 activity (r = 0.673, p = 0.005),
remained significant. Plasminogen activator inhibitor type 1 activity also showed
significant correlations with fasting insulin (r = 0.591, p = 0.041) and with fasting
triglyceride (r = 0.596, p = 0.037).
6.5 DISCUSSION
Episodes of unstable angina or further infarction have a considerable
influence on prognosis after a first myocardial infarction. The balance between
thrombosis and fibrinolysis is central to the evolution of these acute coronary
syndromes. The results presented in this chapter have shown that there is abnormal
activation of the endogenous fibrinolytic system as shown by elevated levels of
tissue-type plasminogen activator antigen and plasminogen activator inhibitor type 1
activity in male survivors of uncomplicated acute myocardial infarction. In addition,
4 weeks treatment with captopril (75 mg daily) in a double-blind, placebo-controlled,
randomised crossover study was associated with a significant fall in tissue-type
plasminogen activator antigen and plasminogen activator inhibitor type 1 activity.
Angiotensin converting enzyme inhibitors have not previously been reported to have
an effect on fibrinolytic parameters and this may help to explain why their use is
associated with a reduction in risk of acute coronary thrombosis.
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Endogenousfibrinolysis in ischaemic heart disease
Elevated levels of tissue-type plasminogen activator antigen at baseline were
associated with a greater risk of subsequent myocardial infarction in the Physicians'
Health Study (Ridker et al 1993b). Two studies have shown that the risk of
subsequent cardiovascular events in patients with unstable angina was predicted by
tissue-type plasminogen activator antigen but not by plasminogen activator inhibitor
type 1 activity (Munkvad 1990b; Jansson et al 1991), and in a study of patients with
prior myocardial infarction those who suffered reinfarction had higher tissue-type
plasminogen activator antigen but lower tissue-type plasminogen activator activity
(Gram et al 1987a and 1987b). A recent study in 213 patients with coronary artery
disease has shown that concentrations of tissue-type plasminogen activator antigen
predict mortality over a 7 year follow up (Jansson et al 1993). An earlier study of
young survivors ofmyocardial infarction (Hamsten 1985) also found higher levels of
tissue-type plasminogen activator antigen and plasminogen activator inhibitor type 1
activity than controls, and a greater risk of further infarction was predicted by
increased levels of plasminogen activator inhibitor type 1 activity in a study in which
the results for tissue-type plasminogen activator antigen were not reported (Hamsten
et al 1987b). Thus, it has been a consistent finding that both tissue-type plasminogen
activator antigen and plasminogen activator inhibitor type 1 antigen and plasminogen
activator inhibitor type 1 activity are elevated in patients with ischaemic heart
disease, whereas tissue-type plasminogen activator activity is decreased. It should be
noted that the results of assays which measure levels of antigen include inactive
complexes of tissue-type plasminogen activator with plasminogen activator inhibitor
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type 1, and therefore it is valuable to have measures of both antigen and activity. It
might initially be thought that elevated levels of tissue-type plasminogen activator
antigen would suggest a decreased risk of thrombosis by indicating a more active
fibrinolytic system. One hypothesis which could help to explain these observations is
that increased secretion of these molecules, measured by the levels of antigen
detected, reflect a response to stimuli which promote thrombosis, and that it is these
which increase the risk of subsequent thrombotic occlusive events. This hypothesis is
supported by evidence that both thrombosis and pharmacological thrombolysis
increase circulating levels of plasminogen activator inhibitor type 1 (Fujii et al 1991)
and the expression of the plasminogen activator inhibitor type 1 gene within the
endothelium (Fujii et al 1992). It is likely that increased circulating plasminogen
activator inhibitor type 1 stimulates release of tissue-type plasminogen activator,
which is supported by the strong correlation between tissue-type plasminogen
activator antigen and plasminogen activator inhibitor type 1 activity seen in this
study and reported by others (Olofsson et al 1989). Acute variations in endogenous
fibrinolytic activity may be best assessed by plasminogen activator inhibitor type 1
activity, since this is the predominant physiological governor of tissue-type
plasminogen activator action. Plasminogen activator inhibitor type 1 exhibits marked
diurnal fluctuation (Angleton et al 1989), whereas tissue-type plasminogen activator
has much less diurnal change, which may have implications for clinical studies and
help to explain why levels of tissue-type plasminogen activator antigen predict risk
of future clinical events (Ridker et al 1993b; Munkvad 1990b; Jansson et al 1991;
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Gram et al 1987a and 1987b) and results for plasminogen activator inhibitor type 1
are less consistent (Munkvad 1990b; Jansson et al 1991; Hamsten et al 1987b).
Possible mechanisms in this study
In this study, the influence of captopril on fibrinolytic function occurred
despite there being no effect upon plasma insulin, glucose, electrolytes, and
lipoproteins. It is important to note, however, that as previously reported (Vague et al
1986; Juhan-Vague et al 1989), there was a positive correlation between plasminogen
activator inhibitor type 1 activity and both fasting insulin and triglyceride, although
each accounts for less than 40% of the variability of plasminogen activator inhibitor
type 1 activity. It may be that the lack of a more marked effect upon plasminogen
activator inhibitor type 1 in this study reflects the absence of a change in metabolic
variables with captopril, but at the same time our results indicate that factors other
than these must be important in the regulation of both plasminogen activator
inhibitor type 1 and tissue-type plasminogen activator. The small fall in blood
pressure with captopril, which was not significant in this study, was comparable to
that reported in the SAVE and SOLVD studies (The SOLVD Investigators 1991; The
SOLVD Investigators 1992; Pfeffer et al 1992). Although angiotensin converting
enzyme inhibitors have been shown to reduce insulin levels in hypertensive subjects
(Pollare et al 1989b), this effect has not been found in all groups (Seghieri et al 1992
and discussed in Chapters 1 and 5). Recently it has been suggested that the renin-
angiotensin system may play a more direct role in the control of endogenous
fibrinolysis (Ridker et al 1993a). In a study in hypertensive subjects, an intravenous
infusion of angiotensin II caused a significant rise in plasminogen activator inhibitor
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type 1 antigen with no effect upon tissue-type plasminogen activator antigen (Ridker
et al 1993a). As angiotensin converting enzyme inhibitors inhibit the formation of
angiotensin II, they might be expected to cause a fall in levels of plasminogen
activator inhibitor type 1, but this would not explain the decrease in tissue-type
plasminogen activator. Angiotensin converting enzyme inhibitors also influence the
kinin system and lead to increased levels of bradykinin (Johnston et al 1982).
Tissue-type plasminogen activator is primarily secreted from the vascular
endothelium, from which its acute release is enhanced by bradykinin (Emeis 1992).
Two possible explanations for the apparent anomaly with my observations are the
relatively long duration of treatment in our study compared to the short term effects
ofbradykinin infusion in experimental models, and my failure to measure the activity
of tissue-type plasminogen activator in addition to mass concentration.
Limitations ofthis study
Although the results from this study are consistent with previous observations
that altered fibrinolysis is associated with an increased risk of myocardial infarction,
and that angiotensin converting enzyme inhibitors reduce the risk of subsequent
coronary thrombosis in patients with first myocardial infarction, there are a number
of limitations to the study. I studied a small, highly selected population for a
relatively short period. Only men under the age of 75 years with a first
uncomplicated myocardial infarction were included. Patients with previous
hypertension or diabetes mellitus, or with any evidence of heart failure, were
excluded because these conditions might influence fibrinolysis directly or via
associated neurohumoral disturbances. All of the patients were taking a
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cardioselective (3 blocker and aspirin, as is the preferred therapy for patients with
myocardial infarction in the absence of any contraindication. Neither p blockers
(Hamsten 1985; Wright et al 1994 ) nor aspirin are thought to influence fibrinolysis.
My study did not include any examination of tissue-type plasminogen activator
release, such as the venous occlusion test (Wiman et al 1983), which might have
provided information on changes in endothelial function. However, a recent study in
diabetic and non-diabetic survivors of myocardial infarction found no difference in
levels of tissue-type plasminogen activator antigen or plasminogen activator inhibitor
type 1 antigen and activity after venous occlusion between patients and controls,
despite significant differences prior to venous occlusion (Gray et al 1993b). Lastly, a
long-lasting hangover effect from acute infarction which might influence the results
of the patient group cannot be excluded, although the blood samples for this study
were taken at least 12 weeks after the initial event. Mitigating against an acute phase
response persisting are the stable lipid values, the uncomplicated recovery from
infarction in this group, and the absence of an order effect in the crossover design.
This also argues against a hangover effect from the captopril treatment period for
those who received captopril first - consistent with the described endocrine response
to captopril withdrawal (Maslowski et al 1981). Previous work has suggested that
fibrinolytic parameters are only disturbed in the first few days after infarction and are
stable after one week (Gram et al 1987a).
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6.6 CONCLUSION
A decrease in the incidence of acute coronary syndromes in those receiving
angiotensin converting enzyme inhibitors was a common and unexplained finding in
three large placebo-controlled trials in patients with mild left ventricular dysfunction
(The SOLVD Investigators 1991; The SOLVD Investigators 1992; Pfeffer et al
1992). This study has shown for the first time that captopril modifies endogenous
fibrinolysis in patients with recent uncomplicated myocardial infarction. This may
help to explain the reduction in thrombotic risk associated with the use of angiotensin
converting enzyme inhibitors.
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(5.3to17.8) 8.6 (3.8to24.5) 6.3* (1.9to19.0)
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Table 25. Pearson correlation matrix for fibrinolytic and
metabolic variables inall subjects
t-PA antigen PAI-1 antigen PAI-1 activity
PAI-1 antigen 0.484 - -
PAI-1 activity 0.610* 0.673** -
Fasting insulin 0.173 0.526 0.591*
Fasting glucose 0.260 0.035 0.392
Total cholesterol 0.259 0.068 0.283
Total triglyceride 0.477 0.424 0.596*
HDL cholesterol -0.475 -0.460 -0.394
PAI-1 = plasminogen activator inhibitor type 1, t-PA = tissue-type plasminogen
activator, HDL = high density lipoprotein
*p < 0.05, w*p < 0.01 after Bonferroni correction
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Figure 9. Tissue-type plasminogen activator (t-PA) antigen levels in 15
patients with recent uncomplicated myocardial infarction treated





Figure 10. Plasminogen activator inhibitor type 1 (PAI-1) antigen levels in 15
patients with recent uncomplicated myocardial infarction treated





Figure 11. Plasminogen activator inhibitor type 1 (PAI-1) activity levels in 15
patients with recent uncomplicated myocardial infarction treated











Insulin is an important molecule. This is not only suggested by its multiple
actions and the problems that develop when it is deficient or when it is present in
excess, but also by its remarkable conservation during evolution.
Ischaemic heart disease is an important disease. It usually becomes manifest
only after the reproductive period and historically is a feature of modern Western
Civilisation. Thus, it can be assumed that ischaemic heart disease has not exerted
selection pressure during evolution.
Adaptational and compensatory systems developed during evolution
(sympathetic nervous system, renin-angiotensin system, thrombotic and haemostatic
systems, and possibly even hyperinsulinaemia and insulin resistance) may exert a
detrimental influence upon the well-being of modern man in his middle age and
beyond.
This should lead us to view these systems with suspicion when considering
the scourge of Western Man - ischaemic heart disease. The work presented in this
thesis has explored the hypotheses that disturbances of insulin and of endogenous
fibrinolysis are a feature of patients with established ischaemic heart disease and
investigated the potential manipulation of these by an angiotensin converting enzyme
inhibitor.
Insulin has many diverse actions mediated through different receptors. Insulin
may affect the development of ischaemic heart disease either indirectly or directly.
Important indirect actions of insulin in this respect include the synthesis of
triglyceride rich lipoproteins, increased sympathetic nervous activity, enhanced
sodium retention of the kidney, and raised blood pressure. Direct actions of insulin
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include stimulating effects on cell growth in those cell types involved in atheroma,
inducing atheroma in vivo, and exerting an unfavourable influence on endogenous
fibrinolysis. Conversely, it is possible that protection from beneficial actions of
insulin may be important in insulin resistant states. This most obviously relates to
glucose uptake into tissues, but may also relate to other potentially advantageous
actions such as skeletal muscle bed vasodilation. The most likely paradigm is that
resistance to some actions of insulin, principally insulin-mediated glucose disposal,
lead to a reactive and compensatory hyperinsulinaemia. If the resistance to insulin is
not present for other important actions of insulin then this may allow an unregulated
expression of those actions and thus have an adverse outcome.
Hyperinsulinaemia has been shown to be a risk factor for developing
ischaemic heart disease in three large prospective studies. The role of insulin
resistance as a risk factor for developing ischaemic heart disease has not been
investigated. Many previous studies have demonstrated that patients with established
ischaemic heart disease exhibit hyperinsulinaemia. The importance of the work
presented in Chapter 3 was that for the first time I sought to demonstrate whether the
nature of the hyperinsulinaemia varied between different states of ischaemic heart
disease - chronic stable angina, recent myocardial infarction, and chronic heart
failure. I have shown that significant fasting hyperinsulinaemia was a feature only of
patients with chronic heart failure. This would explain why fasting
hyperinsulinaemia has been an inconsistent finding in previous studies which have
not stratified in a similar way. It is probable that the mechanism for this relates to the
differing degrees of neurohumoral activation in these groups but I have not
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investigated this. I also showed that the degree of stimulated hyperinsulinaemia was
less in patients with stable angina and more pronounced, but to a similar degree, in
patients with recent myocardial infarction or chronic heart failure. This may again
reflect neurohumoral activation, but it suggests to me that stimulated
hyperinsulinaemia may be associated with an increased risk of coronary thrombosis.
This hypothesis is also consistent with the finding from the primary prospective
studies that the most consistent indicator of risk was the stimulated insulin response
rather than the fasting level.
Impaired glucose tolerance is relatively common amongst the general
population and is associated with both an increased risk of developing ischaemic
heart disease and with hyperinsulinaemia and insulin resistance. Amongst patients
with ischaemic heart disease there is a much higher prevalence of impaired glucose
tolerance, but the degree of associated hyperinsulinaemia had not been studied in this
group using recent definitions of glucose tolerance. In Chapter 4,1 presented the data
obtained from screening a cohort of patients attending the out patient department,
none of whom were suspected of having abnormal glucose tolerance. The prevalence
of impaired glucose tolerance in this sample was 20% and patients with impaired
glucose tolerance had significantly greater hyperinsulinaemia, both fasting and
stimulated, than patients with normal glucose tolerance. This suggests that the group
with impaired glucose tolerance may have a poorer prognosis. Considering all
patients, irrespective of glucose tolerance status, it was possible to show an inverse
relationship between fasting insulin concentration and left ventricular ejection
fraction. This has not previously been reported and it confirms that fasting
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hyperinsulinaemia reflects impaired left ventricular function. This is consistent with
the findings in Chapter 3 where it was only the fasting hyperinsulinaemia which
discriminated the group of patients with heart failure.
Initial reports from patients with essential hypertension suggested that
captopril, an angiotensin converting enzyme inhibitor, improved insulin sensitivity.
This may be important because of the need to establish therapies in hypertension
which not only lower blood pressure but also reduce the risk of developing ischaemic
heart disease. In Chapter 5 the effect of captopril upon hyperinsulinaemia and insulin
sensitivity in patients with recent myocardial infarction was described. In a
randomised, double-blind comparison with placebo, captopril had no effect upon
fasting hyperinsulinaemia, stimulated hyperinsulinaemia, or insulin sensitivity. The
use of an angiotensin converting enzyme inhibitor in patients with recent myocardial
infarction has been shown to improve prognosis. The data presented suggest that this
beneficial effect of angiotensin converting enzyme inhibition is not mediated through
insulin sensitivity or hyperinsulinaemia and also indicates that the mechanism
underlying hyperinsulinaemia in essential hypertension and ischaemic heart disease
may be different.
Over the last decade a number of studies have suggested that components of
the endogenous fibrinolytic system may be important in determining risk of
thrombotic events. In particular, increased plasma concentrations of tissue-type
plasminogen activator (t-PA) antigen and plasminogen activator inhibitor type 1
(PAI-1) activity have been associated with an increased risk ofmyocardial infarction
in patients with ischaemic heart disease. The work presented in Chapter 6 sought to
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investigate the hypothesis that angiotensin converting enzyme inhibition might
convey its benefit of reducing the risk of recurrent acute coronary syndromes in
patients with recent myocardial infarction via an effect upon these components of
endogenous fibrinolysis. In a double-blind, randomised comparison with placebo,
4 weeks treatment with captopril was associated with a significant decrease in t-PA
antigen and in PAI-1 activity. This may help to explain the diminished risk of
coronary thrombosis associated with the use of angiotensin converting enzyme
inhibitors. However, my initial hypothesis that captopril might exert a favourable
effect upon fibrinolysis via altered hyperinsulinaemia or insulin sensitivity was
disproved. More recent work has suggested a direct influence of the renin-
angiotensin system upon fibrinolysis as a more likely explanation, but my studies did
not address this.
Issues which remain to be resolved
Hyperinsulinaemia
The data presented in Chapters 3 and 4 suggest that raised fasting
concentrations of immunoreactive insulin are a feature of patients with chronic heart
failure and that they are negatively correlated to the left ventricular ejection fraction.
It seems most likely that these reflect the neurohumoral activation in heart failure but
an intriguing possibility is that in addition they might relate to the abnormalities of
peripheral muscle function which have been described in heart failure. Two
alternative mechanisms would be impaired peripheral muscle vasodilation in
response to insulin or impaired non-oxidative glucose metabolism.
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Whilst the prevalence of impaired glucose tolerance amongst patients with
ischaemic heart disease has been described before, the data in Chapter 4 raises the
possibility that the marked hyperinsulinaemia in this group might point to a worse
prognosis.
The lack of an effect of captopril upon hyperinsulinaemia and insulin
sensitivity in patients with recent myocardial infarction presented in Chapter 5 raises
a number of questions. The most fundamental is whether there are differences in the
nature of the hyperinsulinaemia and the insulin resistance present in essential
hypertension and in ischaemic heart disease. In addition, the possibility that aspirin
might inhibit the arterial vasodilation caused by angiotensin converting enzyme
inhibition has been raised and if correct this might also extend to the metabolic
effects of angiotensin converting enzyme inhibition.
Fibrinolysis
The most exciting issues which remain to be resolved after completing this
work relate to the mechanism by which captopril might influence the endogenous
fibrinolytic system. In Chapter 6 I showed that captopril was associated with a
significant fall in t-PA antigen and PAI-1 activity. Recent work has shown that short
term infusion of angiotensin II causes an increase in PAI-1 but there was a minimal
effect upon t-PA. This would help to explain my observation of a fall in PAI-1 with
captopril but not the marked reduction in t-PA antigen. Angiotensin converting
enzyme inhibition also leads to an increase in bradykinin because of inhibition of the
kinase enzyme and bradykinin promotes release of t-PA from the vascular
endothelium. However, before formulating a hypothesis to explain the effect of
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angiotensin converting enzyme inhibition upon t-PA it is necessary to confront a
more fundamental paradox - why raised plasma concentrations of t-PA antigen are
associated with an increased incidence of acute coronary thrombosis and stroke.
Measurements in venous plasma of t-PA antigen and t-PA activity are
negatively correlated. This is because the majority of t-PA secreted by the vascular
endothelium circulates as a complex bound to its rapidly acting inhibitor PAI-1 and
is functionally inactive. Thus a high plasma concentration of t-PA antigen indicates
that the endothelium has been actively secreting t-PA in response to a stimulus or
stimuli. The stimuli may be the presence of intravascular thrombus or of factors
which tend to lead to the formation of intravascular thrombus. It seem probable that
the reason that increased concentrations of t-PA antigen indicate increased risk is that
they reflect the presence of a tendency to the formation of intravascular thrombus. A
future thrombotic event might then relate to an overwhelming increase in the pro-
thrombotic state or to a failure of endogenous fibrinolysis.
The mechanisms by which angiotensin converting enzyme inhibition was
associated with a fall in t-PA antigen are most likely to involve a modification of the
stimuli leading to endothelial release of t-PA or a modification of the endothelial
response to those stimuli. An example of the former might be that a fall in PAI-1
preceded the fall in t-PA release. Alternatively, the endothelial response might be
important. T-PA which is incorporated early into a thrombus is more effective in
achieving lysis and therefore an enhanced endothelial response to releasing t-PA
might lead to more effective intravascular lysis and overall reduced total endothelial
release of t-PA. Increased early endothelial release of t-PA following angiotensin
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converting enzyme inhibition might be caused by an increase in local concentrations
of bradykinin.
In the latter halfofthis century considerable effort has been spent in trying to
comprehend the mechanisms which lead to the development of ischaemic heart
disease. The identification of cholesterol within the atheromatous plaque led to a
concentration of resources investigating "the lipid hypothesis." Whilst the role of
dyslipidaemia is important, it has become increasingly apparent that other
distortions of normal metabolism and other systems including the haemostatic
pathways may be very relevant to the development of atheroma and crucial to the
precipitation of the acute coronary syndromes. Within the last decade there have
been many landmark advances in the management of patients with myocardial
infarction: the use of acute thrombolysis and aspirin, the use of beta adrenoceptor
antagonists, the use of angiotensin converting enzyme inhibitors, and the use of 3-
hydroxy-3 methylglutaryl coenzyme A reductase inhibitors. Despite this, our
understanding of this fascinating disease remains incomplete. I hope that the work
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Summary
Elevated circulating insulin levels have been
reported in ischaemic heart disease, and may be of
aetiological importance. Previous studies have not
considered the potential influence of heart failure
or of previous myocardial infarction, as opposed to
stable angina. We therefore measured the insulin
response to a 75 g oral glucose tolerance test in
five groups with normal glucose tolerance, compar¬
ing normal male controls to men with chronic stable
angina, men with recent myocardial infarction (two
groups, 3 weeks and 3 months post infarction), and
men with chronic severe heart failure. Only patients
with chronic heart failure had fasting hyperinsulina¬
emia, probably reflecting associated neuroendocrine
abnormalities. Stimulated hyperinsulinaemia was
present in all patient groups, but was less pro¬
nounced and of shorter duration in patients with
angina. At 120 min, only patients with heart failure
or previous myocardial infarction were hyperinsuli-
naemic. The degree of stimulated hyperinsulinaemia
was not influenced by the presence of heart failure
or by the length of time from infarction. Hyper¬
insulinaemia is associated with impaired peripheral
muscle glucose uptake and metabolism, and might
contribute to muscular fatigue on exertion in
patients with previous myocardial infarction or
heart failure.
Introduction
Hyperinsulinaemia has been described in obesity,
impaired glucose tolerance (IGT), non-insulin
dependent diabetes mellitus, hypertension and isch¬
aemic heart disease (IHD).1 Insulin may have a direct
role in the development of atherosclerosis, or may
influence other risk factors for IHD, such as blood
pressure and lipoproteins.2 The relationship of fasting
and stimulated hyperinsulinaemia to IHD has not
been clearly defined. Studies in which an oral
glucose load was given to patients with IHD have
frequently reported stimulated hyperinsulinaemia,3"14
less often fasting hyperinsulinaemia,3'12'14 and two
studies have failed to show fasting or stimulated
hyperinsulinaemia.15'16 Earlier studies were limited,
as they frequently involved only patients with previ¬
ous myocardial infarction and they failed to differen¬
tiate the importance of heart failure. Often patients
with IGT or diabetes mellitus were not
excluded4"11,13-15 and patients and controls were not
matched for other important confounding variables,
including age, body mass index (BMI) or blood
pressure.3"6,8"16 The administered glucose load has
not been the standard 75 g in all studies, and the
subsequent blood sampling has sometimes been
limited to 60 min.
We measured the immunoreactive insulin (IRI)
response to a 75 g oral glucose tolerance test over
120 min in five groups with normal glucose tolerance
matched for age, BMI and blood pressure. We
compared normal male controls to men with chronic
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stable angina, men with myocardial infarction
assessed either at 3 weeks or 3 months after the




Normal controls (n= 22) were identified at random
from the Lothian Health Board register. They had no
previous history of hypertension, IHD or family
history of diabetes mellitus. They were taking no
regular medication, and had a normal 12-lead elec¬
trocardiogram. Patients with stable angina (n = 15)
were identified on the basis of a typical history of
exertional chest pain and the development of signific¬
ant electrocardiographic changes (>1 mV ST seg¬
ment depression 0.06 s after the J point) during
treadmill exercise testing. None had any clinical
evidence of heart failure. At the time of study they
were receiving nifedipine and none were taking beta
blockers. The two groups of patients with recent
myocardial infarction had an initial diagnosis based
upon WHO criteria.17 One group was studied 3
weeks after the acute event (Ml Group I, n = 26) and
one group was studied 12 weeks after the acute
event (Ml Group II, n = 15). None of these patients
had symptomatic heart failure, and all were taking
aspirin. Twenty (77%) of the patients in Ml Group I
and all those in Ml Group II were taking a beta
blocker. Patients with chronic heart failure (n=16)
were free of oedema, but remained severely restricted
(all NYHA grade III). At the time of study, the heart
failure group were all receiving a loop diuretic with
potassium supplements and none were taking an
angiotensin converting enzyme inhibitor.
We screened 93 patients attending the out-patient
department with established IHD and with fasting
plasma glucose <6.7 mmol/l using a 75 g oral
glucose tolerance test. Twenty-one (23%) patients
were found to have IGT or diabetes mellitus accord¬
ing to WHO criteria (2-h glucose > 11 mmol/l =
diabetes, >7.8 mmol/l = IGT)17 and were excluded
from this analysis, because both of these conditions
have previously been associated with hyperinsuli-
naemia.1
Data from 72 patients and 22 normal controls are
presented. Details of age, BMI (weight/height2), blood
pressure, smoking habit and left ventricular ejection
fraction are given in Table 1. The groups were well
matched for age, BMI and blood pressure. Ten (63%)
of the patients with chronic heart failure were
smokers, compared to < 10% of the other groups.
Measurement of left ventricular function was made
by radionuclide ventriculogram in patients with a
history of myocardial infarction or heart failure. Ml
Group I and Ml Group II had similar and well
preserved left ventricular function, whereas the group
with NYHA grade III heart failure had significantly
decreased left ventricular ejection fraction by com¬
parison with those groups.
Glucose tolerance test
Patients and controls attended the department after
a 12-h overnight fast. An indwelling 16G intravenous
cannula was inserted into an antecubital vein, and
they rested for 30 min. After a baseline blood sample
they took 75 g glucose monohydrate in 200 ml
water. Further blood samples were taken at 30, 60,
90 and 120 min. Samples were placed on ice.
Plasma was separated within 1 h, and stored at
— 40°C. Each sample was assayed for glucose and
IRI. Glucose was measured using a Cobas Bio
analyser by the hexokinase method18 with an interas-
say coefficient of variation of 1.7%. IRI was measured
by radioimmunoassay19 with a coefficient of variation
of 6.8-7.5%. This assay does not differentiate
between insulin, proinsulin and proinsulin split
products.
Statistical analysis
Descriptive data are given as means+ SEM. Areas
under the curve (AUC) were calculated using the
trapezium rule. Glucose values are given as arith¬
metic means (95% CI of mean). Values for insulin
and insulin/glucose ratio were compared after logar¬
ithmic transformation, and are expressed as geomet¬
ric means (95% CI of mean). Analysis of variance
(ANOVA) was used to assess differences among the
means of the groups. Where ANOVA revealed a
significant difference between the five groups, further
pairwise comparisons were made using Fisher's least-
significant-difference test. Statistical analyses used
SYSTAT for Windows, Version 5.20 The level of
significance was p<0.05.
Results
A summary of the results is shown in Table 2
Glucose response to oral glucose
There was no significant difference between the five
groups for glucose at either fasting level, 120 min
level or in AUC value (Figure 1). Despite all patients
having normal glucose tolerance, glucose levels at
120 min tended to be higher in patients with previous
Ml or heart failure, compared to controls.
I
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Table 1 Baseline characteristics of the five groups
Controls Stable angina Heart failure Ml Group I Ml Group II
(n=22) (n=15) (o=16) (o= 26) (o= 15)
Age (years) 56 ±1 60 ±2 60 ±2 61 ±2 63 ±2
BMI (kg/m2) 24.9 + 0.6 26.7 ±0.8 25.3 ±0.7 25.3 ±0.6 25.2 ±0.7
Systolic BP 118 + 4 127 + 5 127 + 5 122+4 127 ±5
Diastolic BP 79 + 2 78 + 3 80 + 3 76 + 2 80 ±3
Smoking 1 1 10 2 1
LVEF NM NM 0.20" ±0.02 0.37 ±0.02 0.39 ±0.02
Ml, myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; NM, not measured. Values are
mean + SEM where applicable.
'p< 0.001; Student's t test vs. both of the Ml groups.
Table 2 Plasma glucose and insulin responses to glucose tolerance test
Controls Stable angina Ml Group I Ml Group II Heart failure ANOVA
(n= 22) (n— 15) (n= 26) (n= 15) (n= 16) p value
Fasting
Glucose 5.0 5.1 5.0 5.3 5.0 0.483
(mmol/l) (4.8, 5.2) (5.0, 5.3) (4.8, 5.2) (5.0, 5.5) (4.7, 5.4)
Insulin 5.5 7.2 6.2 5.4 11.5 0.012
(mU/l) (4.3, 7.0) (5.0, 10.2) (5.1, 7.5) (3.5, 8.1) (7.1, 18.8)
Insulin/ 1.1 1.4 1.2 1.0 2.3 0.007
Glucose (0.8, 1.4) (1.0, 2.0) (1.0, 1.5) (0.7, 1.5) (1.4, 3.7)
(mU/mmol)
120 min
Glucose 5.3 5.1 5.9 6.1 6.0 0.076
(mmol/l) (4.8, 5.8) (4.6, 5.7) (5.4, 6.4) (5.4, 6.8) (5.4, 6.6)
Insulin 30.8 36.9 62.2 56.5 69.1 0.002
(mU/l) (22.0, 43.2) (27.8, 49.0) (46.8, 82.6) (37.2, 85.7) (47.9, 99.8)
Insulin/ 5.9 7.3 10.8 9.5 11.9 0.004
Glucose (4.4, 7.8) (5.8, 9.2) (8.5, 13.7) (6.6, 13.9) (8.6, 16.3)
(mU/mmol)
AUC
Glucose 791 894 848 846 837 0.256
(min.mmol/l) (728, 855) (823, 966) (804, 892) (787, 906) (758, 915)
Insulin 5041 7377 7951 8050 8998 0.011
(min.mU/l) (3985, 6378) (6088, 8939) (6396, 9884) (5947, 10898) (6906, 11721)
Insulin/ 6.1 8.4 9.4 9.6 10.9 0.004
Glucose (5.0, 7.5) (7.1, 9.8) (7.7, 11.6) (7.3, 12.6) (8.8, 13.6)
(min.mU/mmol)
A 75 g oral glucose tolerance test was administered to normal controls and patients with stable angina, patients after
acute myocardial infarction studied at 3 weeks or 3 months, and patients with chronic heart failure. AUC, Area under
the curve calculated from samples at 0, 30, 60, 90 and 120 min; ANOVA, analysis of variance between the five groups.
Values are arithmetic means for glucose and geometric means for insulin and insulin/glucose ratio, with the 95% CI for
the means in parentheses.
Insulin response to oral glucose 120 min (p=0.002) and for AUC (p=0.0H)
(Figure 2). Follow-up pairwise comparisons for fasting
Plasma insulin levels were significantly different insulin showed significant differences between patients
between the five groups for fasting (p= 0.012), at with heart failure vs. normal controls (p=0.002),





























Figure 2. Arithmetic mean plasma insulin concentrations before and after a 75 g oral glucose challenge in the five group
Ml Group I (p= 0.006), and Ml Group II (p= 0.003).
There were also borderline significant difference
between patients with heart failure vs. those with
stable angina (p= 0.06). Follow-up pairwise cor
parisons for 120 min levels showed significant diffe
ences between normal controls vs. Ml Group
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(p= 0.001), Ml Group II (p= 0.02), and chronic
heart failure (p=0.001). In addition, patients
with stable angina were significantly different from
Ml Group I (p=0.03) and from chronic heart failure
(p=0.02). Follow-up pairwise comparisons for AUC
showed significant differences between normal con¬
trols and all patient groups, controls vs. stable angina
(p=0.03), Ml Group I (p= 0.005), Ml Group II
(p= 0.01), and chronic heart failure (p= 0.001), but
there were no significant differences between pa¬
tient groups.
Insulin/glucose ratio response to oral
glucose
The ratio of plasma insulin/glucose was signifi¬
cantly different between the five groups for fasting
(p= 0.007), at 120 min (p= 0.004) and for AUC
(p= 0.004)(Figure 3). Pairwise comparisons for
fasting ratios showed significant differences be¬
tween patients with heart failure vs. normal controls
(p=0.001), stable angina (p= 0.04), Ml Group I
(p=0.005) and Ml Group II (p=0.001). Pairwise com¬
parisons showed significant differences for values at
120 min between normal controls vs. Ml Group I
(p= 0.0012), Ml Group II (p=0.03) and chronic
heart failure (p= 0.001), and between stable angina
vs. chronic heart failure (p= 0.03). Pairwise compar¬
isons between the groups for AUC showed significant
differences between normal controls vs. stable angina
(p= 0.05), Ml Group I (p= 0.003), Ml Group II
(p= 0.005) and chronic heart failure (p<0.001).
Discussion
The most important finding of this study is the
suggestion that the presence and nature of insulin
resistance in patients with IHD may be crucially
influenced by previous myocardial infarction or the
extent of left ventricular dysfunction. Unlike previous
studies,4-16 we have taken care to minimize the
influence of other conditions known to influence
insulin sensitivity1 by excluding patients with
impaired or abnormal glucose tolerance and by
matching patient groups and controls for age, BMI
and blood pressure. Fasting hyperinsulinaemia was
only a feature of patients with chronic heart failure.
Stimulated hyperinsulinaemia was present in chronic
stable angina, for at least 3 months following recent
acute myocardial infarction without clinically signi¬
ficant left ventricular impairment, and in chronic
heart failure. Although patients with angina or recent
infarction had similar fasting levels of insulin, at 120
min patients with recent infarction had persistently
elevated insulin, similar in magnitude to that of the
heart failure group and significantly higher than
controls, while patients with angina did not differ
significantly from controls at this time, but were
significantly lower than Ml group I or patients with
Insulin/Glucose
0 30 60 90 120
Time (min)
-s- Controls Stable Angina -0~ Heart Failure
—Ml Group I —Ml Group II
Figure 3. Arithmetic mean plasma glucose/insulin ratios before and after a 75 g oral glucose challenge in the five groups.
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chronic heart failure. It may be that the persistent
elevation of insulin at 120 min in those with
recent myocardial infarction, as opposed to a return
to normal insulin levels in those with stable angina,
is associated with an increased tendency to occlusive
thrombus formation in addition to atheroma. This
hypothesis is supported by evidence linking hyperin-
sulinaemia to impaired endogenous fibrinolysis.21
Alternatively, stimulated hyperinsulinaemia may
occur as a response to the presence of left ventricular
dysfunction, irrespective of the presence of symp¬
toms. If this were the case, then the degree of the
stimulated response is not critically dependent upon
the extent of ventricular impairment, as the 120 min
and AUC values were similar in those with a well-
preserved left ventricular ejection fraction and those
with severely impaired ejection fraction. The degree
of stimulated hyperinsulinaemia in those with recent
myocardial infarction did not differ between Group
I, studied 3 weeks after the acute event, and Group
II, studied 3 months after. We cannot say whether
stimulated hyperinsulinaemia was present prior to
infarction or developed as a consequence. Three
large longitudinal population studies have suggested
that hyperinsulinaemia is a risk factor for subsequent
myocardial infarction.22-24 Our data would support
this hypothesis and in addition, would suggest that
fasting hyperinsulinaemia is a late development con¬
fined to patients with moderate or severe heart
failure.
Low fasting insulin levels and an impaired
response to intravenous tolbutamide were found in
a previous study in eight patients with heart failure
secondary to rheumatic heart disease.25 The effect of
an oral glucose load was not tested, and the patients
studied were severely ill and bedridden despite
treatment with digoxin and diuretics. In end-stage
disease it is conceivable that pancreatic hypoper¬
fusion might lead to reduced insulin secretion, but
in less severe heart failure there are a number of
possible influences on insulin action which might
lead to insulin resistance and hyperinsulinaemia. The
neuroendocrine response in heart failure leads to
increased secretion of catecholamines, Cortisol and
growth hormone,26 all of which antagonize the
peripheral action of insulin. The physical inactivity
associated with severe grades of heart failure may
also play a role.27 Although there is no evidence
from studies in man to support a primary role for
hyperinsulinaemia or insulin resistance in the devel¬
opment of heart failure, impaired ventricular function
associated with prolonged insulin resistance has
recently been described in a rat model of streptozoc-
in-induced diabetes.28 This would be of particular
importance because of evidence that angiotensin
converting enzyme inhibitors favourably modify insu¬
lin resistance.29
Hyperinsulinaemia is an important finding in IHD,
because it is associated with dyslipidaemia, hyperten¬
sion, impaired fibrinolysis and sodium retention by
the kidney.1,2 In addition, hyperinsulinaemia, particu¬
larly in the presence of normal glucose levels,
suggests a defect in utilization of substrate by peri¬
pheral muscle, as has been shown in diabetes
mellitus,30 and this may be relevant to the symptoms
of fatigue and diminished effort tolerance which are
prevalent in patients with heart failure or after
myocardial infarction. Secondly, studies in patients
with hypertension have illustrated the potential
adverse effects of beta blockers31 and beneficial
effects of angiotensin converting enzyme inhibitors29
on insulin resistance, and these are classes of drug
widely prescribed to patients with IHD.
Study limitations
Nearly all current insulin immunoassays crossreact
with proinsulin and 32-33 split proinsulin, and these
molecules may form a considerable part of total
insulin immunoreactivity after a glucose stimulus in
subjects with non-insulin-dependent diabetes mel¬
litus.32,33 However, there is no information to suggest
that insulin precursor levels are increased in non-
diabetic subjects with IHD, and even amongst those
with non-insulin-dependent diabetes, it appears that
those with mild or diet-controlled disease do not
show excess secretion of insulin precursor molec¬
ules.34 The stimulated hyperinsulinaemia in some
groups may in part reflect relative hyperglycaemia.
The elevated ratio of insulin/glucose in those with
heart failure or recent myocardial infarction does not
support this, however, and suggests that the available
insulin was not acting normally to increase glucose
uptake, which indicates the presence of insulin
resistance.
Although there are no studies of the effect of
chronic beta blockade on insulin resistance in
patients with IHD, in patients with hypertension,
beta blockers have been associated with impaired
insulin sensitivity and hyperinsulinaemia.31 In our
study, the groups taking beta blockers were those
with a recent history of myocardial infarction and
without heart failure. In Ml Group I and Ml Group
II, fasting levels of insulin were similar to both
normal controls and men with stable angina who
were not taking a beta blocker. Stimulated levels of
insulin in Ml Group I and Ml Group II were similar
to those with heart failure who were not taking a
beta blocker. This suggests that beta blockers were
not responsible for hyperinsulinaemia in this study.
All of the patients in the group with chronic heart
failure were taking loop diuretics with potassium
supplements and there are case reports of these
being associated with IGT.35 However, the proposed
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Table 3 Plasma insulin response to a 75 g oral glucose
tolerance test in patients with chronic heart failure—
smokers vs. non-smokers
Time (min) Smokers (n= 10) Non-smokers (n= 6)
0 15.6 ±7.5 19.4 ±5.8
30 80.3 ±25.4 80.6 + 19.7
60 98.2 ±26.2 112.8±20.3
90 106.7 ±26.4 99.8 + 20.4
120 105.7 ±18.3 71.4 ±14.2
Plasma insulin in mU/l. Values are mean±SEM.
mechanism is not through increased insulin release
but through inhibition of insulin secretion, and this
has been confirmed in an animal study.36 In studies
which have examined the effect of frusemide on
glucose tolerance and insulin response in patients
with hypertension37 and following myocardial infarc¬
tion,38 there was no effect on fasting or stimulated
insulin.
In this study, the group of patients with heart
failure was the only group to contain a high propor¬
tion of smokers (10/16) and cigarette smoking has
been associated in normal volunteers with stimulated
hyperinsulinaemia in response to an OG7T and
increased insulin resistance.39 However, a compar¬
ison of the smokers and non-smokers in the heart
failure group (Table 3) showed no significant differ¬
ence between smokers and non-smokers.
Conclusion
We have shown that, in patients with ischaemic
heart disease, fasting hyperinsulinaemia is only pre¬
sent in severe heart failure, whereas stimulated
hyperinsulinaemia is prominent amongst those with
previous myocardial infarction and those with heart
failure, and is also present, but less marked, in those
with chronic stable angina.
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Effects of Captopril Therapy on Endogenous Fibrinolysis in Men With
Recent, Uncomplicated Myocardial Infarction
ROBERT A. WRIGHT, MRCP, ANDREW D. FLAPAN, MRCP,
K. GEORGE M. M. ALBERTI, FRCP,* CHRISTOPHER A. LUDLAM, FRCP,t
KEITH A. A. FOX, FRCP
Edinburgh, Scotland and Newcastle upon Tyne, England, United Kingdom
Objectives. This study investigated the effects of captopril
therapy on endogenous fibrinolysis in men with recent, uncompli¬
cated myocardial infarction.
Background. Angiotensin-converting enzyme inhibitors reduce
the incidence of acute coronary syndromes in patients with mild
left ventricular dysfunction after myocardial infarction. Abnor¬
mal endogenous fibrinolysis, reflected in increased levels of endo¬
genous tissue-type plasminogen activator (t-PA) antigen and plas¬
minogen activator inhibitor type 1 activity, is associated with an
increased risk of myocardial infarction in patients with ischemic
heart disease.
Methods. In a randomized, double-blind crossover study be¬
ginning 8 weeks after uncomplicated myocardial infarction, pa¬
tients received 4 weeks of placebo and 4 weeks of captopril (75 mg
daily) therapy. At the end of each treatment period, we measured
t*PA antigen and plasminogen activator inhibitor type 1 antigen
and activity.
Results. Median values in the 15 patients after placebo and in
12 normal men matched for age and body mass index were,
respectively, t-PA antigen 16.0 versus 9.5 ng/ml (p = 0.001),
plasminogen activator inhibitor type 1 antigen 17.3 versus
8.6 ng/ml (p = 0.29) and plasminogen activator inhibitor type 1
activity 13.2 versus 6.3 AU/ml (p = 0.04). After 4 weeks of
treatment with captopril in the 15 patients, the estimated (95%
confidence interval) median reduction in t-PA antigen was
7.3 ng/mi (-4.6 to -10.3 ng/ml, p = 0.001), in plasminogen
activator inhibitor type 1 antigen 3.1 ng/mi (+1.5 to -8.4 ng/ml,
p = 0.17) and in plasminogen activator inhibitor type 1 activity
-2.2 AU/ml (-1.0 to -4.3 AU/mi, p = 0.02).
Conclusions. Treatment with captopril after uncomplicated
myocardial infarction is associated with a significant decrease in
elevated levels of t-PA antigen and plasminogen activator inhibitor
type 1 activity. This may help to explain the reduction in risk of
coronary thrombosis associated with the use of angiotensin-
converting enzyme inhibitors.
(J Am Coll Cardiol 1994^4:67-73)
Data from three large placebo-controlled studies have indi¬
cated that the administration of angiotensin-converting en¬
zyme inhibitors in patients with mild left ventricular dys¬
function after myocardial infarction results in a reduced
incidence of acute coronary syndromes (1-3). The mecha¬
nism by which this is achieved is not clear, but suggestions
have included effects on blood pressure, angiotensin II or the
arterial intima (4).
Impaired endogenous fibrinolysis is associated with an
increased risk of intravascular thrombosis (5). The activity
of the fibrinolytic system is reflected in circulating levels of
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tissue-type plasminogen activator (t-PA) and its most phys¬
iologically important inhibitor, plasminogen activator inhib¬
itor type 1 (6). Increased levels of t-PA antigen have been
shown to be a marker of risk for coronary thrombosis in
healthy men (7), in patients with angina (8,9) and in patients
with myocardial infarction (10) and most recendy have been
shown to predict long-term mortality in patients with coro¬
nary artery disease (11). Elevated levels of plasminogen
activator inhibitor type 1 activity have been identified in
young survivors ofmyocardial infarction (12) and were also
shown to be associated with an increased risk of reinfarction
(13). Studies in normal subjects (14) and in patients with
angina (15) have shown a correlation between levels of
fasting insulin and both t-PA activator and plasminogen
activator inhibitor type 1. This is supported by in vitro
evidence that insulin increases the production of plasmino¬
gen activator inhibitor type 1 by hepatocytes (16,17).
Angiotensin-converting enzyme inhibitors have been shown
to improve hyperinsulinemia in hypertensive padents (18)
and thus might influence endogenous fibrinolysis through
this pathway. Recently it has been shown that an intrave¬
nous infusion of angiotensin II results in an increase in
plasma levels of plasminogen activator inhibitor type 1 (19),
0735-1097/94/57.00
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Table 1. Details of the Index Myocardial Infarction in the 15
Study Patients
No. of Pts or Mean
Value (range)
Cigarette smoker





Peak creatine kinase (IU/liter)
Cardiothoracic ratio










IHD = ischemic heart disease; LVEF = left ventricular ejection fraction;
Pts = patients.
providing a link between the renin-angiotensin system and
risk of thrombosis and an alternative path by which
angiotensin-converting enzyme inhibitors might influence
fibrinolysis.
We investigated the hypothesis that the angiotensin-
converting enzyme inhibitor captopril might modify endog¬
enous fibrinolysis in men after myocardial infarction that is
uncomplicated by clinically manifest heart failure, arrhyth¬
mia and recurrent ischemia.
Methods
Subjects. Eighteen men <75 years old and with their first
myocardial infarction were recruited 6 weeks after admis¬
sion to hospital. In addition to a typical history, subjects had
to show pathologic Q waves on the electrocardiogram
(ECG) or to have had a peak creatine kinase (CK) level
>800 IU/liter, or both. Patients with a history of hyperten¬
sion or diabetes mellitus were excluded. All patients had
been taking a cardioselective beta-adrenoceptor blocking
agent and 300 mg of aspirin daily from the time of admission
to hospital, and no other medication was permitted. None
had previously taken an angiotensin-converting enzyme in¬
hibitor. At the time of recruitment a full clinical assessment
was made, and a chest radiograph, symptom-limited tread¬
mill exercise test and radionuclide ventriculogram were
performed. Any patient with clinical or radiologic signs of
heart failure or evidence of ischemia or arrhythmia requiring
additional therapy was excluded, and only those considered
to have made an uncomplicated recovery from their infarc¬
tion and without other significant illness were admitted to the
study. Three patients were excluded from analysis: one
patient whose compliance was <90% by tablet count (75%),
one patient whose beta-blocker was withdrawn by his gen¬
eral practitioner during the study and one who moved to a
different city during the study and was unwilling to continue
with study medication. Details of the index admission to
hospital for the 15 patients are given in Table 1.
To provide comparison for fibrinolytic variables, 12 nor¬
mal men similar in age to the patients were identified at
random from the Lothian Health Board Register. None of
these men gave a history of ischemic heart disease, hyper¬
tension or diabetes mellitus, and none was taking any
medication. They all had a normal physical examination and
normal 12-lead ECG.
All subjects gave their oral and written consent to partic¬
ipate in the study, and the study was approved by the
Lothian Health Board Ethical Committee.
Study design. The study was designed as a randomized,
double-blind, placebo-controlled crossover study. Entry into
the study was 8 weeks after the onset of myocardial infarc¬
tion to avoid any acute-phase response or short-term fluctu¬
ation in fibrinolytic function (20). Patients received a test
dose of placebo or 6.25 mg of captopril under medical
supervision at the beginning of each treatment period, and
this was followed by one tablet of placebo or 25 mg of
captopril three times daily. After 4 weeks of therapy the
patients crossed over to the other treatment arm for a further
4 weeks. No patient had a significant hypotensive response.
Measurements of fibrinolytic and other variables were made
on one occasion only in normal subjects and at the end of
each 4-week treatment period in patients (i.e., at 12 and 16
weeks from the onset of myocardial infarction). Patients
fasted from 10 pm the previous night, took their beta-
blocker, aspirin and placebo/captopril with a glass of water
at 7 am and attended the outpatient department at 8:30 am.
The patients lay recumbent, and a 16-G intravenous cannula
was inserted into a large antecubital vein and flushed with
saline solution. Thirty minutes later, 5 ml of blood was
drawn and discarded. A further 10 ml of blood was drawn
into potassium citrate anticoagulant for fibrinolytic assays;
10 ml into lithium heparin for immunoreactive insulin, urea
and electrolytes; 2.5 ml into fluoride oxalate for glucose; and
10 ml into a plain glass tube for serum lipoproteins. Ten
minutes later a further 5 ml of blood was drawn and
discarded, and an additional 10-ml sample for fibrinolytic
assays was drawn into potassium citrate. The samples for
fibrinolytic assays and insulin were placed into melting ice.
Within 1 h, plasma was separated by centrifugation (20 min
at 2,000 x g and -4°C), immediately frozen in dry ice and
stored at -40°C.
Assays. All fibrinolytic assays were performed at the
same time after completion of the study. Assays for t-PA and
plasminogen activator inhibitor type 1 antigen were by a
two-site enzyme-linked immunosorbent assay (Biopool AB)
and were performed as instructed by the manufacturer,
according to the method ofRanby et al. (21) in which plasma
samples are incubated in microtiter plates coated with mono¬
clonal antibodies against the relevant antigen, unbound
antigens are washed off, and bound antigen is detected by
addition of a second specific antibody conjugated to horse¬
radish peroxidase. Standard curves were constructed using
purified antigen diluted in plasma to known concentrations.
The amount of t-PA and plasminogen activator inhibitor type
1 antigen in samples was deduced by comparing absorbance
with the standard curve. The coefficients of variation for
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Table 2. Baseline Characteristics of the 12 Normal Men and 15




Height (m) 1.77 (0.02) 1.78 (0.01)
Weight (kg) 79.5 (2.2) 79.5 (2.2)
BMI (kg/nr) 25.4 (0.6) 25.2 (0.6)
Pulse (beats/min) 67(2) 60(2)
Systolic BP (mm Hg) 120 (4) 124 (5)
Diastolic BP (mm Hg) 80(3) 77(3)
Cholesterol (mmol/liter) 6.2 (0.3) 6.9 (0.2)
Triglyceride (mmol/liter) 1.5 (0.2) 2.0 (0.2)
HDL cholesterol (mmol/liter) 1.3(0.1) 1.1 (0.1)
Glucose (mmol/liter) 4.9(0.1) 5.2(0.1)
Insulin (mU/liter) 7.3 (1.8) 7.7 (2.3)
Data presented are mean values (SE). BM1 = body mass index; BP =
blood pressure; HDL = high density lipoprotein.
repeated measures of t-PA antigen and plasminogen activa¬
tor inhibitor type 1 antigen in our laboratory were 9.2% and
5.5%, respectively. Plasminogen activator inhibitor type 1
activity was measured by chromogenic assay (Biopool AB)
according to the manufacturer's instructions and according
to the method first presented by Chmielewska et al. (22).
Briefly, a fixed amount of t-PA is added to the plasma sample
and allowed to react with the plasminogen activator inhibitor
type 1 present. The residual t-PA activity is measured by its
ability to catalyze the conversion of plasminogen to plasmin,
assessed colorimetrically and compared with standard
curves. The plasminogen activator inhibitor type 1 activity is
defined as the difference between the amount of t-PA added
and the amount of t-PA found. The coefficient of variation
for repeated measures of plasminogen activator inhibitor
type 1 activity in our laboratory was 5.9%. Total immuno-
reactive insulin was measured by radioimmunoassay (23).
Urea and electrolytes were measured on an autoanalyzer.
Total plasma cholesterol and triglyceride levels were deter¬
mined enzymatically, and HDL cholesterol, using magne¬
sium dextran and plasma glucose, was measured using the
hexokinase method (Cobas Bioanalyzer).
Statistical analyses. For fibrinolytic variables, the mean
of two samples taken 10 min apart was calculated, and the
values are presented as median (range) because of their
skewed distribution. Other variables are given as mean
values (SE). Comparison of fibrinolytic variables between
the normal subjects and patients with myocardial infarction
taking placebo was by Mann-Whitney U test. Comparison of
fibrinolytic variables between the patients with myocardial
infarction at the end of each treatment period was by
Wilcoxon rank-sum test, and the estimated median and 95%
confidence intervals (CI) were calculated using Minitab
Release 7 (Minitab Inc.) on a personal computer. Compari¬
son of other variables between groups was by paired or
unpaired Student t test, as appropriate. To examine relations
between hemostatic and metabolic variables for all subjects
(normal men and patients with myocardial infarction on
placebo), a Pearson correlation matrix using log-transformed
data for variables that were not normally distributed (insulin,
t-PA, plasminogen activator inhibitor type 1 antigen, plas¬
minogen activator inhibitor type 1 activity) was constructed
with Systat forWindows, Version 5 (Systat Inc.) on a personal
computer. The significance level for correlations is given after
applying the Bonferroni correction for multiple comparisons.
All p values reported are two-tailed.
Results
Baseline characteristics. There were no significant differ¬
ences in the baseline characteristics of the 12 normal men
and the 15 patients (Table 2).
Fibrinolytic variables. Normal men versus myocardial
infarction patients. The t-PA antigen levels at the end of the
placebo period were significantly elevated in patients com¬
pared with normal men (p = 0.001). Plasminogen activator
inhibitor type 1 antigen tended to be higher in patients, and
plasminogen activator inhibitor type 1 activity was signifi¬
cantly increased (p = 0.04) (Table 3).
Patients with myocardial infarction: placebo versus cap-
topril therapy. Nine patients received placebo first, and six
received captopril first in the crossover design. There was no
evidence of an order effect, and therefore summary results
Table 3. Fibrinolytic Variables in Normal Men and in Patients With Recent Myocardial Infarction After 4 Weeks of Placebo and 4 Weeks
of Captopril Therapy
Normal
Myocardial Infarction Group Estimated Median Difference
Value Placebo Captopril (95% CI, captopril - placebo)
t-PA antigen (ng/ml) 9.5* 16.0 10.3* -7.3 (-4.6 to-10.3)
(5.3 to 17.8) (9.0 to 34.8) (4.0 to 21.8)
PAI-1 antigen (ng/ml) 8.6 17.3 7.8 -3.1 (+1.5 to -8.4)
(3.8 to 24.5) (3.3 to 36.5) (2.5 to 28.3)
PAI-1 activity (AU/ml) 6.31" 13.2 9.0t -2.2 (-1.0 to -4.3)
(1.9 to 19.0) (4.0 to 21.9) (2.6 to 29.8)
*p = 0.001 and tp < 0.05 versus myocardial infarction (placebo therapy). Data presented are median values (range). PA1-1 = plasminogen activator inhibitor
type 1; t-PA = tissue-type plasminogen activator.
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Figure 1. Ussue-type plasminogen acti¬
vator (t-PA) antigen levels and plasmin¬
ogen activator inhibitor type 1 (PAI-1)
antigen and activity levels in 15 patients
with recent, uncomplicated myocardial
infarction treated for 4 weeks with pla¬





Placebo Captopril Placebo Captopril
are presented combined in Table 3; individual results are
given in Figure 1.
Tissue-type plasminogen activator antigen. After 4
weeks of therapy with captopril compared with 4 weeks of
placebo, there was a highly significant decrease in t-PA (p =
0.001), with a median reduction of 46% (95% CI -29% to
-64%). Fourteen patients showed a reduction, and one
showed a small increase.
Plasminogen activator inhibitor type 1 antigen. After
captopril therapy compared with placebo therapy, 10 pa¬
tients showed a decrease in plasminogen activator inhibitor
type I antigen, one patient showed no change, and four
patients showed an increase. There was no overall signifi¬
cant effect, although there was a median reduction of 18%
(+9% to -49%, p = 0.17).
Plasminogen activator inhibitor type I activity. After
captopril therapy, there was a significant reduction in plas¬
minogen activator inhibitor type 1 activity (p = 0.02), with a
median reduction of 17% (-8% to -33%); 13 patients
showed a reduction in plasminogen activator inhibitor type 1
activity, and two showed an increase.
Other variables. Patients with myocardial infarction:
placebo versus captopril therapy. After 4 weeks of therapy
with placebo compared to 4 weeks of captopril, there was no
significant effect on blood pressure or plasma urea, electro¬
lyte, lipoprotein, glucose or insulin levels (Table 4).
Relation between metabolic and hemostatic variables for all
subjects. Based on combined results from normal men and
patients with myocardial infarction treated with beta-
blockers, aspirin and placebo, Table 5 shows the Pearson
correlation coefficients between fibrinolytic variables and
plasma glucose, insulin and lipid levels. After adjustment for
multiple comparisons, the correlations between t-PA antigen
and plasminogen activator inhibitor type 1 activity (r = 0.61,
p = 0.027) and between plasminogen activator inhibitor type
1 antigen and plasminogen activator inhibitor type 1 activity
(r = 0.673, p = 0.005) remained significant. Plasminogen
activator inhibitor type 1 activity also showed significant
l I
Placebo Captopril
correlations with fasting insulin (r = 0.591, p = 0.041) and
with fasting triglyceride (r = 0.596, p = 0.037) levels.
Discussion
Episodes of unstable angina or further infarction have a
considerable influence on prognosis after a first myocardial
infarction. The balance between thrombosis and fibrinolysis
is central to the evolution of these acute coronary syn¬
dromes. Our results have shown that there is abnormal
activation of the endogenous fibrinolytic system, as shown
by elevated levels of t-PA antigen and plasminogen activator
inhibitor type 1 activity in male survivors of uncomplicated
acute myocardial infarction. In addition, we have shown in a
double-blind, placebo-controlled, randomized crossover
study that 4 weeks of treatment with captopril (75 mg daily)
is associated with a significant decrease in t-PA antigen and
plasminogen activator inhibitor type 1 activity. Angiotensin-
converting enzyme inhibitors have not previously been
reported to have an effect on fibrinolytic variables, and this
may help to explain why their use is associated with a
reduction in risk of coronary thrombosis.
Table 4. Effect of 4 Weeks of Placebo and 4 Weeks of Captopril
Therapy on Other Variables
Placebo Captopril
Systolic BP (mm Hg) 117(4) 114 (4)
Diastolic BP (mm Hg) 69(3) 68(4)
Urea (mmol/liter) 6.3 (0.3) 6.5 (0.4)
Sodium (mmol/liter) 141 (1) 141 (1)
Potassium (mmol/liter) 4.1 (0.1) 4.1 (0.1)
Creatinine (/rmol/liter) 105 (3) 105 (3)
Cholesterol (mmol/liter) 6.9 (0.2) 6.8 (0.2)
Triglyceride (mmol/liter) 2.0 (0.2) 2.2 (0.3)
HDL cholesterol (mmol/liter) 1.1 (0.1) 1.1 (0.1)
Glucose (mmol/liter) 5.3 (0.1) 5.2 (0.2)
Insulin (mU/liter) 7.7 (2.3) 6.8 (1.4)
Data presented are mean values (SE). Abbreviations as in Table 2.
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Table 5. Pearson Correlation Matrix for Fibrinolytic and
Metabolic Variables in All Subjects
t-PA Antigen PAI-1 Antigen PAM Activity
PAI-1 antigen 0.484 — —
PAI-1 activity 0.610* 0.673t —
Fasting insulin 0.173 0.526 0.591*
Fasting glucose 0.260 0.035 0.392
Total cholesterol 0.259 0.068 0.283
Total triglyceride 0.477 0.424 0.5%*
HDL cholesterol -0.475 -0.460 -0.394
*p < 0.05, tp < 0.01 after Bonferroni correction. Abbreviations as in
Tables 2 and 3.
Endogenous fibrinolysis in ischemic heart disease. Ele¬
vated levels of t-PA antigen at baseline were associated with
a greater risk of subsequent myocardial infarction in the
Physicians' Health Study (7). Two studies have shown that
the risk of subsequent cardiovascular events in patients with
unstable angina was predicted by t-PA antigen but not by
plasminogen activator inhibitor type 1 activity (8,9), and in a
study of patients with previous myocardial infarction, those
with reinfarction had higher t-PA antigen but lower t-PA
activity (10). A recent study in 213 patients with coronary
artery disease has shown that concentrations of t-PA antigen
predict mortality over a 7-year follow-up (11). An earlier
study of young survivors of myocardial infarction (12) also
found higher levels of t-PA antigen and plasminogen activa¬
tor inhibitor type 1 activity than control subjects, and a
greater risk of further infarction was predicted by increased
levels of plasminogen activator inhibitor type 1 activity in a
study in which tissue-type plasminogen activator antigen
was not reported (13). Thus, it has been a consistent finding
that t-PA antigen and plasminogen activator inhibitor type 1
antigen and plasminogen activator inhibitor type 1 activity
are all elevated in patients with ischemic heart disease,
whereas t-PA activity is decreased. It should be noted that
the results of assays that measure levels of antigen include
inactive complexes of t-PA with plasminogen activator in¬
hibitor type 1, and therefore it is valuable to have measures
of both antigen and activity.
It might initially be thought that elevated levels of t-PA
antigen would suggest a decreased risk of thrombosis by
indicating a more active fibrinolytic system. One hypothesis
that could help to explain these observations is that in¬
creased secretion of these molecules, measured by the levels
of antigen detected, reflects a response to stimuli that
promote thrombosis and that it is these that increase the risk
of subsequent thrombotic occlusive events. This hypothesis
is supported by evidence that both thrombosis and pharma¬
cologic thrombolysis increase circulating levels of plasmin¬
ogen activator inhibitor type 1 (24) and the expression of the
plasminogen activator inhibitor type 1 gene within the endo¬
thelium (25). It is likely that increased circulating plasmino¬
gen activator inhibitor type 1 stimulates release of t-PA,
which is supported by the strong correlation between t-PA
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antigen and plasminogen activator inhibitor type 1 activity
seen in this study and reported by others (26). Short-term
variations in endogenous fibrinolytic activity may be best
assessed by plasminogen activator inhibitor type 1 activity,
because this is the predominant physiologic governor of t-PA
action. Plasminogen activator inhibitor type 1 exhibits
marked diurnal fluctuation (27), whereas t-PA has much less
diurnal change, which may have implications for clinical
studies and help to explain why levels of t-PA antigen predict
risk of future clinical events (7-10), and why results for
plasminogen activator inhibitor type 1 are less consistent
(8,9,13).
Possible mechanisms in this study. In our study, the
influence of captopril therapy on fibrinolytic function oc¬
curred despite there being no effect on plasma insulin,
glucose, electrolyte and lipoprotein levels. It is important to
note, however, that, as previously reported (14,15), there
was a positive correlation between plasminogen activator
inhibitor type 1 activity and both fasting insulin and triglyc¬
eride levels, although each accounts for <40% of the vari¬
ability of plasminogen activator inhibitor type 1 activity. It
may be that the lack of a more marked effect on plasminogen
activator inhibitor type 1 in this study reflects the absence of
a change in metabolic variables with captopril therapy, but at
the same time our results indicate that factors other than
these must be important in the regulation of both plasmino¬
gen activator inhibitor type 1 and t-PA.
The small decrease in blood pressure with captopril
therapy, which was not significant in this study, was com¬
parable to that reported in the Survival and Ventricular
Enlargement (SAVE) and Studies of Left Ventricular Dys¬
function (SOLVD) studies (1-3). Although angiotensin-
converting enzyme inhibitors have been shown to reduce
insulin levels in hypertensive subjects (18), this effect has not
been found in all groups (28). Recently it has been suggested
that the renin-angiotensin system may play a more direct
role in the control of endogenous fibrinolysis (19). In a study
in hypertensive subjects, an intravenous infusion of angio¬
tensin II caused a significant increase in plasminogen acti¬
vator inhibitor type 1 antigen with no effect on t-PA antigen
(19). Because angiotensin-converting enzyme inhibitors in¬
hibit the formation of angiotensin II, they might be expected
to cause a decrease in levels of plasminogen activator
inhibitor type 1, but this would not explain the decrease in
t-PA. Angiotensin-converting enzyme inhibitors also influ¬
ence the kinin system and lead to increased levels of
bradykinin (29). Tissue-type plasminogen activator is pri¬
marily secreted from the vascular endothelium, from which
its release is enhanced by bradykinin (30). Two possible
explanations for the apparent anomaly with our observations
are the duration of treatment in our study compared with the
short-term effects of bradykinin infusion in experimental
models and our failure to measure the activity of t-PA in
addition to mass concentration.
Study limitations. Although our results are consistent
with previous observations that altered fibrinolysis is asso-
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dated with an increased risk of myocardial infarction and
that angiotensin-converting enzyme inhibitors reduce the
risk of subsequent coronary thrombosis in patients with first
myocardial infarction, there are a number of limitations to
our study. We studied a small, highly selected population for
a relatively short period. We included only men <75 years
old with a first uncomplicated myocardial infarction. Pa¬
tients with previous hypertension or diabetes mellitus or
with any evidence of heart failure were excluded because
these conditions might influence fibrinolysis directly or
through associated neurohumoral disturbances. All of our
patients were taking a cardioselective beta-blocker and
aspirin, as is the preferred therapy for patients with myocar¬
dial infarction in the absence of any contraindication. Nei¬
ther beta-blockers (12,31) nor aspirin is thought to influence
fibrinolysis.
Our study did not include any examination of t-PA
release, such as the venous occlusion test (32), which might
have provided information on changes in endothelial func¬
tion. However, a recent study in diabetic and nondiabetic
survivors of myocardial infarction found no difference in
levels of t-PA antigen or plasminogen activator inhibitor type
1 antigen and activity after venous occlusion between pa¬
tients and control subjects despite significant differences
before venous occlusion (33). Finally, we cannot exclude a
long-lasting hangover effect from acute infarction that might
influence the results of the patient group, although the blood
samples for this study were taken at least 12 weeks after the
initial event. Mitigating against an acute-phase response
persisting are the stable lipid values, the uncomplicated
recovery from infarction in our group and the absence of an
order effect in the crossover design. This also argues against
a hangover effect from the captopril treatment period for
those who received captopril first, consistent with the de¬
scribed endocrine response to captopril withdrawal (34).
Previous work has suggested that fibrinolytic variables are
only disturbed in the first few days after infarction and are
stable after 1 week (20).
Conclusions. A decrease in the incidence of acute coro¬
nary syndromes in those receiving angiotensin-converting
enzyme inhibitors was a common and unexplained finding in
three large placebo-controlled trials in patients with mild left
ventricular dysfunction (1-3). This study has shown for the
first time that captopril modifies endogenous fibrinolysis in
patients with recent uncomplicated myocardial infarction.
This may help to explain the reduction in thrombotic risk
associated with the use of angiotensin-converting enzyme
inhibitors.
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Abstract. This double-blind, randomized parallel group
study investigated the effect of 6 months /^-adrenoceptor
antagonist therapy with either metoprolol (/^-selective
without intrinsic sympathomimetic activity [ISA]) or
epanolol (//,-selective with ISA) on markers of endogen¬
ous fibrinolysis in 20 patients with chronic stable angina
receiving concurrent treatmentwith nifedipine.
Neither drug had an effect on tissue-type plasminogen
activator or plasminogen activator inhibitor type 1 (PAI-
1). A significant correlation between fasting insulin and
PAI-1 has previously been described and was confirmed in
this study. The group treated with metoprolol showed a
significant rise in fasting insulin after 6 months with no
change in PAI-1.
This suggests that the previously described link be¬
tween these two may not be causal.
Key words: Metoprolol, Epanolol, Ischaemic heart dis¬
ease; tissue-type plasminogen activator, plasminogen acti¬
vator inhibitor type 1
Tissue-type plasminogen activator (t-PA) [1, 2] and plas¬
minogen activator inhibitor type 1 (PAI-1) [3, 4] have
been implicated in the incidence and recurrence of
myocardial infarction. Beta blockers are effective in the
secondary prevention of myocardial infarction [5] and are
also widely prescribed to patients with angina and hyper¬
tension. The long term effects of //-adrenoceptor block¬
ade upon t-PA and PAI-1 are unknown, although a
possible benefit has been suggested [6], with the caveat
that //-adrenoceptor selectivity or the presence of intrinsic
sympathomimetic activity (ISA) might be necessary.
This study investigated the effect of6 months treatment
with either metoprolol, a //,-selective adrenoceptor anta¬
gonist, orepanolol, a //, -selective adrenoceptor antagonist
with ISA ofapproximately 20% that of isoprenaline [7], on
Correspondence to: R.A.Wright, Department of Cardiology, Royal
Infirmary. Lauriston Place, Edinburgh EH3 9YW, UK
t-PA and PAI-1 antigen levels in 20 patientswith stable an¬
gina. Fasting plasma lipids, glucose and insulin were also
measured at the beginning and end ofthe treatmentperiod.
Subjects and methods
Twenty male patients who had chronic stable angina with a typical
history and a positive treadmill exercise test (> 0.1 mV ST segment
depression on a 12 lead electrocardiogram) were recruited. Patients
with a history of hypertension or diabetes mellitus were excluded.
Subjects attended between 08.30 and 10.00 h having fasted for at
least 10 h and lay recumbent for 30 min prior to a blood sample being
drawn from an antecubital vein with a 19G needle and without ve¬
nous stasis. Samples were immediately placed into melting ice and
within 1 h they were centrifuged at 4°C, 2000 G for 20 min. Plasma
was collected, immediately frozen and stored at -40°C. Three
weeks later this procedure was repeated to provide a second baseline
measure. At this time (week 3), patients were randomised to receive
either metoprolol 100 mg twice daily and placebo once daily, or
epanolol 200 mg once daily and placebo twice daily. Further visits
were made at 6,9,15 and 27 weeks. Patients received nifedipine and
sublingual GTN throughout the study. The mean (SD) age (60(6) v
54( 10) years, NS) and duration of angina (4(5) v 2(4) years, NS) were
similar in the metoprolol and epanolol groups respectively. Two pa¬
tients in each group had a history of previousmyocardial infarction.
PAI-1 antigen and t-PA antigen were determined using enzyme-
linked immunosorbent assays [8, 9], Total cholesterol and trigly¬
cerides were determined enzymatically, HDL cholesterol using
Mg"+ dextran. plasma glucose by the hexokinase method and total
immunoreactive insulin by radioimmunoassay [10].
Statistical methods
Data are expressed as mean (range) for fibrinolytic variables and
mean (SEM) for all others. Data which were not normally dis¬
tributed were log transformed prior to statistical testing. The ba¬
seline values of t-PA and PAI-1 for the 2 groups were compared
using Student's r-test for unpaired data. To assess the effect of the
2 beta blockers, analyses were made separately for the 2 groups. Re¬
peatedmeasures analysis ofvariance was used to compare PAI-1 and
t-PA at the end of the baseline (week 3), and at 6,9,15 and 27 weeks
treatment. Student's t -test for paired data was used to compare other
variables measured at 3 weeks and 27 weeks. To assess the influen¬
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Fig.l. The effect of 6 months treatment with metoprolol on tissue-
type plasminogen activator antigen (t-PA Ag) and plasminogen acti¬
vator inhibitor-1 antigen (PAI-1 Ag) after 2 baseline measures at
week - 3 and week 0
Fig.2. The effect of6 months treatmentwith epanolol on tissue-type
plasminogen activator antigen (t-PA Ag) and plasminogen activator
inhibitor-1 antigen (PAI-1 Ag) after 2 baselinemeasures atweek -3
and week 0
nolytic function at baseline, the results for all patients were com¬
bined and Pearson correlation coefficients were calculated. The
2 way level of significance was taken as P < 0.05.
Results
For the metoprolol and the epanolol groups respectively
baseline levels of t-PA antigen (8.3 (2.5-12.1) vs 6.1 (2.5-
11.7) ng-ml"1, NS) and PAI-1 antigen (65 (18—152) vs 101
(24-383) ng-ml-1, NS) were similar. Neither metoprolol
(Fig.l) nor epanolol (Fig.2) had a significant effect on
t-PA antigen or PAI-1 antigen over the 6 month period.
The mean values of the other measured parameters are
given in Table 1. After 6 months both beta blockers had
induced a significant fall in resting heart rate which was
less marked with epanolol. in keeping with its partial
agonist activity. There was no significant effect of either
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rol, HDL cholesterol or serum triglycerides. There was r
tendency for fasting glucose to rise in both groups (NS)
The metoprolol group showed a significant rise in fasting
immunoreactive insulin (P < 0.05) but there was nc
change with epanolol.
At baseline, there were significant positive correlations
for PAI-1 with fasting insulin (r - 0.59, P < 0.01) and BMI
(r =0.49, P < 0.05) and for t-PA with fasting cholesterol
(r - 0.53, P < 0.05) and triglyceride (r = 0.49, P < 0.05).
Discussion
In this study there was no effect of long-term treatment
with beta blockers on markers of endogenous fibrinolysis
in patients with ischaemic heart disease. There was no
difference between metoprolol (/?,-selective, without
ISA) and epanolol (/?,-selective, with ISA). The baseline
measurements confirmed previously described correla¬
tions between t-PA and fasting cholesterol and trigly¬
cerides [11], and between PAI-1 and fasting insulin and
body mass index [11]. Neither drug affected body mass
index, fasting lipoproteins or glucose, but metoprolol was
associated with a significant rise in fasting insulin, a find¬
ing previously described in hypertensives [12]. Despite
the increase in fasting insulin, there was no effect upon
PAI-1. Thus, the link between fasting hyperinsulinaemia
and impaired fibrinolysis may not be a direct one. There
was no change in fasting lipids in this study, possibly
Table 1. The effect of 6 months treatmentwith metoprolol or epanolol on cardiovascular risk factors in 2 groups of patients with chronic stable
angina
Metoprolol group (n = 10) Epanolol group (n = 10)
Baseline 6 months Baseline 6 months
Body mass index (kg/m:) 27.5 (3.1) 27.9 (2.9) 27.4 (4.2) 27.5 (4.3)
Pulse (bpm) 79 (15) 59 (5)*** 76(7) 67 (5)**
Systolic blood pressure (mmHg) 124 (18) 122 (16) 132 (19) 123 (10)
Diastolic blood pressure 76(11) 75(6) 84(13) 82(8)
Total cholesterol (mmol/1) 7.1 (1.2) 7.1 (0.7) 6.7(1.0) 7.1 (0.6)
HDL cholesterol (mmol/1) 1.2 (0.3) 1.1 (0.2) 1.1 (0.2) 12 (0.2)
Triglycerides (mmol/1) 2.2 (0.9) 2.1 (1.0) 2.0(1.0) 2.8(1.8)
Fasting glucose (mmol/1) 5.0 (0.4) 5.5 (0.8) 5.1 (0.3) 53 (0.4)
Fasting insulin (mu/1) 7.2 (3.6) 15.0 (15.7)* 16.6 (8.6) 14.4 (7.8)
Values are mean (SD) * P < 0.05, **P < 0.01, *** P < 0.001
because both drugs investigated were /7,-selective [13].
As both total fasting cholesterol and triglyceride were
positively correlated with t-PA at baseline, it is possible
that /J-adrenoceptor blockade might influence fibrino¬
lytic variables in a situation in which lipoproteins were
also altered.
In the one previous study [14] examining the effect of
/^-adrenoceptor blockade on fibrinolysis in patients with
ischaemic heart disease, which predated assays of t-PA
and PAI-1, alprenolol (a nonselective beta blocker with
ISA) prolonged euglobulin clot lysis time at rest but did
not influence the response to exercise. Metoprolol caused
no change in PAI-1 in 10 normal subjects [15], but in
15 hypertensive patients it caused a decrease [16]. In
15 patients with hypertension, the long-acting, non-selec¬
tive beta blocker nadolol had no effect upon t-PA, PAI-1
or platelet aggregability [17]. The duration of treatment in
these studies has not exceeded 3 weeks, whilst beta
blockers are prescribed for long periods, and often in the
hope of preventing long-term thrombotic complications.
Limitations ofthis study
Although we included more subjects than previous pa¬
tient studies, the wide range of values for the fibrinolytic
parameters in this study limited the power to show a sig¬
nificant effect. However, the figures illustrate well the
complete absence of any effect with either agent. After
the randomisation code was broken, it was apparent that
the baseline fasting insulin concentrations were lower in
the metoprolol group. This may explain the tendency for
the baseline PAI-1 levels to be lower in this group. The dif¬
ference at baseline might suggest that the epanolol group
were initially more insulin resistant, but there is no reason
to believe that thiswould alter the response of fibrinolysis
to beta blockade.
Our subjects maintained treatment with nifedipine
throughout, so our results were obtained in the presence
of a calcium antagonist. However, nifedipine does not
alter t-PA antigen and activity in normal volunteers [18].
Only 20% of our patient group had suffered a previous
myocardial infarction, and there may be differences in fi¬
brinolytic function between patients with angina who suf¬
fermyocardial infarction and those who do not [11].
Conclusion
Long-term administration of cardioselective beta block¬
ade to patients with chronic stable angina is not associ¬
ated with any alteration in t-PA or PAI-1. The presence
of ISA did not confer any benefit. After 6 months treat¬
ment with metoprolol there was a rise in fasting insulin
with no change in levels of plasminogen activator type 1,
suggesting that the previously described link between
basal insulin secretion and impaired fibrinolysis is not
causal.
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